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Abstract 
Cancer is one of the commonest conditions among patients admitted to Intensive 
Care Units (ICU). However, little is known about how it affects likelihood of ICU 
admission and subsequent clinical progress. What literature does exist is often 
not generalisable to current UK practice.  
The aims of the studies presented in this thesis are to determine the features 
that are associated with ICU admission in patients with solid tumours; to 
describe how the solid tumour population in ICU differs from the ICU population 
without cancer; how this impacts upon survival; and finally, to describe the 
long-term outcomes of solid tumour patients that have survived ICU and those 
features associated with mortality. 
I undertook a detailed systematic review of the international literature relating 
to survival following ICU admission for patients with solid tumours. This revealed 
a paucity of high quality studies and led to recommendations for improving the 
conduct and reporting of future research in this field. 
Using retrospective cohorts from prospectively collected databases, variables 
relating to patients in the West of Scotland diagnosed with a cancer between 1st 
January 2000 and 31st December 2009 were analysed. The rate of ICU admission 
within two years following cancer incidence was investigated, and the factors 
associated with admission described. The Scottish Intensive Care Society Audit 
Group (SICSAG) database was used to detail information pertaining to critical 
illness and to provide data on patients without an underlying tumour that were 
admitted to ICU during the same study period. Three cohorts were defined: 
patients with a solid tumour that were admitted to ICU, patients with a solid 
tumour that were not admitted to ICU, and ICU patients without a cancer 
diagnosis. 
One in twenty patients diagnosed with a solid tumour (5.2%) were admitted to 
ICU with the majority receiving organ support during their ICU stay. ICU 
admission tended to occur soon after cancer diagnosis and was therefore likely 
related to the cancer diagnosis or its treatment. The rate of ICU admission was 
greatest for bowel malignancies (16.5% of colorectal cancer patients) and for 
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those tumours that require peri-operative ICU support for tumour resection 
surgery such as head and neck cancers (12.8%), stomach cancer (11.3%) and 
oesophageal cancer (10.2%). When compared with the ICU population without 
cancer, patients with solid tumours tended to be older (median age 68 years vs. 
59 years, respectively), with a higher proportion of elective hospitalisations 
(52.7% vs. 10.0%) and were predominantly admitted to ICU with a surgical illness 
(89.3% vs. 55.0%).  
Surgical ICU admissions have a favourable ICU and hospital mortality if they have 
an underlying cancer diagnosis compared with surgical ICU patients without 
cancer (hospital mortality 22.9% vs. 28.1%, respectively). A potential explanation 
for this would be a higher proportion of level 2 admissions, lower utilisation of 
multi-organ support and an opportunity for pre-operative optimisation within the 
cancer group. ICU cancer patients admitted with a medical diagnosis have 
poorer short-term survival than those without cancer (hospital mortality 49.1% 
vs. 41.7%, respectively) and this difference is even more pronounced in those 
that received organ support (62.5% vs. 46.2%).  
In patients that survive an admission to ICU the presence of cancer has the 
largest impact upon mortality risk in the longer-term with a risk of death over 
three times greater than in the population of ICU survivors without cancer. Long-
term survival varies considerably by underlying tumour type with four-year 
survival varying from 10.0% in patients with hepatocellular carcinoma to 73.3% in 
patients with testicular cancer. Cancer-related factors such as tumour stage 
have an important role in determining mortality risk in the longer term for 
survivors of ICU with cancer. In patients with colorectal cancer that had survived 
an ICU admission the risk of death after six-months was significantly higher in 
patients with Dukes D stage vs. Dukes A (HR 8.66). 
The work presented in this thesis systematically reviews and summarises the 
current published outcomes of patients with solid tumours admitted to ICU, 
demonstrates that among the solid tumour population ICU admission is common 
and shows that short-term outcomes vary significantly by features associated 
with both the critical illness and the underlying tumour type. In patients that 
survive an ICU admission the presence, type and stage of cancer is important for 
determining on-going mortality risk. This information may be used when 
  
4 
clinicians are discussing potential outcomes following admission to critical care 
with cancer patients. Future studies should focus on the administration of 
treatments for cancer after critical illness and whether they differ from those 
received by those patients without an ICU admission. Prospective studies are 
required to describe the pre-ICU deteriorations in physiology in cancer patients 
with critical illness including those considered, but not admitted, to ICU. 
Outcomes for this latter group are unknown and given the high burden of illness 
severity documented in ICUs within the UK, these studies may identify a group of 
patients for whom critical care would be beneficial but is not currently 
provided.  
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Chapter 1 Introduction 
 
1.1 Intensive Care Medicine 
To understand the role that Intensive Care has in the management of patients 
with cancer, it is relevant to describe what Intensive Care comprises and the 
clinical factors that are known to influence outcomes. Intensive care units (ICU) 
have unique systems for monitoring the physiological status of patients and 
delivering treatments that are not available in standard hospital wards. This 
specialised area of medicine deals with providing care to the sickest patients in 
the hospital and, as such, mortality rates in ICU are high. Longer-term outcomes 
are also affected by an ICU admission with deterioration in chronic disease 
states, worsening quality of life and elevated mortality risk persisting for several 
years after discharge from ICU. It is therefore important to identify factors that 
impact on both short and long-term outcome after patients are admitted to ICU. 
This will facilitate clinicians to have individualised discussion with patients 
regarding potential outcome after admission to ICU. 
 
1.1.1 History of Intensive Care Medicine 
ICU, also called critical care or intensive therapy units, are departments within a 
hospital that look after patients with life-threatening conditions who need 
constant, close monitoring and support from specialist equipment and 
medication. They have higher levels of staffing, specialist monitoring and 
treatment equipment only available in these areas and the staff are highly 
trained in caring for the most severely ill patients. 
The need for intensive care arose after a polio epidemic struck Denmark in 1952, 
when 2722 patients were admitted to Blegdan Hospital in a six-month period. A 
large proportion of these patients suffered respiratory or airway muscle paralysis 
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resulting in respiratory failure, pooling of secretions and ultimately death if left 
untreated. At the time treatment had involved the use of negative pressure 
respirators, but these devices, while helpful, were limited to six within this 
hospital site. At times there were up to 70 patients in this institution requiring 
artificial ventilation and therefore alternative solutions were sought.  
Dr Bjorn Ibsen, a Copenhagen anaesthetist, changed management by instituting 
protracted positive pressure ventilation by means of intubation of the trachea 
with a cuffed rubber tube and intermittent insufflation of the lungs via manual 
compression of a rubber bag. Due to the high demand for respiratory support 
during this time Dr Ibsen enlisted over 200 medical students to deliver this 
respiratory support by manually pumping oxygen and air into the patients lungs. 
This was performed on a dedicated ward with each patient allocated his or her 
own nurse. A total of 232 patients were treated in Copenhagen in this manner 
and mortality in this cohort decreased from over 87% to approximately 40% [1]. 
This experience heralded the widespread use of positive pressure ventilation for 
respiratory failure and is considered to be the origin of intensive care medicine 
[2]. 
In the decades that followed there was an expansion of intensive care across 
Europe and North America. Hospitals started to develop specially equipped areas 
with a higher proportion of staff and specialist equipment such as heart 
monitors, arterial blood gas analysers, and mechanical ventilators. Over time the 
specialty has expanded to include support of other forms of organ failure such as 
cardiovascular and renal failure. Today the ICU is the area within the hospital 
where the sickest patients are managed. Medical advances have meant that 
within the ICU setting it is now possible to temporarily support or replace the 
function of multiple failing organs. This supportive care is provided both to treat 
the underlying condition and allow time for the patient to recover. 
Not all patients with critical illness require the same level of support and most 
hospitals with an ICU will also have a high dependency unit (HDU) to provide an 
intermediate level of care. To determine which patients should be best managed 
in each location the Department of Health produced recommendations entitled 
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"Comprehensive Critical Care" [3]. This report defined four different levels of 
care encompassing all patients in hospital. 
The definitions of these levels of care are: [3] 
“Level 0: Patients whose needs can be met through normal ward care 
in an acute hospital 
Level 1: Patients at risk of their condition deteriorating, or those 
recently relocated from higher levels of care, whose needs can be met 
on an acute ward with advice and support from the critical care team. 
Level 2: Patients requiring more detailed observation or intervention 
including support for a single failing organ system or post-operative 
care and those stepping down from higher levels of care. 
Level 3: Patients requiring advanced respiratory support alone or basic 
respiratory support together with support of at least two organ 
systems. This level includes all complex patients requiring support for 
multi-organ failure.”[3] 
High dependency most commonly provides level 1 or 2 care whereas intensive 
care usually means level 2 or 3 care. In Scotland, the intensity of treatment is 
high with 66% of patients treated in ICU or a mixed ICU/ HDU in 2016 requiring 
level 3 treatment [4]. 
 
1.1.2 Critical illness, organ failure and organ support 
Critical illness is an illness or injury that acutely impairs the function of one or 
more vital organ system. Severe infection, cardiac ischaemia, trauma, poisoning, 
surgical complications and burns can all cause critical illness although this list is 
not exhaustive. Patients with critical illness are admitted to ICU for monitoring 
of organ dysfunction, provision of organ support and treatment of the underlying 
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cause. For patients to recover from their critical illness the underlying disease 
process must be potentially reversible with treatment.  
The management of a patient with critical illness will be individualised 
depending on the type and degree of organ dysfunction. However, there are 
principles of organ dysfunction and subsequent support that can be applied to all 
patients. 
 
1.1.2.1  Respiratory system 
The respiratory system involves gas exchange across alveolar membranes in the 
lungs. Respiratory failure occurs when there is a failure in gas exchange function 
either oxygenation or carbon dioxide elimination. Hypoxic respiratory failure 
(type I) is characterised by low arterial oxygen tension (PaO2) with a normal or 
low arterial carbon dioxide tension (PaCO2). This is the commonest cause of 
acute respiratory failure and is caused by intra-pulmonary pathology such as 
pneumonia, pulmonary oedema, and pulmonary haemorrhage. Hypercapnic 
respiratory failure (type II) occurs when PaCO2 is elevated and is often 
associated with low PaO2 that can usually be overcome with supplemental 
oxygen. The cause of type II respiratory failure includes reduced consciousness, 
drug overdose, neuromuscular disease, severe airway disorders and chest wall 
deformity. 
Monitoring of respiratory function includes the use of pulse oximetry to provide 
continuous measurement of oxygenation and arterial blood gas analysis of PaO2 
and PaCO2. Additional monitors are used in specific situations such as peak 
expiratory flow for asthma and vital capacity in neurological conditions. 
Organ support can be provided with supplemental oxygen via nasal cannula or 
facemask. In more severe cases specialist equipment can be used to deliver high 
flow nasal oxygen, continuous positive airway pressure (CPAP) or non-invasive 
ventilation (NIV) in either a HDU or ICU environment. Invasive mechanical 
ventilation (IMV) involves the use of an endotracheal tube and requires ICU care. 
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There are many different modes of IMV but most provide delivery of a 
mechanically generated breath to facilitate oxygenation and carbon dioxide 
removal. 
Mechanical ventilation can be a life-saving intervention in acute respiratory 
failure. However, mechanical ventilation itself can cause damage to the lungs 
and can worsen or provoke acute respiratory distress syndrome. It is now well 
established that lung protective ventilation with low tidal volumes reduces 
ventilator induced lung damage and this strategy is now accepted as a standard 
of care.[5] Since the widespread adoption of lung protective ventilatory 
strategies there has been a reduction in mortality due to ventilator-associated 
lung injury.[6] 
In certain extreme circumstances IMV is insufficient to improve gas exchange and 
life-threatening hypoxia persists. Extra-corporeal membrane oxygenation (ECMO) 
involves circulating the patient’s blood through an external circuit that performs 
the functions of oxygenation and carbon dioxide removal before returning the 
blood to the patient. ECMO is only available in a few specialist centres and 
requires patient transfer to the nearest facility. 
 
1.1.2.2  Circulatory system 
The circulatory system is responsible for maintaining the flow of blood through 
the body and comprises the heart, blood vessels and blood volume. Critical 
illness can affect each of these components individually or in combination 
resulting in inadequate tissue perfusion and shock. If shock persists the function 
of vital organs becomes impaired and can lead to multi-organ failure. 
Haemodynamic monitoring is therefore of vital importance in the patient with 
critical illness [7]. 
Monitoring of the circulatory system requires blood pressure measurement either 
by the use of a non-invasive blood pressure cuff or with placement of an intra-
arterial catheter. Central venous catheters are frequently utilised in ICU to 
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allow measurement of central venous pressure (CVP) and central venous oxygen 
saturations in addition to providing a means for safe infusion of drugs. Cardiac 
output can be measured within the ICU setting by using dilutional techniques 
such as LiDCO and PiCCO, with oesophageal Doppler ultrasonography, or by 
insertion of a pulmonary artery catheter. 
Circulatory support includes fluid replacement and the provision of vasoactive 
drugs. These include vasoconstrictor medications to increase vascular tone and 
inotropic medication to increase cardiac output. Mechanical support in the form 
of intra-aortic balloon pumps, ventricular assist devices and cardiac-ECMO are 
generally only provided in cardiac ICUs where specialist expertise is available. 
Haemodynamic optimisation with adequate pre-load and inotropic support in 
patients with critical illness has been reported to reduce mortality [8].  
 
1.1.2.3  Renal system 
Renal dysfunction is common amongst critically ill patients. This arises as a 
result of hypotension or shock, sepsis, rhabdomylolysis, or nephrotoxic drugs [9]. 
Renal replacement therapy (RRT) is the use of haemodialysis or haemofiltration 
to support the kidneys. This is often employed temporarily in the ICU whilst the 
patient recovers from the initial insult. RRT is so effective that renal failure, as 
the only organ failing, is seldom a cause of death in the critically ill patient [10]. 
However, most patients in ICU requiring RRT have multi-organ failure (MOF) with 
associated respiratory and circulatory failure [9]. The development of acute 
renal failure in a patient with MOF indicates that this initial insult was severe 
and therefore the risk of death is high [11]. 
 
1.1.2.4  Other supportive care interventions 
In the past most patients in ICU received sedation whilst ventilated to improve 
synchronisation with mandatory modes of ventilation. However, sedation use is 
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associated with prolonged ventilator time and can leave patients vulnerable to 
delirium and critical illness weakness [12, 13]. With improvement in ventilator 
technology, sedative infusions are utilised less frequently and the majority of 
ICU patients are awake and thus able to have some form of communication with 
staff. This allows staff to monitor neurological function using Glasgow Coma 
Scale (GCS) and confusion assessment method for ICU (CAM-ICU) scoring systems. 
During their ICU stay, patients with critical illness may require artificial nutrition 
either as a consequence of sedation, inability to swallow (due to endotracheal 
tube) or impaired gastrointestinal (GI) function. Where possible this is provided 
as enteral nutrition via nasogastric tubes, although parenteral nutrition is 
occasionally required when enteral nutrition is not tolerated [14]. Artificial 
nutrition is commenced within the first 72 hours of their ICU stay and continued 
until the patient is able to recommence adequate oral intake. 
Blood glucose concentration is monitored during the critical illness as this is 
often elevated as a result of increased counter-regulatory hormones. 
Hyperglycaemia is avoided with the use of insulin infusions although target blood 
sugar ranges are higher than the normal physiological range [15]. 
 
1.1.3 ICU demographics 
While many medical specialties deal with specific body systems or organs, 
intensive care medicine manages patients with a wide range of diseases.  
Some hospitals have specialist ICUs that manage specific types of patients. 
These include paediatric intensive care (PICU), cardiac intensive care (CICU), 
neurological intensive care (Neuro ICU), and medical intensive care (MICU). Out-
with the specialist setting, patients admitted to general ICUs usually reflect the 
hospital case-mix and require multidisciplinary input. 
In 2009 Vincent et al described features of over 1200 ICUs across 75 countries 
that took part in the EPIC II study to document the point prevalence of 
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infections in ICU during a single day. The population comprised ICUs from 
Western Europe (53%), Central and South America (17%), Asia (11%), Eastern 
Europe (8%), North America (6%), Oceania (4%) and Africa (1%). They found that 
over 66% of ICUs admitted a general case-mix, the remainder being specialist 
units with 17% surgical, 11% medical and 7% a mixture of PICU, Neuro ICU and 
CICU [16]. Of over 13,000 ICU patients included in the study, 39% were admitted 
after emergency surgery, 23% were planned admissions after elective surgery, 
10% were admitted following trauma and 28% were medical admissions. Within 
this group the mean age was 60.7 years with a male preponderance at 62.3%. 
Internationally, there are wide variations in the number of ICU beds available. 
The UK has fewer ICU beds relative to acute hospital beds in comparison to other 
European countries. In Germany there are over 20 critical care beds per 100 000 
population (5.1% of all inpatient beds) compared with the United Kingdom where 
there are 6.6 critical care beds per 100 000 population (2.8% of all inpatient 
beds) [17]. The difference is even more marked in comparison to the United 
States of America (USA), where critical care accounts for around 9% of all 
inpatient beds [18]. This leads to critical care beds in the UK admitting more 
severely ill patients who, on average, require higher levels of organ support than 
those in other countries. This is demonstrated in the study by Wunsch et al that 
described mechanical ventilation rates of 68% in UK ICUs compared with 28% in 
ICUs in the USA [18].  
 
1.1.3.1  Scottish Intensive Care Society Audit Group 
The Scottish Intensive Care Society Audit Group (SICSAG) collects data on all 
patients admitted to ICU within Scotland, which is then summarised in an annual 
report. From this information the activity and outcomes across ICUs in Scotland 
can be compared and changes with time noted. The number of patients 
admitted to ICU has steadily increased over the past 10 years with an expansion 
in critical care bed numbers both in terms of level 2 and level 3 capacity. In 
2016 there were 10,870 patients admitted to general ICU with 56% of patients 
admitted to units in the West of Scotland [4]. This compares with 7,644 patients 
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admitted in 2005 [19]. Across Scotland in 2016 66% of patient admitted to ICU or 
combined ICU/HDU required level 3 care with 60% of patients receiving invasive 
ventilation, 50% of patients receiving cardiovascular support and 8% of patients 
receiving renal replacement therapy at some point during their ICU stay.  
 
1.1.4 ICU scoring systems 
Various attempts have been made to quantify severity of illness using scoring 
systems. These scores can allow comparisons or audit of different ICUs as well as 
an overall measure of health care standards. They can also be used as a method 
of bench-marking heterogeneous patient groups for research purposes, 
especially in non-randomised or observational studies [20]. 
Outcome in ICU depends not only on the level of care or medical input, but also 
the underlying pathology and pre-existing health of the patient. Advancing age, 
a greater severity of illness, co-morbidity, emergency surgery immediately 
before admission and the clinical condition necessitating admission all affect 
outcome and increase the risk of death. Scoring systems take account of these 
factors and the resulting score can be used to estimate outcome. 
A variety of scoring systems exist, some being disease specific and others 
generic. The first generic physiological scoring system that quantified severity of 
illness by patient factors was the acute physiology and chronic health evaluation 
score (APACHE) [21]. Subsequently the simplified acute physiology score (SAPS) 
[22] and mortality prediction model (MPM) [23] were developed. Another 
approach is to assess the degree of organ dysfunction by attributing a score to 
each organ system based on physiological parameters. This is the basis of the 
sequential organ failure assessment (SOFA) score [24]. 
Examples of disease specific scoring systems include Glasgow coma scare (GCS) 
for assessment of consciousness in patients with head injury [25], Ranson’s 
criteria for mortality prediction in acute pancreatitis [26], and Child-Pugh score 
in patients with chronic liver disease [27].  
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Scoring systems can give an estimate of mortality for a group of ICU patients but 
are not designed to predict individual patient mortality. Instead they are 
increasingly being used to compare the quality of care provided by different ICUs 
and hospitals. By providing mortality rates adjusted for severity of illness and 
case-mix ICUs can be benchmarked against similar institutions and their own 
performance over time can be monitored. 
 
1.1.4.1  Acute Physiology and Chronic Health Evaluation score 
The APACHE II score is the most widely used scoring system within UK ICUs. The 
original APACHE score was first used in 1981 [21] but was superseded in 1985 
[28] by APACHE II which was a simpler version. It combines scores based on age, 
co-morbidities and physiological parameters during the first 24 hours of ICU 
admission with a weighting on the acute physiology. It controls for case-mix and 
emergency/ non-operative admissions. APACHE II is measured during the first 24 
hours of ICU admission. Predicted hospital mortality can then be derived from 
this score and represents the proportion of patients that would be expected to 
die within a group of patients with the same severity of illness. The maximum 
APACHE II score is 71 with a score of 25 representing a 50% predicted mortality 
in non-operative patients and a score of greater than 35 representing a 
predicated mortality of 80% in all patient groups. 
APACHE II has only been validated for use within the ICU setting and is not 
validated for certain disease states such as patients undergoing coronary artery 
bypass grafting or patients with burns. It cannot be used as a tool on which to 
base admission decisions due to the requirement of data collected from the 24 
hours after ICU admission. 
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1.1.4.2  Simplified acute physiology score 
The SAPS II [22] calculates a score based on 12 physiological variables, age, type 
of admission and 3 variables related to underlying disease. Like APACHE the 
score is obtained from the worst values obtained during the initial 24 hours of 
admission to ICU. The score can then be converted into a predicted mortality 
that is represented as a percentage of patients within a similar population 
expected to die. 
 
1.1.4.3  Mortality prediction model 
The MPM II [23] (the second version of MPM) utilises commonly used variables 
such as physiology, chronic health status, and acute diagnosis to calculate a 
probability of in-hospital death. It can be calculated at the time of presentation 
and therefore has the theoretical advantage that it could be used as an ICU 
admission decision tool. However, it requires a complex mathematical 
calculation involving 16 variables thus making it cumbersome to calculate at the 
bedside and while the MPM system performs well at cohort level it cannot 
accurately predict the outcome for an individual. As such it is not routinely used 
for informing admission decisions. 
 
1.1.4.4  Sequential organ failure assessment 
The SOFA score [24] was initially used to describe the degree of organ 
dysfunction associated with sepsis but has since been validated to describe the 
degree of organ dysfunction in patient groups with organ dysfunctions not due to 
sepsis [29]. Six organ systems—respiratory, cardiovascular, central nervous 
systems, renal, coagulation, and liver are assigned a point based on physiological 
parameters and summed to give a total score of between 0 and 24. This score is 
calculated 24 hours after admission to ICU and repeated every 48 hours to give 
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sequential scores. Both the mean and highest SOFA scores are predictors of 
outcome. 
 
1.1.5 Determinants of survival in ICU patients 
Survival following critical illness will depend on a number of patient specific and 
critical illness factors. Organ dysfunction has been noted to impact upon survival 
with increased risk of death in patients with specific organ failure [30] and in 
those with increasing number of organ failures [31]. An early paper describing 
outcomes relating to organ failure was published by Knaus et al [32] in 1985. 
They described hospital mortality rates by the number of failing organs with 40% 
for single organ failure, 60% for two-organ failure and 98% for three-organ failure 
that persisted for three days. While this data is now historical in terms of 
current ICU practices and expected outcomes, it does demonstrate the impact 
that disease severity and associated number of organ failures has on mortality.  
Central nervous system failure encompasses a wide variety of presentations and 
has a strong impact upon survival. Subtle changes in cognition can be a sign of 
delirium and this has been demonstrated to have an impact on mortality 
following ICU, with hazard ratio for death of 3.2 [33]. The study by Mayr et al 
found relative risk of ICU mortality 16 times greater and hospital mortality five-
times greater in patients suffering CNS failure. The same study reported nearly a 
12-fold increase in ICU mortality and four-fold increase in hospital mortality for 
cardiovascular failure. Renal failure has also been demonstrated to be 
associated with poorer survival and patients that receive renal replacement 
therapy have a four-fold increase in hospital mortality [34].  
Outcomes following respiratory failure are linked to the underlying cause in 
addition to complications encountered during mechanical ventilation rather than 
the presence of respiratory failure itself [35]. The causes of respiratory failure 
are widespread and can be either due to direct pulmonary injury (such as 
pneumonia or COPD) or indirect in the case of Acute Respiratory Distress 
Syndrome (ARDS) secondary to many systemic processes (such as burns, 
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pancreatitis or sepsis). Higher hospital mortality is seen in patients with ARDS 
compared with other causes of respiratory failure (OR 1.44) [35]. 
Admission to ICU following an operative procedure is associated with a more 
favourable outcome than medical admissions. Hospital mortality is significantly 
lower for the post-operative group for all APACHE II scores up to a value of 30, 
such that APACHE mortality prediction takes account of this fact [28]. By 
dividing patients into operative and non-operative admissions, the study by 
Rowan et al demonstrated a mortality of nearly twice that in the non-operative 
ICU population at 37.6% compared with 19.1% in the post-operative ICU 
population [36]. Furthermore, there were significant differences between those 
undergoing elective surgery compared with emergency surgery with the latter 
having a hospital mortality nearly three-times higher (10.2 vs. 29.8%). 
Pre-existing factors will also impact upon outcomes in critical illness. Patient’s 
age has been demonstrated to have an association with hospital mortality 
increasing by 3-4% with each additional year [37, 38]. Co-morbidity influences 
survival following critical illness with higher mortality seen in patients with any 
significant comorbidity compared to those without [36]. This was most marked 
for patients with hepatic disease where hospital mortality was more than double 
that for patients without hepatic disease. Prior cardiopulmonary resuscitation 
(CPR) also had a negative impact upon outcome with over twice the hospital 
mortality seen in the population that did not require CPR.  
Severity of illness scores take account of many of these factors and are 
consistently demonstrated to be related to short-term outcome in patients 
admitted to ICU [35-39]. 
 
1.1.6 Short term survival after critical illness 
In 2016 over 80% of patients admitted to ICU in Scotland survived to hospital 
discharge [4]. This had been steadily improving but appears to have reached a 
plateau over the last 4 years. Most deaths occur within ICU with an approximate 
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ICU mortality of 14%. Standardised Mortality Ratio (SMR) is where the actual 
mortality is compared with the expected mortality calculated by APACHE II. 
Using a recently recalibrated APACHE II methodology, SMR for ICUs in Scotland 
was 0.9 in 2016. This would suggest that more patients are surviving ICU than 
would be expected from their adjusted APACHE II scores. 
The mortality rates due to infections and sepsis have decreased with the 
introduction of better antimicrobial agents and improved supportive care [40]. 
Large international research collaborations such as the “Surviving sepsis 
campaign” have played an important role in these improvements [41]. 
Interventions aimed at improving quality of care, such as standardisation of ICU 
processes and optimisation of organisational structures have also been reflected 
in improved outcome of intensive care patients [42]. Furthermore, 
establishment of multidisciplinary care teams has contributed to lowering of ICU 
mortality [43]. Collectively, these advances have improved the management of 
critically ill patients and resulted in increased survival. 
 
1.1.7 Recovery after ICU and longer term survival 
ICU survivors have an excessive risk of mortality that may take up to 15 years to 
return to the population baseline [44]. This increased mortality is most 
pronounced in older patients and those with severe co-morbidity. The duration 
of ICU delirium has also been associated with an increased one-year mortality 
[33]. 
Post intensive care unit syndrome (PICS) is the experience in an ICU survivor of 
impairment in cognition, mental health, or physical functions following discharge 
from ICU [45]. Post ICU cognitive impairment is common and in patients who 
suffer ICU delirium up to 71% will have continued cognitive impairment at one 
year [46]. Many ICU survivors will experience post-traumatic stress disorder as a 
result of traumatic or delusional ICU memories. A systematic review by Davydow 
et al. assessed the prevalence of PTSD and anxiety in ARDS survivors. They found 
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that the median prevalence was 28% (range 23 – 35%) and 24% (range 23 - 48%) 
respectively [47]. 
Critical illness has a significant impact on physical function both in the short and 
longer term. A recent UK study by Griffiths et al found that at one-year post 
discharge 22% of patients required assistance with activities of daily living, 54% 
had mobility problems and 70% experienced moderated to severe pain [48]. 
Patients with acute respiratory distress syndrome have been shown to have 
persistent exercise limitations and a reduced physical quality of life 5 years after 
their critical illness [49]. In ICU survivors who have experienced critical illness 
polyneuropathy, 84% to 95% will have continued neuromuscular dysfunction 5 
years after discharge [50, 51].  
PICS can have a significant impact on day-to-day living for those patients that 
survive ICU. For example, of those that were in employment prior to their ICU 
admission, only half have returned to work at one-year post ICU discharge [52] 
Quality of life (QoL) is an increasingly important measure of health-related 
outcomes. A large number of investigations have demonstrated reduced QoL 
measures following a critical illness that requires ICU admission. A systematic 
review of the literature pertaining to QoL in ICU survivors described reduction in 
QoL measures following ICU [53]. However, they also noted that ICU patients 
have reduced QoL at baseline (i.e. prior to ICU admission) when compared to the 
general population. While QoL measures fell after ICU they improved to baseline 
levels by 12 months post ICU discharge. However, only one study in the 
systematic review followed patients for the full 12-months. A more recent study 
by Cuthbertson et al followed patients for up to five years post ICU discharge 
[54]. This study described the same improvement in QoL in the first year, 
however, noted a subsequent deterioration in the physical components of QoL 
measures between 2.5 and 5 years. 
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1.2 Cancer 
Having described the role of the ICU in general, it is germane to define cancer 
and recent trends in outcomes before considering what is known about the two 
together. 
 
1.2.1 Definition of cancer 
Cancer is the term given to a collection of diseases where the body’s cells divide 
without stopping, ultimately spreading into surrounding and occasionally distant 
tissues. Cancer cells differ from normal cells in ways that allow them to grow 
out of control. This arises from genetic changes within the cancer cells that may 
have been inherited or due to damage to DNA caused by environmental exposure 
to carcinogens such as smoke, radiation or ultraviolet rays. 
There are more than 100 different types of cancer. Typically, cancer is named 
after the organ where the cancer originated (for example, lung cancer when the 
original cancerous cells started in the lung). However, cancers may also be 
described by the type of cell that formed them. Carcinomas are the commonest 
type of cancer and originate from the epithelial cells that cover the surfaces of 
the body. Subtypes of carcinoma include adenocarcinoma (epithelial cells that 
produce fluids or mucous such as breast, colon and prostate), squamous cell 
carcinoma (epithelial cells that lie just beneath the surface of the skin or organ 
such as stomach, lungs and intestines), basal cell carcinoma (originating in the 
epidermis of the skin) and transitional cell carcinoma (within the transitional 
epithelium of the urinary tract). Sarcomas are cancers that form within bone and 
soft tissues (including muscle, connective tissue and vessels). Osteosarcoma is 
the most common type of sarcoma and this can be subdivided further based on 
histological findings. Other solid tumour forming cancers include melanoma 
(cancer originating from melanocytes), germ cell tumours (cancer originating 
from cells that differentiate into sperm or eggs), and neuroendocrine tumours 
(cancer originating from cells that release hormones in response to CNS 
activation). Leukaemia, lymphoma and multiple myeloma are all cancers of 
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blood-forming and immune tissue and are regarded as types of haematological 
malignancies. 
 
1.2.2 Trends in cancer incidence and survival 
Over the last 10 years the number of cancers diagnosed in Scotland has 
increased from 27,095 cases in 2003 to 31,013 in 2013 [55]. Approximately 2 in 5 
people in Scotland will receive a diagnosis of cancer during their lifetime. The 
risk of cancer increases significantly with age and rates are increasing as more 
people live to an old age [56]. Prostate, lung and colorectal cancers account for 
52% of cancers in men, where breast, lung and colorectal cancers account for 
56% of cancer in women. While cancer rates are falling for males, there is an 
increasing trend for females and this is due to a combination of factors across 
different cancer types. Incidence of breast cancer has increased following 
improved attendance at the National Screening Programme. Increasing incidence 
rates for lung cancer in women are likely due to historic trends in smoking 
prevalence. Changes in factors associated with childbearing such as family size, 
maternal age at the birth of her first child and increases in levels of obesity may 
impact upon incidence rates of breast and uterine cancer, both of which are 
increasing.  
The prevalence is increasing as more people are living long enough to develop 
cancer and the survival following diagnosis improves. It is anticipated that, 
within the UK, the prevalence of cancer will increase over the next three 
decades by approximately one million cases per decade [57]. The majority of 
these patients are expected to be living with a cancer diagnosis made more than 
five years previously and may be considered to have “survived” their cancer.  
Survival following a diagnosis of cancer has been improving over the last 40 years 
[58]. However, survival rates vary significantly between tumour types, 
geographical areas, socioeconomic groups, age groups and ethnic backgrounds. 
Social deprivation is associated with poorer outcomes for all solid tumours and 
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this change has been consistent in spite of the overall trends in improved 
survival.   
Reasons for the improvement in life expectancy can be attributed to better 
prevention efforts, improved screening programmes, and treatment that is more 
aggressive and specific. Cancer care has been leading the way in personalised 
medicine and has been the forerunner for genomics guided precision medicine 
[59]. Gene sequencing can be used to better predict prognosis and response to 
different treatments thus allowing the clinician to match the patient to the most 
effective drug. In addition to advances in genomics there have been recent 
successes in anti-cancer immunotherapy such as the use of monoclonal 
antibodies to bind to cancer antigens [60]. With an increasing number of anti-
cancer treatment options and new combinations in modalities, there is the 
potential for a functional cure for many malignancies. These changes are 
transforming cancer into a chronic but treatable disease. 
 
1.2.3 Determinants of survival in cancer patients 
Multiple factors impact upon survival of patients with cancer. Tumour type is 
important, with significant variation in one-year survival reported for lung 
cancer (29.7%) when compared with breast cancer (94.2%) [61]. International 
variation exists such that outcomes vary for the same tumour type depending on 
the country of diagnosis. For example, one-year survival following colorectal 
cancer is 74.7% in England, Northern Ireland and Wales compared with 84.9% in 
Australia, 83.5% in Canada, 83.8% in Sweden, 82.4% in Norway and 77.7% in 
Denmark [61].  
One of the strongest influences on outcomes is cancer stage at presentation. 
Cancer staging varies by cancer type but generally takes into account the degree 
of local invasion, lymph node involvement and distant spread with poorer 
survival associated with more aggressive disease. Stage one generally means that 
a cancer is relatively small and contained within its originating organ. Stage two 
most commonly refers to a larger tumour but may also include local lymph node 
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spread. Stage three may indicate some local spread or lymph node involvement. 
Stage four indicates that the cancer has spread to another part of the body i.e. 
it has metastasised. Table 1-1 describes the one-year net survival for common 
tumour types at different stages at presentation [62]. Across all cancer types, 
one-year survival can be seen to decrease with increasing cancer stage. 
 
Site Sex Stage 1 
(%) 
Stage 2 
(%) 
Stage 3 
(%) 
Stage 4 
(%) 
Unknown 
stage (%) 
Bladder Men 95 71 67 35 59 
 Women 91 63 56 27 45 
Breast Women 100 99 95 63 85 
Colorectal Men 98 93 89 44 57 
 Women 98 91 85 35 50 
Kidney Men 96 89 95 38 73 
 Women 94 91 89 34 68 
Lung Men 81 66 42 15 23 
 Women 85 69 46 19 28 
Melanoma Men 101  97 92 47 91 
 Women 101  98 96 54 95 
Ovary Women 99 94 71 51 46 
Prostate Men 101 101 100 85 88 
Uterus Women 99 94 83 45 53 
Table 1-1 Age standardised one-year net survival for common cancers. Adapted from Office 
for National Statistics, Cancer Survival by stage at diagnosis Statistical bulletin [62]. Note: 
survival estimates take into account the normal rates of death in the general population and 
net survival is a measure of the extra deaths caused by the specific cancer. 
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Studies have shown poorer survival among cancer patients with co-morbidity, 
with hazard ratios ranging from 1.1 to 5.8 [63]. This may be due to the impact of 
co-morbidity on the cancer cells themselves or due to limitations to treatment 
choices. Performance status is an attempt to quantify cancer patients’ general 
well-being and ability to perform activities of daily living. This measure was 
developed to determine treatment options (particularly chemotherapy) but has 
been shown to be an independent predictor of survival [64-67]. The most 
commonly used assessment of performance status is the Eastern Cooperative 
Oncology Group (ECOG) score (Table 1-2) [68]. A score of three correlates with a 
prognosis of less than three months and a score of four with a prognosis of less 
than one month [67]. 
 
Grade   Criteria 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, 
office work 
2 Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to 
bed or chair 
5 Dead 
Table 1-2 ECOG Performance status with credit to the Eastern Cooperative Oncology Group, 
Robert Comis M.D., Group Chair. 
 
Poor socioeconomic status is associated with poorer survival in patients with 
cancer, with a review by Kogevinas and Porta reporting relative risks varying 
between 1 and 1.5 depending on cancer type. The largest differences were 
noted in patients with breast, uterine, bladder and colorectal cancers [69]. 
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Within the UK, patients with breast cancer belonging to the least deprived 
scocioeconomic group will survive, on average, one year longer than those from 
the most deprived group [70]. This might be explained by factors related to the 
cancer (such as more advanced disease at presentation), the patient (such as 
increased co-morbidity) or the cancer treatment (patients may have limited 
access to healthcare, be less able to advocate for themselves and are less likely 
to interact with screening programs).  
The treatment delivered and its intent will have an impact on survival times. 
Treatment combinations are tailored to the individual patient based on tumour 
type and stage, patient performance status and co-morbidities, and more 
recently based on the genomic profile of the patient and the tumour. Successful 
treatments given with the intention of cure will have the most favourable 
survival times. However, chemotherapy and radiotherapy may still have a role in 
extending life where cure is not possible.  
A systemic inflammatory response, as measured by elevated C-reactive protein, 
has been associated with reduced survival [71] and has led to the development 
of prognostic scores encompassing C-reactive protein and albumin measurement 
[72]. Activation of the systemic inflammatory response has a detrimental impact 
on the outcome of patients with cancer although it is unclear whether it is due 
to the cancer activating the response or a different pathology. This is of 
particular interest in patients with critical illness where the systemic 
inflammatory response is often excessive. 
 
 
1.3 Solid tumour patients in ICU 
Having set out the role of ICU, and then trends in cancer occurrence and 
outcomes, this section considers what is known about their co-existence. 
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1.3.1 Critical illness in patients with malignancy 
Cancer patients may require critical care due to a manifestation of their 
malignancy or a complication of their treatment, although there are times when 
the malignancy is not diagnosed until after ICU admission. Examples of oncologic 
emergencies that may require ICU treatment include malignant pericardial 
effusion, tumour lysis syndrome, hypercalcaemia of malignancy, or superior vena 
cava syndrome [73]. Patients with malignancy (particularly gastrointestinal, 
breast and lung cancers) have an increased risk of thromboembolic events. This 
risk increases with tumour stage and treatment with chemotherapy [74]. 
Pulmonary embolism may therefore precipitate ICU admission in patients with 
cancer. In patients with pelvic malignancy urinary obstruction can lead to renal 
failure, which may require ICU for temporary renal replacement therapy. While 
neurological presentations such as confusion, coma or seizures are uncommon, 
the resulting airway compromise means that ICU may be necessary to provide 
airway protection. All of these conditions may occur at any time to the patient 
with cancer and in some cases will be the first presentation of the disease. 
The most common drug-related cause of critical illness in cancer patients is 
sepsis following chemotherapy-induced immunocompromise. This may lead to 
respiratory failure, circulatory instability, acute renal failure or multi-organ 
failure with subsequent need for ICU care. Chemotherapy agents can also 
precipitate anaphylaxis, [75] nephrotoxicity, [76] myocardial infarction [77] or 
cytokine release syndrome [78] any of which may necessitate ICU admission. 
Those cancer patients that undergo surgical intervention are at risk of critical 
illness in the peri-operative period. This may be due to surgical complications, 
haemorrhage, or adverse drug reactions. Furthermore, some patients will 
require routine post-operative monitoring and support in an ICU if the operation 
has been extensive or the patient has any high-risk co-morbidities. 
Rarely, ICU admission is considered for patients with advanced cancer and no 
curative treatment options. Given the lack of subsequent cure an aggressive ICU 
approach should not be recommended for this patient group, however, short-
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term ICU admission may be appropriate for the management of reversible 
conditions, such as cardiac tamponade or seizures.  
 
1.3.2 Historical attitudes to cancer patients in ICU 
Due to the unpleasant and invasive nature of ICU care it has been reserved for 
patients for whom there is a likely benefit and where cure can be achieved. In 
the past, patients with cancer were considered poor candidates for ICU 
admission due to their underlying disease. Initial studies of cancer patients in 
ICU described a hospital mortality of 63 - 91% [79-81]. This resulted in 
reluctance among ICU physicians to admit, with cancer being the second most 
common cause cited for ICU refusal [82]. Furthermore, recommendations by a 
task force of the American College of Critical Care Medicine in 1999 suggested 
that patients with haematological or metastatic solid tumours should be 
considered poor candidates for ICU admission [83].  
As the outcomes for cancer improve it is no longer considered to be the terminal 
disease it once was. As more treatment options become available there is an 
increasing demand for these patients to be considered candidates for ICU care. 
Azoulay et al reported a 30-day mortality in mechanically ventilated cancer 
patients of 60.9% in those admitted between 1996 and 1998, a significant 
improvement when compared to a death rate of 81.8% in a historical cohort 
admitted from 1990 to 1995 [84]. More recently studies that report mortality in 
critically ill cancer patients have shown promising results with hospital mortality 
rates less than 50% in a study of cancer patients with respiratory failure [85] and 
as low as 30% in a large study of all ICU cancer admissions [86].  
In 2009, a study by Taccone et al compared survival of solid tumour cancer 
patients with that of a non-cancer population. They found that ICU and hospital 
mortality was similar in both groups (20% vs. 18%, and 27% vs. 23%) [87]. In 
general, the current literature shows a steady trend towards improved outcomes 
in patients with solid cancers admitted to the ICU. This evidence would suggest 
  
52 
that outcomes for critically ill cancer patients receiving ICU treatment are such 
that these patients should not be automatically excluded from ICU admission. 
 
1.3.3 Scoring systems and prognostication for cancer patients in 
ICU 
Estimates of prognosis and the appropriateness of ICU admission is a very 
challenging task but there are several validated measures that have been 
developed and widely used. Several professional societies provide guidelines for 
the admission of patients to the ICU. However, those guidelines contain little 
concrete advice for cancer patients. Reliable, specific evidence-based 
recommendations for the admission of cancer patients are currently lacking. 
Many investigators have assessed the predictive value of different criteria for 
the selection of cancer patients for critical care treatment. While disease 
severity scores such as APACHE II, SAPS II, or SOFA can be used to give a guide to 
short term prognosis they are not accurate enough to be used for informing the 
decision to admit individual cancer patients to the ICU [88, 89]. 
The ICU Cancer Mortality Model (CMM) was developed by Groeger et al to 
specifically predict outcome in critically ill cancer patients with initial promising 
results [90]. Soares et al. conducted a large study to externally validate the CMM 
along with assessing performance of other general scoring systems including 
APACHE, SAPS, and MPM [88].  While the CMM performed well, external 
validation did not find it to be superior to the general ICU scores. Of interest, 
this study found that the general scores tended to underestimate mortality while 
in contrast the CMM tended to overestimate mortality.  
Currently, there is no single scoring system that can be recommended for 
evaluating the eligibility of cancer patients for ICU admission. The inconsistent 
results regarding the prognostic value of many clinical parameters are likely a 
consequence of the considerable heterogeneity of the cancer patient 
population. Identifying those cancer patients who are likely to benefit from ICU 
remains challenging. A study by Thiery et al. found that physicians’ judgement in 
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this situation is an unreliable predictor of outcome for critically ill cancer 
patients [91]. Of the patients that were considered too sick for ICU admission 
according to the judgment of the Intensivist, 26% were still alive after 30 days 
and 16.7% at 180 days. Conversely, of the patients that were judged to be too 
well for ICU admission 21.3% died within 30 days. This would suggest that 
clinicians are unreliable at predicting outcomes in this group of patients. 
The evolution of organ dysfunction in response to aggressive treatment may be a 
more reliable predictor of outcome than clinician judgement or static 
parameters or scores. Rather than basing the decision to provide intensive care 
therapy on static parameters that can be assessed at the time of admission, the 
choice to continue full organ support should be based on the trajectory of the 
patient’s condition. In a study by Lecuyer et al. any cancer patient with an 
unclear benefit from ICU admission was admitted for full treatment with 
reassessment of the patient’s condition at pre-specified intervals [92]. From this 
study they were able to demonstrate that patients with new organ failure after 
day three or deteriorating organ dysfunction scores were unlikely to survive. 
Based on these findings the authors recommend that this ‘ICU trial’ strategy 
should be applied to any critically ill cancer patient with any potential to benefit 
from ICU care with early assessment of response. A recent simulation study 
comparing time-limited ICU care to time-unlimited aggressive care found that in 
patients with solid tumours a trial duration of up to four days offered mean 
survival that was not significantly different from time-unlimited care [93]. 
 
1.3.4 Short term survival of solid tumour patients in ICU 
Currently, patients with malignancies account for approximately 13 to 21.5% of 
all ICU patients [86, 87]. The reported mortality rates for cancer patients 
treated in the ICU vary widely. These variations are partly the result of 
international differences in ICU admission policies and also due to dissimilarities 
in types of tumour and reasons for admission. Patients with solid tumours are 
often admitted to critical care after definitive treatment of the malignancy and 
at times for routine post-operative care. These patients generally have a good 
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prognosis and low hospital mortality, recently reported as 4.7% in those patients 
after elective surgery [94]. Emergency surgical admissions to ICU have a worse 
severity of illness score and in the same series were found to have a higher 
hospital mortality of 17.4% [95]. Furthermore, patients admitted with a medical 
diagnosis had the highest severity of illness scores and a hospital mortality of 
44.6%. Similar results have been reported in a study by Soares et al. that 
described hospital mortality rates of 11% for elective surgical patients, 37% for 
emergency surgical patients and 58% for medical patients [86]. Variations in case 
mix between individual studies will therefore have significant impact on 
reported outcomes and should be interpreted accordingly. 
Due to improvements in critical care, several prognostic factors that have 
previously been important predictors of poor outcome have become less 
relevant. For instance, neutropenia has been a major negative prognostic factor 
but with increasing availability of better antimicrobial agents and granulocyte 
colony stimulating factor (G-CSF), the significance of neutropenia for the 
prognosis of cancer patients has decreased [96-98]. Sepsis, however, has 
continued to be associated with an increased mortality in spite of the 
improvements of supportive care [97, 99, 100]. 
Negative predictive factors, which have remained relevant over time are age, 
performance status, need for mechanical ventilation and multi-organ failure.  
Despite advances in intensive care management, age and poor performance 
status have maintained their negative prognostic value with poor performance 
status associated with increased hospital mortality between two- and six-fold 
[86, 99, 101, 102]. Organ failure has a significant impact upon short-term 
outcomes. Mechanical ventilation increases mortality by approximately six-fold 
[103, 104] and acute renal failure is predictive of poor outcome especially if 
dialysis is required [105, 106]. Vasopressor requirement has also been found to 
confer a negative prognosis in the short term [100, 103, 107]. Increasing number 
of organ failures is associated with a corresponding decrease in survival. Taken 
together, the data demonstrate that severity of disease is the major 
determinant of outcome in critically ill cancer patients. Individually, these 
factors can identify patients with a worse prognosis but by themselves are 
insufficient to determine the appropriateness of ICU admission. 
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While underlying tumour type has not been demonstrated to be associated with 
short-term outcomes [86], the stage of the cancer may be important. Studies by 
Mendoza et al. and Fisher et al. have both demonstrated that in patients with 
solid tumours, metastatic disease was independently associated with hospital 
mortality [107, 108]. This has also been demonstrated in patients with head and 
neck cancer [102]. Furthermore, recurrence or progression of cancer status was 
associated with hospital mortality in a study by Soares et al. [109] looking at 
cancer patients on ventilatory support. However, the results are not all 
consistent across all published studies. Tumour stage was found to be unrelated 
to short term outcome by studies by Taccone [87], Christodoulou [101] and 
Maccariello [105]. 
This initial review of the literature suggested that there were large variations in 
reported outcomes among ostensibly similar patient groups. It was therefore felt 
that a systematic review was indicated to comprehensively identify all relevant 
literature and to identify, if possible, the underlying explanations for variations 
in outcomes between studies. 
 
1.3.5 Longer term outcomes in solid tumour patients after ICU 
Since the majority of studies to date have assessed short-term survival, less is 
known about the longer-term outcomes of cancer patients with critical illness. In 
2000 Staudinger et al. published a study that compared one year mortality of ICU 
cancer patients with a group of ICU patients without cancer and a group of 
cancer patients that did not require ICU [110]. The ICU cancer group had a 
mortality rate of 78%. This compared to 37% in the ICU group without cancer and 
44% in the cancer group who were not admitted to ICU. While there are clear 
differences between the groups, this study is on a historical cohort and both ICU 
and oncological therapies have developed significantly in the intervening years. 
Whether this degree of difference still exists between groups is unknown. 
More recently, a European study described a cohort of ICU cancer patients with 
a one-year mortality of only 36% [111]. However, this group consisted of a large 
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proportion of elective surgery patients and had a very low ICU and hospital 
mortality at 5% and 13% respectively. This may not represent longer-term 
outcome for the standard UK ICU patient. A recent UK study found that 6 month 
mortality in ICU patients with solid tumours was 47.8% [112]. This study was 
performed in a group of patients admitted to an oncological ICU where admission 
patterns may vary from that seen in general ICUs. Longer term survival has been 
demonstrated to be particularly poor in those patients with metastatic disease, 
with a one year mortality of 88% and two year mortality of 97.6% [113]. 
Long-term quality of life is an important concern in cancer patients that survive 
ICU treatment. Oeyen et al. report that quality of life measures in patients with 
solid tumours decrease significantly after an ICU admission and remain below 
baseline at one year [111]. Intensive care treatment of cancer patients is 
therefore associated with a reduced quality of life in survivors.  
 
1.3.6  The future of critical care for cancer patients 
While there is an established volume of literature pertaining to outcomes in 
critical illness, there remains a paucity of information pertaining to the group of 
patients with an underlying malignancy. Although many problems that are 
encountered in critically ill cancer patients also apply to patients without 
cancer, this patient population has specific characteristics and needs. The rising 
number of patients with malignancies and the resulting increase in cancer 
patients for whom intensive care is required has led to a growing recognition of 
the need for evidence-based recommendations for the management of critically 
ill oncology patients. 
In the face of major advances in both critical care and oncology, cancer critical 
care is likely to continue to develop. Innovations in oncology will result in 
therapeutic options for a greater number of patients but this is likely to come at 
the cost of a greater burden of critical illness. While the literature to date 
suggests that outcomes for cancer patients in ICU are improving, it falls short of 
providing evidence to guide ICU admission policies. Further detail of which 
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cancer patients are admitted to ICU and how survival varies by underlying 
clinical features is needed to allow clinicians to prognosticate with critically ill 
cancer patients about the likelihood of a good outcome following ICU admission. 
 
 
1.4 Summary of aims and research questions 
Cancers are common among ICU patients but the literature identified in a 
conventional review suggests that a systematic appraisal is needed to better 
understand large variations in reported outcomes. With this work I aim to 
provide a better understanding of the specifics of ICU care for cancer patients 
and how the survival following critical illness is different in ICU patients with 
cancer from those without. Furthermore, in addition to short-term outcome I 
will also describe longer-term survival. 
I aim to address the following research questions: 
 
1.4.1 What is already known about short and long-term outcomes 
for patients with solid tumours admitted to ICU? 
To inform data analysis it is first important to understand what is already 
published on this topic. I will perform a systematic review of the literature 
pertaining to survival of cancer patients after ICU admission.  
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1.4.2 What proportions of cancer patients are admitted to ICU and 
what are the features associated with admission? 
To gain a better understanding of the risk of critical illness in cancer patients it 
is first necessary to establish the baseline rate of ICU admission among cancer 
patients and to then describe how it varies by patient and cancer specific 
features. For each cancer type it is important to document the likelihood of ICU 
admission, as this will be influenced by underlying pathology and treatment 
regimes. Due to these differences it is possible that mortality rates will vary by 
cancer type and it is imperative to describe not just overall mortality for ICU 
cancer patients but also mortality for each tumour type. 
 
1.4.3 What proportions of patients admitted to ICU have a 
diagnosis of cancer and how do they differ from the non-
cancer ICU population? 
There is a limited understanding of the clinical indications for ICU admission 
among patients with cancer and how they are managed during their ICU stay. It 
is therefore of value to describe the proportion of cancer patients within the ICU 
population and how they differ from the non-cancer population in terms of 
reason for admission, severity of illness, organ support and mortality.  
 
1.4.4 What are the longer-term outcomes of cancer patients who 
have survived an ICU admission?  
ICU and hospital survival are inadequate end-points for most patients who are 
looking for a more meaningful period of survival. It is understood that ICU 
survivors have a higher mortality rate than the general population for several 
years following ICU discharge. It has not yet been demonstrated how this 
increased mortality risk interacts with a co-morbidity such as cancer. It would be 
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of significant value to understand how long term mortality differs between ICU 
survivors with and without cancer and which factors are associated with changes 
to mortality risk. 
 
 
1.5 Key points 
 The ICU is the area within the hospital where the sickest patients are 
managed. Within this setting it is possible to temporarily support or replace 
the function of multiple failing organs while the patient recovers from 
critical illness. 
 Mortality is high after admission to ICU, with recent figures for Scotland 
reporting a hospital mortality of 20%. This is largely determined by the 
severity of critical illness. 
 Morbidity following ICU is common and ICU survivors have an excessive risk of 
mortality that takes years to return to the population baseline. 
 Cancer patients may require ICU care due to a manifestation of their 
malignancy or a complication of their treatment and approximately 13 – 
21.5% of ICU patients have an underlying malignancy. 
 Historically, cancer patients were not considered good candidates for ICU 
admission. However, with recent improvements in ICU and hospital mortality 
for cancer patients this general rule no longer holds true. 
 In spite of the significant proportion of cancer patients within ICU little is 
known about which factors are associated with admission and subsequent 
clinical progress. 
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Chapter 2 Survival in solid cancer patients 
following intensive care unit admission: a 
systematic review and meta-analysis 
2.1 Introduction 
While there have been a number of reports on outcomes of cancer patients after 
admission to ICU, the large variations in reported outcomes suggest that there 
may be significant differences in the case-mix or care provided. There has been 
no attempt to systematically review the literature on outcomes of cancer 
patients after ICU admission. The aim of this chapter was to assess mortality 
among cancer patients admitted to ICU by carrying out a systematic review of 
published studies. 
 
 
2.2 Methods 
A systematic review attempts to identify, appraise and synthesise all the 
evidence that meets pre-specified eligibility criteria to answer a given research 
question. This requires an explicit and reproducible protocol to locate and 
evaluate the available data. By providing a summary of all the available studies 
addressing a specific clinical question, systematic reviews take into account all 
relevant findings from research on a particular topic and not just the results of 
one or two studies known to the author. As a result they can be used to establish 
whether findings are consistent and generalisable across populations and settings 
or whether they vary by particular subgroups. As the methods used in systematic 
reviews are explicit, any potential bias should be clear to those appraising the 
review. 
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Prior to performing the systematic review I consulted the Cochrane Handbook for 
Systematic Reviews of Interventions [114]. This identified the need for a well-
framed question specifying the population, intervention and outcomes to be 
studied, in addition to ensuring definition of eligibility criteria. It emphasised 
the need for a robust search strategy to ensure identification of all possible data 
and methods of data collection, in addition to advice of data analysis and 
assessment of the risk of bias. 
A meta-analysis involves the combination of results of individual studies to 
produce an overall statistic with the aim of providing a more precise estimate of 
an effect. Advantages of a meta-analysis include an increase in power, an 
improvement in precision and the ability to analyse data not fully interpreted by 
the individual studies. However, they can be misleading where studies are 
included with significant biases or where there is variation across studies. 
Heterogeneity across the studies should therefore be reported when performing 
a meta-analysis. 
 
2.2.1 Study question 
Among patients with a solid tumour (population) that are admitted to ICU 
(intervention) what are the subsequent survival rates (outcomes)? 
 
2.2.2 Study identification and eligibility criteria 
Studies were included if they reported survival outcomes in patients with known 
solid tumours who had been admitted to intensive care. Studies that reported 
outcomes for a mixed group of solid and haematological malignancies were 
excluded, as survival in haematological cancers has been associated with 
consistently poorer ICU survival. 
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2.2.3 Search strategy 
OVID MEDLINE and EMBASE to April 2014 were searched using a combination of 
medical subject headings (MeSH), title and abstract keywords. The MeSH terms 
“neoplasm” and “critical care”/ “intensive care”/ “intensive care units”/ 
“critical illness” were exploded and articles containing both terms were 
combined. We then searched for the terms “death”, “mortality”, “surviv$”, 
“prognos$”, “hospital$” or “outcome”. Articles that featured in both searches 
were then limited to human studies published in English. Paediatric studies and 
review articles were excluded from the search.  
 
2.2.4 Study selection and data extraction 
From the initial search results, a title review was performed by two separate 
reviewers as per Cochrane recommendations [114]. At this stage editorials, 
letters or case reports were excluded. Studies were required to report survival 
outcomes in patients with solid tumours who were admitted to ICU. Where only 
one reviewer felt that the title might represent an article of interest the 
abstract was sought. The abstracts were then scrutinised by both reviewers to 
ascertain whether the article was of significance for this study. The full texts of 
all relevant articles were then obtained.  
Studies were excluded if outcomes were reported for a group of cancer patients 
consisting of a mix of solid tumours and haematological tumours, if the study 
reported outcomes from a study population that had already been included in 
another study or if the study population entirely pre-dated 1st January 2000. This 
latter criterion was chosen to ensure ICU care was relatively contemporaneous 
with current management practices [5, 115, 116]. 
The following information, where available, was collected: study design, 
country, year of data collection, total number of patients and type of ICU. Data 
describing the study population including mean/ median age, severity of illness 
score (APACHE II/III, SAPS II/III, SOFA) and the mix of tumour types were also 
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collected from each paper. Several studies reported the severity of illness scores 
and average age for a mixed cohort of patients with solid and haematological 
tumours and did not differentiate these demographics for patients with solid 
tumours. We did not place any restrictions on these studies. Reported survival 
data was collected. This was most commonly ICU mortality, hospital mortality, 
6-month mortality and 1-year mortality. The authors were contacted for 
additional information when clarification was required. 
STROBE criteria for reporting on cohort, case-control, and cross-sectional studies 
were used to examine what was reported in each study [117]. This included 
features pertaining to study design, variables, data sources, participants, 
descriptive data and outcome data. 
 
2.2.5 Distribution of mortality estimates 
All statistical analyses were performed using Stata version 13.1 (Stata 
Corporation, College Station,TX). 
ICU and hospital mortality with exact 95% confidence intervals (CIs) were 
calculated for each study. With statistician input, the average of the reported 
mortality distribution with 95% CIs was calculated using a meta-analysis 
procedure (Freeman-Tukey). The extent of variation between study outcomes 
was measured by Mr Philip McLoone, statistician, using the I2 statistic. This 
indicates the proportion of the total variation across study outcomes 
attributable to heterogeneity. Values greater than 50% suggest substantial 
heterogeneity.  
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2.2.6 Contributors 
Dr David Morrison acted as the second reviewer during paper selection as 
described earlier. Statistical analysis for this chapter was performed by Mr Philip 
McLoone, Statistician.  
 
2.3 Results 
2.3.1 Study selection 
Electronic database searches identified 668 references to April 2014, of which 47 
papers were included in the final selection. The studies broadly fell into two 
groups: those reporting on a mixture of solid cancers together and those 
reporting on specific tumour types. Details of the selection processes are 
described in Figure 2-1.   
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Figure 2-1 Selection of studies for inclusion. Modified from “Survival in solid cancer 
patients following intensive care unit admission” Puxty et al. Intensive Care Med (2014) with 
permission. 
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2.3.2 Description of included studies and assessment of bias 
Forty-seven studies that reported mortality (including short-term ICU or in-
hospital mortality) for patients with solid tumours after admission to ICU were 
identified. These studies and their study population are described in Appendix 1 
(Tables 8-1 and 8-2) [85-87, 92, 95, 97, 99, 101-107, 111, 113, 118-149]. The 
populations vary widely in terms of the mix of tumour types, ICU characteristics, 
survival analysis and overall study aim. 
 
2.3.2.1  Studies that report on an unselected general ICU population with a 
mix of cancer types 
Eight of the identified studies reported outcomes for an unselected group of 
patients (in terms of ICU and cancer features) admitted to general ICUs. These 
studies best describe the target population of patients with unspecified solid 
tumours admitted to ICU. 
Bos et al described the largest single cohort of patients [95]. This multi-centre 
study collected data on all cancer patients with an unplanned admission to ICU 
in the Netherlands between 2007 and 2011. This cohort included 12,290 patients 
with solid tumours of which 30% had metastatic disease. The cancer patients 
were compared to a group of 124,943 non-cancer patients with an unplanned 
admission to ICU. The authors described the medical and surgical population 
separately due to the differences in demographics, severity of illness and 
outcomes. Short-term survival is reported as ICU and hospital mortality. Data 
was collected retrospectively from a national ICU database. Cancer patients 
were identified where the reason for ICU admission made reference to 
malignancy. It is possible that this under-represents the ICU cancer population if 
cancer patients are coded with a diagnosis that does not directly reference their 
cancer (for example, a chest infection in a patient with lung cancer).  
The study by Christodoulou et al, based in a single centre general ICU in Greece 
between 2001 and 2005 reported on 69 patients with a mixture of solid tumours 
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admitted to ICU [101]. This cohort of patients had a number of poor prognostic 
features; 89.9% of included patients had metastatic disease, a significant 
proportion of patients had lung cancer (39.1%) and over a third of the group 
were classified as performance status 3-4. Therefore overall outcomes may be 
expected to be poor. The study aimed to identify factors that were predictive of 
short-term outcome and the authors reported ICU and 30-day mortality. 
Kopterides et al described the admission characteristics and severity of illness 
scores of cancer patients admitted to two general ICUs in Greece from 2005 to 
2007 [99]. This included 90 patients with solid tumours of which there were a 
reasonable mix of common cancer types. Data had been collected prospectively 
allowing for reliable information pertaining to the cancer type and the critical 
illness. The objective was to compare the effectiveness of APACHE II, SAPS II and 
SOFA as prognostic models within the cancer population and ICU mortality was 
reported as part of this. The severity of illness scores for this population were 
suggestive of a population with a moderate burden of critical illness. 
Mendoza et al have reported on 147 patients with solid tumours admitted to a 
single centre general ICU in the USA from 2003 to 2004 [107]. Patients were 
identified by retrospective analysis of an ICU database and case note review was 
subsequently performed. Their population represented most of the common 
tumour types and metastatic disease was present in 51.7% of these patients, 
suggesting a group of patients with advanced malignancy. Severity of illness was 
not reported for this group, however, 63% received invasive mechanical 
ventilation, 45% received vasopressors and 10% received renal replacement 
therapy suggesting a moderate degree of critical illness. They described hospital 
mortality and the proportion of patients that were discharged home. 
Oeyen et al have described a cohort of mixed cancer patients admitted to a 
general ICU in Belgium between 2008 and 2009 [111]. This included 398 patients 
with solid tumours of which 46% had metastatic disease. Data was collected 
prospectively allowing reliable detailing of cancer and severity of illness. Median 
APACHE II score was 13 and SOFA score 3 representing relatively low level of 
organ support provided (29% IMV, 8% vasoactive drugs, 4% RRT). It is likely that 
this reflected the high proportion of patients that were admitted following 
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elective surgery (71%). It is therefore possible that the population described had 
a large quantity of HDU-type patients that were admitted for post-operative 
monitoring only. These types of patients were routinely excluded from other 
studies, as they may not represent typical ICU patients. This study described 
survival up to one year following ICU admission. This study also assessed quality 
of life measures in cancer patients following ICU admission. 
In 2010, Soares published a multi-centre study that included all patients with 
cancer admitted across 28 ICUs in Brazil over a two-month period in 2007 [86]. 
The majority were general ICUs (82%) although a small proportion were 
dedicated oncological ICUs (18%). There were a total of 717 patients with 
cancer, of which 667 patients had solid tumours and 29.1% had metastatic 
disease. The characteristics of those patients are described in addition to 
outcome analysis and description of variables associated with mortality. The mix 
of tumour types was representative of the common malignancies. More than half 
of the patients with solid tumours were admitted to ICU following elective 
surgery. This group had multiple favourable features including good performance 
status, low severity of illness scores, fewer comorbidities and low utilisation of 
organ support. These patients were more likely to represent level 2 admissions 
rather than the sicker level 3 ICU populations and as such outcomes would be 
expected to be better. 
The study by Taccone et al is a sub-study of the Sepsis Occurrence in Acutely Ill 
Patients (SOAP) study [87]. The SOAP study collected a large volume of data on 
all patients admitted to one of 198 general ICUs across Europe during a two-
week period in 2002 and aimed to describe the incidence of sepsis among the 
population. Of the 3,147 patients enrolled, 473 patients had a malignancy of 
which 404 patients had a solid tumour and 24.8% had metastatic disease. This 
study was able to compare the demographic characteristics, critical illness 
features and survival outcomes of patients with solid tumours to those patients 
with haematological tumours (n= 69) and those patients without cancer (n= 
2,674). This was a large multi-centre study with robust prospective data 
collection. While information pertaining to the ICU features is detailed, there is 
limited description of the cancer group beyond the term “solid tumour” with and 
without metastatic disease. Given that this study collected patient data from 
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nearly 200 sites it seems likely that it represents a large mix of the common 
tumour types. 
Unseld et al describe those patients with malignancy admitted to a general ICU 
in Switzerland in 2002 [147]. Patients were identified retrospectively using a 
hospital database. This included 42 patients with solid tumours with a high 
proportion of urogenital tumours. As a single centre study, the case-mix would 
have been determined by the specific specialties practicing within that hospital 
and may not represent the cancer population as a whole. They reported ICU, 
hospital and one-year survival and described outcome by the number of organ 
failures present. 
 
2.3.2.2  Studies that report on a specialist oncological ICU population with a 
mix of cancer types 
Seven studies reported on outcomes from single centre oncological ICUs. While 
oncological ICUs benefit from having a large number of patients with cancer on 
which to report it is unlikely that the case-mix will be similar to that seen in 
general ICU in terms of the presenting critical illness. 
Caruso et al have described a population of 83 patients with metastatic solid 
cancer admitted to an oncological ICU in Brazil over a one-year period [113]. 
They went on to report short and long-term survival up to two years, as well as 
assessing which factors were associated with hospital mortality. The cohort 
included a mix of common cancer types with a moderate degree of critical 
illness as demonstrated by severity of illness score and organ support.  
Chawla et al report on a small group of patients within a single centre 
oncological ICU who were admitted to ICU within 48 hours of planned or actual 
discharge from hospital [125]. This included 21 patients with solid tumours. The 
purpose of the study was to determine incidence, reasons for, and outcomes of 
patients with cancer admitted to the ICU shortly after planned or actual hospital 
discharge. In addition they analysed whether the need for ICU admission was 
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related or unrelated to the previous/ current hospitalisation. The inclusion 
criteria meant that only a subgroup of the ICU cancer admissions were included 
and therefore they may not be representative of the overall ICU cancer cohort. 
The group did not report any severity of illness scores although mechanical 
ventilation and vasopressor medication was utilised for 60% and 32% of all 
patients respectively. 
The study by de Almeida et al described a population of patients with 
malignancy admitted to a single centre oncological ICU in Brazil during 2009 
[127]. This included 106 patients with solid tumours of which 35.2% had 
metastatic disease. The severity of illness score reported was low, suggesting a 
low threshold for ICU admission. Although data was collected prospectively, the 
authors did not report the underlying tumour types that contributed to the solid 
tumour group. Therefore it was not possible to comment on whether they were 
representative of the general solid tumour population. The study was designed 
to assess the impact of positive fluid balance on survival in this group of 
patients. In addition to ICU mortality they also assessed which factors were 
associated with mortality. 
The study by Libório et al was set in a single centre oncological ICU in Brazil 
[106]. Patients with cancer admitted from 2006 to 2008 were included of which 
there were 258 patients with solid tumours made up of a standard mix of tumour 
types. Severity of illness scores in this group of patients were lower than many 
of the other studies with a mean APACHE II score of 10.3, SAPS II 35 and SOFA 
5.8. The study went on to evaluate the discriminatory value of RIFLE 
classification of acute kidney injury (AKI) versus other prognostic scores in 
predicting hospital mortality. 
McGrath et al have described cancer patients admitted to a single centre 
oncological ICU in the UK over 2004 to 2008 [131]. This included 70 patients with 
solid tumours. Commonest tumour types included lung (21.4%), breast (15.7%), 
oesophageal (11.4%) and ovarian (5.7%) suggesting tumours that may have been 
treated with aggressive chemotherapy. Metastatic disease was relatively 
common within the group at 41.4%. Severity of illness scores suggested a slightly 
lower burden of critical illness than that described in many of the other studies, 
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although patients admitted for routine post-operative monitoring were excluded 
from analysis a priori. The authors reported survival at ICU discharge and at six 
months.  
The first of the studies by Namendys-Silva et al was published in 2010 and 
described 177 patients with solid tumours admitted to a single centre 
oncological ICU during 2007 [134]. There was a wide mix of tumour types 
included although the presence of metastatic disease was not reported. Median 
APACHE II score was 12 and SOFA score 3 suggestive of an overall low severity of 
critical illness that may not accurately reflect a standard ICU population. With 
this study the authors aimed to describe demographic, clinical and survival data 
(including median survival time) and to identify factors associated with 
mortality.  
Soares et al has published several outcome studies on a cohort of patients from 
May 2000 variously to December 2004 [150], to December 2005 [151] and to 
January 2004 [109, 141]. We chose the single most comprehensive of these 
papers, “Impact of two different comorbidity measures on the 6-month mortality 
of critically ill cancer patients” published in 2005, [141] for inclusion in the solid 
tumour analysis. This paper described 772 cancer patients admitted to a single 
centre oncological ICU in Brazil from 2000 to 2004 and excluded routine post-
operative admissions. Within this group there were 642 patients with a solid 
tumour diagnosis of which 21.4% had metastatic disease. Common tumour types 
were all represented within the cohort. SOFA and SAPS II scores indicated 
patients had a moderate severity of critical illness. Data collection was 
prospective and appeared robust in methodology. 
 
2.3.2.3  Studies that report on cancer patients with a pre-specified critical 
illness feature on admission to ICU 
Features associated with the critical illness are likely to influence the short-term 
outcomes. By selecting out specific features such as respiratory failure, multi-
organ failure, renal failure or septic shock, it would be expected that these 
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groups were not necessarily representative of all ICU patients with cancer. Nor 
would they have the same survival outcomes. Eleven of the identified studies 
assessed outcomes for a group of cancer patients with a specific feature of their 
critical illness. 
The single centre study by Azoulay et al was on a mixed cohort of cancer 
patients of which there were only 19 patients with solid tumours (ten lung 
cancer, nine breast cancer) admitted to a general ICU in France between 1997 
and 2002 [85]. All patients were admitted with acute respiratory failure. Survival 
was described in addition to those factors that were associated with mortality. 
The admission dates to ICU span the 1st January 2000 cut off and the study only 
identified a subset of the ICU cancer population. However, the number of 
patients in this study was small and unlikely to overly bias the pooled results. 
Darmon et al reported on a population of patients requiring admission to a single 
centre general ICU in France from 1997 to 2003 [103]. All patients had a new 
diagnosis of inoperable malignancy (within previous 30 days) and organ failure 
necessitating ICU admission. In addition, patients had been deemed to be in 
need of immediate chemotherapy due to life-threatening cancer complications. 
Within this cohort of 100 patients there were 12 patients with solid tumours. The 
objective was to determine outcomes in patients with a new cancer diagnosis, 
organ failure and treatment with chemotherapy in the ICU environment. More 
than half of the data collection period occurred prior to 2000 and as such may 
not reflect contemporary ICU practice as previously discussed. The mix of 
tumour types was unusual with soft tissue sarcomas and adenocarcinoma of 
unknown primary making up more than half of the cohort. This may be reflective 
of the case-mix within this single centre hospital or alternatively due to the 
inclusion criteria of inoperable tumour requiring immediate chemotherapy. 
Although this group may not represent the standard mix of solid tumours the 
number is small and unlikely to significantly bias the pooled results of this meta-
analysis. 
Lecuyer et al studied all consecutive admissions to ICU with active malignancy 
that required mechanical ventilation and at least one additional organ failure 
[92]. Patients were excluded if they had a previously untreated malignancy, 
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acute tumour lysis syndrome, bulky or infiltrating tumours at the earliest phase 
of treatment or patients who were in complete remission. Patients were then 
entered into an “ICU Trial” with full aggressive treatment for four days 
followed, on day five, by a reappraisal of the appropriate level of care based on 
response to treatment. The study was set in a single general ICU in France over 
2001 to 2004 and within this cohort there were 56 patients with solid tumours. 
By specifying mechanical ventilation with at least one additional organ failure 
the study was reporting outcomes for a group of cancer patients with multi-
organ failure and as such short-term mortality would be expected to be 
significantly poorer than that for an unselected group of ICU cancer patients.  
Maccariello et al report on 773 consecutive patients in ICU that required renal 
replacement therapy (RRT) for AKI within general ICUs in Brazil from 2004 to 
2008 [105]. This group included 86 patients with a variety of common solid 
tumours of which 31.4% had metastatic disease. They compared short-term 
outcomes in the cancer group to a group of non-cancer ICU patients with AKI 
requiring RRT. The use of RRT within the general ICU cancer population tends to 
be low and therefore this study was not necessarily representative of overall ICU 
cancer patients. Furthermore, severity of illness scores in this study were higher 
than that reported by many of the others suggesting a higher burden of critical 
illness within the population of ICU cancer patients with AKI. 
Mourad et al have described a cancer population admitted to an oncological ICU 
in France during 2009 to 2011 with septic shock requiring vasopressor therapy 
[133]. The aim of the study was to assess the impact of early diastolic 
dysfunction, identified using echocardiography, on ICU mortality. They excluded 
patients with underlying heart disease. Within this group there were 26 patients 
with solid tumours. There were a number of features suggestive that this group 
was not representative of the general ICU cancer population. The study was 
performed in a single centre oncological ICU where the case-mix may be 
different from that seen in general ICUs. The authors did not report the cancer 
types included nor the proportion of patients with metastatic disease, which 
may have influenced outcomes. Median SAPS II was 57 and SOFA 11 for all 
patients, which is among the highest of all severity of illness scores across the 
included studies (although this is a median value for all patients within the study 
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including those with haematological malignancies). As such ICU mortality would 
be expected to be higher than that seen for the more general group. The authors 
reported ICU mortality and identified factors that are associated with outcome 
in this subset of extremely unwell ICU cancer patients.  
The second study by Namendys-Silva et al to be included was published in 2011 
and reported on a mixed group of cancer patients with septic shock admitted 
from 2008 to 2010 to a single centre oncological ICU [104]. Within this group 
there were 56 patients with a mix of solid tumours of which 33.9% had 
metastatic disease. This group had high severity of illness with mean SOFA scores 
of 9.1 in survivors and 11.7 in non-survivors (although APACHE II scores were 
lower, this may be attributable to the relatively young age of patients and the 
favourable performance status). This paper went on to assess long term outcome 
following ICU discharge and calculated survival time and hazard ratios for factors 
associated with death after ICU discharge.  
The group led by Song reported outcomes in ICU cancer patients in South Korea. 
The first study published in 2007 described a group of 94 patients who were 
readmitted to ICU after initial recovery from major thoracic oncological surgery 
between 2001 and 2005 [143]. This included surgery for oesophageal and lung 
cancer but excluded patients undergoing single wedge resection of lung. While 
this type of intervention represents major surgery it is likely that patients were 
preselected based on limited comorbidity, good functional status and favourable 
tumour features. Patients would also have benefitted from pre-operative 
assessment and the opportunity for optimisation. It is unlikely that this 
population of lung and oesophageal cancer patients are representative of most 
patients with these malignancies.  
Their second study published in 2011 looked at outcomes in a group of patients 
who received chemotherapy for the first time in ICU from 2002 to 2008 [144]. 
This group consisted predominantly of haemato-oncology patients. However, 
there were 13 patients in the cohort with solid tumours. The study reported 
survival based on a number of features including solid vs haematological cancer. 
Features including reason for chemotherapy, reason for admission and severity 
of illness were only reported for the group as a whole of which 79% were 
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haematological cancers. It is difficult to ascertain whether these patients were 
representative of the solid cancer ICU population without this data. While 
recognising this limitation, with only 13 patients, it is unlikely that this study 
will bias the overall pooled results significantly.  
The third paper published by Song et al in 2012 reported outcomes for cancer 
patients that were admitted to an oncological ICU via medical emergency team 
intervention in 2010 [145]. This included 104 patients with an unspecified solid 
tumour. The study aimed to assess the impact of early intervention by medical 
emergency team on mortality among critically ill cancer patients admitted to 
ICU. Medical emergency teams assessed patients on wards with signs of critical 
illness. The aim was to intervene in an attempt to prevent worsening of disease 
or to transfer to a critical care setting at a timely point. As such patients may 
have been admitted to ICU at an earlier stage with a lower burden of critical 
illness. This did not appear to be the case, with both high severity of illness 
scores and mortality rates reported. The study did not report the tumour types 
or proportion of patients with metastatic disease and, as a single centre study, 
this group may not be representative of the solid tumour population. While 
severity of illness scores were high for the group overall it this may have been 
skewed by those patients with haematological malignancy as the scores were not 
reported for the different tumour groups. 
Souza-Dantas et al described a group of neutropenic cancer patients admitted to 
an oncological ICU and matched them to a group of non-neutropenic ICU cancer 
patients [97]. There were 188 patients in this study and this included a total of 
60 patients with solid tumours. They aimed to assess the impact of neutropenia 
on the outcomes of critically ill cancer patients. Severity of illness scores were 
extremely high with median SOFA 11 and SAPS II 61.6, although these values 
represented all patients including those with haematological malignancy. As this 
was a specialised oncological ICU it is possible that the case-mix did not reflect 
that seen within the general ICU setting. It would be unusual, within the general 
ICU population, for 50% of patients to have neutropenia at presentation. As this 
was a matched case-control study half of the patients had this clinical feature. 
However, neutropenia was not found to be associated with outcome and it may 
be that this is not necessarily a significant prognostic factor. 
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Zuber et al performed a secondary analysis of a database of 225,481 ICU patients 
across 41 general ICUs in France from 1997 to 2008 [149]. Their objective was to 
assess survival and prognostic factors in cancer patients with septic shock. They 
identified 2,119 patients with solid tumours admitted to ICU with septic shock of 
which 41.9% had metastatic disease. These patients had a high burden of critical 
illness as reflected by a mean SAPS II score of 63.4 and frequent use of organ 
support. Due to the severity of septic shock in terms of severity of illness and 
associated poor survival it is likely that by reporting only on this subset of ICU 
cancer patients the outcomes would be worse than that seen in the overall 
population. They went on to assess trends in survival over time and also the 
impact of case volume. Within this subgroup of ICU cancer patients with septic 
shock they demonstrated a significant fall in hospital mortality over time (72.1% 
in 1997 to 56.1% in 2008). Inclusion of ICU patients pre-2000 may negatively 
impact upon the overall outcomes reported in this study.  
 
2.3.2.4  Studies that report on a specific cancer type admitted to ICU 
Twenty-one studies reported on a specific cancer type admitted to ICU. Lung 
cancer was the commonest tumour type to be reported upon in this way with 13 
studies choosing to report solely on patients with lung cancer. Outcomes for lung 
cancer patients tend to be worse than for many of the other cancer types, and 
as a result these patients are often not admitted to ICU. By including a large 
proportion of papers that report solely on the lung cancer population it may be 
that this group becomes over-represented and negatively impacted upon the 
overall outcomes for pooled survival that is later reported for all tumour types. 
Adam et al reported outcomes for a cohort of 139 lung cancer patients (69% Non-
Small Cell Lung cancer (NSCLC)) admitted to a medical ICU in the USA between 
1998-2005 [118]. Of these patients, 40% had metastatic disease. Less than half of 
the cohort required invasive mechanical ventilation during their ICU stay 
suggesting a low threshold for ICU admission compared with other studies. ICU 
mortality and associated risk factors are described along with hospital mortality. 
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The study by Aldawood was set in a Saudi Arabian general ICU between 1999-
2009 and included all patients with a prior diagnosis of lung cancer and excluded 
postoperative lung resection patients [119]. Over the time period there were 51 
patients admitted (51% NSCLC). This study had the highest reported APACHE II 
score of 25.6 and organ support was provided for the majority of patients 
reflecting a high severity of illness. In addition to patient characteristics and 
survival this paper also described the resuscitation status of patients at 
admission and at discharge from ICU. 
Andréjak et al described 76 patients with advanced lung cancer defined as stage 
IIIB or IV (64.5% NSCLC) admitted to medical ICU in France between 1996 and 
2006 [120]. Patients with metastatic disease accounted for 59.2% of this cohort. 
This group of patients had a significant burden of critical illness with a high 
proportion of patients receiving organ support. It might be anticipated that 
negative factors associated with the cancer (lung malignancy associated with 
metastatic disease in more than half) combined with a significant burden of 
critical illness would demonstrate poorer outcomes than that expected for a 
standard population of ICU cancer patients. The authors described short-term 
survival in addition to risk factors for ICU mortality in this cohort.  
Anisoglou et al reported on 105 lung cancer patients (80% NSCLC) with acute 
respiratory failure admitted to an oncological ICU in Greece between 2008 and 
2011 [121]. There were a high proportion of patients with metastatic disease 
(72.4%) and severity of illness scores were high (mean APACHE II 23.4, SOFA 9.4) 
with a large utilisation of organ support. These factors are likely to lead to poor 
survival amongst this group. The authors described ICU, hospital and six-month 
mortality along with risk factors for poor outcomes. 
Bissell et al described 43 patients following elective oesophagectomy for 
malignancy that subsequently required emergency readmission to ICU during the 
same hospital stay [122]. None of these patients had metastatic disease. The 
study was performed in a single centre UK hospital with a general ICU between 
1998 and 2009. Short-term and longer-term survival was described in addition to 
predictors of survival. 
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The study by Bonomi et al described a large population of lung cancer patients 
that were admitted to ICU [123]. This multi-centre study from the USA used the 
Surveillance, Epidemiology, and End Results- Medicare Registry (SEER) and 
Medicare files between 1992 and 2005. They identified 1,134 patients aged over 
65 years with stage IIIB or IV NSCLC admitted to medical ICU with respiratory, 
cardiac, neurological diseases, renal failure, or sepsis. Of this cohort 54.5% had 
metastatic disease. The study reported rates and predictors of death during 
hospitalisation. Longer-term outcome was described as 90 day and one-year 
survival post hospital discharge. As it was a retrospective review of healthcare 
files it was unable to provide detail on the characteristics of the critical illness 
such as severity of illness. Mechanical ventilation was held within the dataset 
and was received by 26% of patients that died in hospital and 8% of patients that 
survived hospitalisation. These rates are extremely low and may not reflect 
typical ICU demographics outwith the USA. 
Cense et al have studied a population of 109 patients following elective 
transthoracic oesophagectomy for adenocarcinoma of the mid-distal oesophagus 
or gastric cardia between April 1994 and February 2000 [124]. Patients were 
admitted to ICU following the procedure but length of ICU stay varied. The aim 
of the study was to analyse the effects of prolonged ICU stay (≥6 days vs. ≤5 
days) on quality of life and long-term survival. The vast majority of the study 
period predated the 1st January 2000 cut off for inclusion and as such the 
outcomes reported in this study might not be representative of what would be 
expected with contemporary practice. All patients included in this study were 
admitted following elective major surgery. They would be subject to selection 
bias having only been selected due to favourable feature and undergone pre-
operative assessment and optimisation. 
Chou et al have described 70 patients with stage III or IV lung cancer that were 
ventilated for sepsis related respiratory failure [126]. The study was set in a 
single centre general ICU in Taiwan from 2007 to 2008. Severity of illness scores 
were at the higher end of the range with mean APACHE II 24.3 and SOFA 7.1. 
Additional negative prognostic factors included advanced lung cancer, sepsis and 
respiratory failure all of which might have selected out a group of patients at 
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risk of a poor outcome. The authors reported ICU and hospital survival along 
with variables associated with survival. 
Ertan et al studied patients admitted to a single centre general ICU in Turkey 
after emergency surgery for colorectal cancer between 1998-2004 [128]. A total 
of 102 patients were included. The study evaluated the predictive accuracy of 
different scoring systems in this population including SAPS II, APACHE II, APACHE 
III, MPM II, and Colorectal physiologic and operative severity score for the 
enumeration of mortality and morbidity (Cr-POSSUM). While it reported the area 
under the receiver-operator characteristic curve for each of the scores it did not 
give detail of the actual severity of illness. There were no features pertaining to 
the ICU stay or cancer described beyond the type and location of surgical 
procedure. As a result of this lack of detail little can be determined about the 
cohort and whether it was representative of the colorectal cancer ICU 
population. 
Jennens et al reported on 20 patients with small cell lung cancer (SCLC) who had 
been admitted to one of three general ICUs in Australia from 1993 to 2001 [129]. 
Patients were excluded if they were admitted with complications of 
chemotherapy. Only 15% of patients were diagnosed with lung cancer prior to 
ICU admission, with 35% diagnosed during admission and 50% diagnosed after ICU 
admission. It is unclear if the ICU team knew about the cancer diagnosis in those 
who were diagnosed after their ICU admission. The study described treatment 
with chemotherapy in addition to ICU and median survival. Most of the patients 
were admitted prior to 2000 and outcomes may have been influenced by 
historical ICU practices, however, this is a small study and unlikely to influence 
the pooled results in a significant way. 
The paper by Leath et al, based in a single centre in the USA over 1999 to 2004 
reported on short-term mortality for 185 patients with a gynaecological 
malignancy that required post operative admission to ICU [130]. Patients were 
excluded if they were a non-surgical admission. This study reported a relatively 
low mean APACHE II score (11.6) compared with other studies, suggesting that 
these patients may have had a lower severity of critical illness. This may be 
attributable to the elective nature of surgery and the low incidence of co-
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morbidity reported in this cohort. By excluding non-surgical admissions and 
reporting on a group of patients with favourable features it is possible that this 
paper introduces a bias that flatters outcomes for ICU cancer patients. 
Namendys-Silva et al have published a third study that reports on 92 patients 
with gynaecological malignancy admitted in 2007 to a single centre oncological 
ICU [135]. The majority of patients had uterine cancer (67.3%). Mean APACHE II 
score for this group was 12.4 suggesting low severity of illness. Utilisation of 
mechanical ventilation was high at 76.9%. However, the median duration of 
ventilation was low at only one day and utilisation of vasopressors was in very 
few patients. They reported ICU and hospital mortality along with prognostic 
factors. As an oncological ICU the outcomes may be different from that seen in 
general ICUs. 
Okiror et al have reported on 30 patients admitted to a UK single centre thoracic 
ICU as an emergency after lung resection for lung cancer between 2003 and 2008 
[136]. All of these patients had NSCLC and had been assessed by a number of 
investigations and a multi-disciplinary team pre-operatively to determine fitness 
for surgery. The authors did not report features associated with the ICU 
admission and the severity of illness experienced by these patients is unknown. 
They assessed which peri-operative factors were associated with ICU admission 
in addition to reporting ICU mortality. However, there was not enough detail in 
the results to determine whether this paper introduces potential bias to the 
results of this meta-analysis. 
Park et al have utilised the Intensive Care National Audit and Research Centre 
(ICNARC) database in England, Northern Ireland and Wales to report on all 
patients admitted to ICU following elective oesophageal surgery for malignancy 
from 1995 to 2007 [137]. This spanned 181 ICUs and included 7,227 patients with 
a mean SAPS II 25.1 and APACHE II 13.9 indicating a low burden of critical 
illness. The study evaluated prognostic models for this patient population 
including APACHE II, SAPS II and ICNARC models. While oesophageal cancer 
generally has a poor prognosis, the subgroup of patients deemed suitable 
candidates for surgery are different in terms of disease spread and may have 
benefitted from peri-operative assessment of co-morbidities and optimisation. 
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They may therefore be expected to perform disparately to the majority of 
patients. This paper reported outcomes in this favourable subgroup of 
oesophageal cancer patients who were admitted to ICU with low severity of 
illness. It would be anticipated that these patients would have significantly 
better survival outcomes than an unselected population of oesophageal cancer 
patients admitted to ICU. 
Reichner et al described 47 patients with lung cancer that were admitted to a 
single centre medical ICU in the USA from 2002 to 2004 [138]. This included a 
mix of NSCLC and SCLC and metastatic disease was present in 64%. Mean SOFA 
scores and use of mechanical ventilation suggest a moderate degree of critical 
illness. The aim of the study, in addition to describing short-term outcome and 
predictors of outcome, was to examine the code status at admission to ICU and 
prior to death. 
Roques et al report the six-month survival for a cohort of 105 lung cancer 
patients admitted to a general ICU in France from 1997 to 2006 and excluded 
those patients who were admitted following lung resection [139]. Both NSCLC 
and SCLC patients were included and 64% had metastatic disease. Nearly half of 
the group had performance status ≥2, which will have negatively impacted upon 
short and long-term survival. Mortality was described at discharge from hospital 
and at six months along with predictive factors for both. 
The study by Slatore et al is the largest of the ICU lung cancer studies to be 
included, with 49,373 lung cancer patients that had been admitted to ICUs 
across the USA between 1992 and 2007 [140]. These patients were identified 
using the SEER database. Patients aged over 66 years at diagnosis and who were 
admitted to an ICU within 5 years of diagnosis, were included. Routine post-
operative ICU admissions, carcinoma in situ and post mortem cancer diagnosis 
were listed as exclusion criteria. The cohort included a mix of NSCLC and SCLC, 
with 45.7% having metastatic disease. They have reported survival at hospital 
discharge and at six months along with factors associated with these outcomes. 
This study is limited by the nature of being a retrospective review of a national 
cancer database and is unable to provide detail on the characteristics of the 
critical illness. Mechanical ventilation was provided to 21% of the ICU lung 
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cancer patients. This might suggest a low burden of critical illness with a low 
threshold for ICU admission for monitoring. However, it is also possible that 
patients with severe critical illness were not being treated with mechanical 
ventilation due to perception of futility. Without additional information 
pertaining to the critical illness the level of bias introduced by this large study of 
ICU lung cancer patients was unclear.  
Soares has also led groups that have described outcomes in specific tumour types 
including two studies published in 2007 [102, 142]. The first reported on 121 
patients with head and neck cancer (35% of patients with metastatic disease) 
admitted to an oncological ICU from 2000 to 2005 [102]. There was a moderate 
burden of critical illness as demonstrated by severity of illness scores and 
utilisation of organ support. Data was collected prospectively and methodology 
appeared robust. The second study described 152 lung cancer patients admitted 
to one of two oncological ICUs, with metastatic disease present in 31% [142]. 
Patients were identified retrospectively and then underwent case note review 
allowing detailed reporting of ICU and cancer characteristics. Severity of critical 
illness was representative of that seen in most other studies with moderate 
severity of illness scores and utilisation of organ support. Both studies reported 
survival outcomes in addition to analysis of variables associated with outcome. 
Toffart et al included 103 ICU patients with non-resectable lung cancer that 
were admitted to one of three general ICUs in France from 2000 to 2007 [146]. 
Within this group of patients, 20% had SCLC and 61% had metastatic disease. 
While these patients represent a group with unfavourable cancer features their 
ICU characteristics suggest a low burden of critical illness in terms of severity of 
illness scores and utilisation of organ support. Hospital and 90-day mortality was 
reported in addition to factors associated with 90-day mortality. 
Welsch et al have reported on 96 patients undergoing resection of pancreatic 
head adenocarcinomas where the post-operative ICU stay exceeded the standard 
24 hours [148]. Other pancreatic tumour types were excluded and only 7% of 
patients had metastatic disease. The study described the risk factors for 
extended postoperative ICU stay in addition to survival analysis. Due to the 
major surgery involved this operation would only have been performed after 
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thorough pre-operative assessment by a multi-disciplinary team and optimisation 
of any co-morbidities. These patients represent a subset of the pancreatic 
cancer population where outcomes are more favourable particularly after 
successful surgery. However, survival even within this subgroup remains 
significantly poorer than that for most other tumour types. Any bias that is 
introduced by this trial is likely to flatter results for the ICU pancreatic cancer 
group but negatively impact on results for the overall solid tumour ICU group. 
 
2.3.3 Study characteristics 
While the inclusion criteria required that admissions from 2000 onward were 
reported, the studies spanned admissions between 1997 and 2011.  Where 
cancer site-specific outcomes were reported, the commonest were for lung 
cancers (20 studies) [85, 95, 106, 107, 113, 118-121, 123, 125, 126, 129, 136, 
138-140, 142, 143, 146]. Four papers each reported head and neck [102, 106, 
113, 125], breast [85, 106, 107, 113] and colorectal cancers [95, 107, 113, 125]. 
Oesophageal [122, 137, 143] and pancreatic cancers [113, 125, 148] each were 
reported in three papers. Stomach [113, 125] and gynaecological cancers [130, 
135] each had two papers and single papers were identified for upper 
gastrointestinal [95], all gastrointestinal [106], urological [106], prostate [113] 
and melanomas [113].  
The mean age of patients, where given, ranged from 47 to 75 years and unless 
tumours were sex-specific, patients comprised a mixture of men and women.  
When the cancer population comprised a mix of tumours the proportion of 
different tumour types, when reported, varied considerably with, for example, 
Song’s series comprising 46% lung cancers and Libório’s comprising 7% of them. 
Where the presence of metastatic disease was reported this ranged from 0 – 
100%. There was significant variation in population size across the 47 studies. 
The largest study included was by Slatore et al [140], with 49,373 patients whilst 
Azoulay, Darmon and Song reported on a mixed cancer cohort of which solid 
tumours made up 10, 12 and 13 patients, respectively [85, 103, 144]. The 
majority of the studies (36/47) included a measure of physiological status. The 
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physiology scoring system used differed between studies and there was wide 
variation between mean/ median scores; 20 studies provided mean SAPS II 
scores, ranging from 25.1 to 63.4, and 15 studies gave mean APACHE II scores, 
ranging from 10.3 to 25.6.   
With respect to information or measurement biases, it is possible that studies 
misclassified whether patients had cancer or not or misclassified the site of the 
primary tumour. However, because no additional sources of information were 
available to validate the classification it is not possible to evaluate the extent, if 
any, of such biases. As all studies reported total and not cause-specific 
mortality, misclassification of outcomes is unlikely although the timing of death 
may have been incorrect. Mortality could be misrepresented in those studies 
that excluded routine postoperative patients, patients with ICU stays of less than 
24 hours, readmissions or inclusion only of patients requiring specific 
interventions, such as renal replacement therapy or mechanical ventilation.   
 
2.3.4 Reported mortality 
Short-term mortality was reported for ICU, hospital, 1 and 3 months (Table 2-1)
  
85 
 
 
Author 
 
Number of patients  
Mortality (%), 95% CI 
ICU Hospital 1 month 3 month 
Adam (2008) 139 22.3 (15.7-30.2) 40.3 (32.1-48.9)   
Aldawood (2010) 51 49.0 (34.8-62.4) 60.8 (46.1-74.2)   
Andréjak (2011) 76 47.4 (35.8-59.2)    
Anisoglou (2013) 105 44.8 (35.0-54.8) 56.2 (46.2-65.9)   
Azoulay (2004) 19  57.9 (33.5-79.7)   
Bissell (2013) 43 25.6 (13.5-41.2) 32.6 (19.1-48.5)   
Bonomi (2012) 1134  33.2 (30.4-36.0)   
Bos (2012) 12314 14.4 (13.8-15.0) 24.5 (23.7-25.2)   
Caruso (2009) 83 44.6 (33.7-55.9) 71.1 (61.3-80.8)   
Cense (2006) 109    0.9 (0.0-5.0) 
Chawla (2009) 21 14.3 (3.0-36.3) 19.0 (2.3-35.8)   
Chou (2012) 70  58.6 (46.2-70.2)   
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Author 
 
Number of patients  
Mortality (%), 95% CI 
ICU Hospital 1 month 3 month 
Christodoulou (2007) 69 46.4 (34.6-58.1) 66.7 (55.5-77.8)   
Darmon (2005) 12  41.7 (15.2-72.3) 40a (30.3-50.3)  
de Almedia (2012) 106 17.9 (11.2-26.6)    
Ertan (2007) 102   16.7 (10.0-25.3)  
Jennens (2002) 20 85.0 (62.1-96.7)    
Kopterides (2011) 90 33.3 (23.6-43.1)    
Leath (2006) 185 8.1 (4.6-13.0) 11.4 (7.2-16.8) 12.4 (8.0-18.1)  
Lecuyer (2007) 56  76.8 (65.7-87.8)   
Libório (2011) 258 34.9 (29.1-40.7)    
Maccariello (2010) 86  73.3 (63.9-82.6)   
McGrath (2010) 70 27.1 (16.7-37.6)    
Mendoza (2008) 147 28.6 (21.3-35.9) 39.5 (31.6-47.4)   
Mourad (2014) 72 48.6 (36.7-60.7)   61.1 (48.9-72.4) 
Namendys-Silva (2010) 177 21.5 (15.4-27.5)    
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Author 
 
Number of patients  
Mortality (%), 95% CI 
ICU Hospital 1 month 3 month 
Namendys-Silva (2011) 56 39.3 (26.5-52.1)    
Namendys-Silva (2013) 52 17.3 (8.2-30.3) 23.1 (12.5-36.8)   
Oeyen (2013) 398 5.0 (2.9-7.2) 12.6 (9.3-15.8)  17.3 (13.7-21.4) 
Okiror (2012) 30 16.7 (5.6-34.7)    
Park (2009) 7227 4.5 (34.0-4.9) 10.8 (10.1-11.5)   
Reichner (2006) 47 42.6 (28.3-57.8) 59.6 (44.3-73.6)   
Roques (2009) 105 42.9 (33.2-52.9) 54.3 (44.3-64.0)   
Slatore (2012) 49373  23.5 (23.2-23.9)   
Soares (2005) 642 31.0 (27.4-34.6) 44.2 (40.4-48.1) 42.1a (38.6-45.7)  
Soares (2007) 143 42.0 (33.8-50.5) 58.7 (50.2-66.9)   
Soares (2007) 121 38.8 (30.1-48.1) 56.2 (46.9-65.2)   
Soares (2010) 667  28.0 (24.7-31.6)   
Song (2007) 94 33.0 (23.7-43.4)    
Song (2011) 13 53.8 (26.7-80.9)    
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Author 
 
Number of patients  
Mortality (%), 95% CI 
ICU Hospital 1 month 3 month 
Song (2012) 104 45.2 (35.4-55.3)    
Souza-Dantas (2011) 60  73.3 (62.1-84.5)   
Taccone (2009) 404 20.0 (16.1-24.0) 27.0 (22.7-31.3)   
Toffart (2011) 103 31.1 (22.3-40.9) 47.6 (37.6-57.6)  63.1 (53.0-72.4) 
Unseld (2013) 42 16.7 (7.0-31.4) 28.6 (15.7-44.6)   
Welch (2010) 540  4.6 (3.0-6.8) 2.6 (1.4-4.3)  
Zuber (2012) 2119 57.2 (55.1-59.4)    
Table 2-1 Short-term mortality in solid tumour patients after ICU. (
a 
includes a mixed group of solid and haematological malignancy patients) Modified from 
“Survival in solid cancer patients following intensive care unit admission” Puxty et al. Intensive Care Med (2014) with permission. 
 ICU mortality was reported in 35 studies and ranged widely from 4.5% to 85%. 
Hospital mortality was reported in 31 studies ranging from 4.6% to 76.8%. ICU 
and hospital mortality were plotted showing the pooled estimate of mortality 
rates in Figure 2-2.  
 
Figure 2-2 Short-term mortality of ICU patients with solid tumours. Modified from “Survival 
in solid cancer patients following intensive care unit admission” Puxty et al. Intensive Care 
Med (2014) with permission. 
 
The pooled estimate of mortality summarises only those studies using 
independent samples, so where several papers reported on the same group of 
patients, only one representative paper was used. The overall pooled mortality 
within ICU was 31.2% (95% CI 24.0% to 39.0%) based on a total sample of 25,339 
patients with a solid tumour, of which Bos’s study comprised nearly half of the 
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patients. There was substantial variation between studies in the proportion of 
patients who died in ICU (I2=99.1%, χ2=3483, df=31, p < 0.001). The pooled 
hospital mortality was 38.2% (95% CI 33.8% to 42.7%) among a total sample of 
74,061 patients with solid tumours, of which Slatore’s study comprised two 
thirds of the patients. Again, there was substantial variation in hospital 
mortality between studies (I2=98.8%, χ2=1829, p<0.001).   
Longer-term mortality in ICU patients with solid tumours was reported for 6 
months and up to 5 years after ICU admission (Table 2-2).  
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Table 2-2 Longer-term mortality in solid tumour patients after ICU. Modified from “Survival in solid cancer patients following intensive care unit admission” 
Puxty et al. Intensive Care Med (2014) with permission.
 
Author 
 
Number of patients  
Mortality (%), 95% CI 
6 month 1 year 2 year 3 year 5 year 
Adam (2008) 139 48.2 (39.7-56.8)     
Anisoglou (2013) 105 77.1 (67.9-84.8)     
Bissell (2013) 43   58.1 (42.1-73.0)  62.8 (46.7-77.0) 
Caruso (2009) 83  88.0 (79.0-94.1) 97.6 (91.6-99.7)   
Cense (2006) 109 17.4 (10.8-25.9) 39.4 (30.2-49.3) 56.0 (46.2-65.5) 68.8 (59.2-77.3)  
Oeyen (2013) 398  35.9 (31.2-40.9)    
Roques (2009) 105 72.4 (62.8-80.7)     
Slatore (2012) 49373 65.4 (64.9-65.8)     
Soares (2005) 642 54 (50.1-58.0)     
Soares (2007) 121 71.9 (63.0-79.7)     
Song (2007) 94  54.3 (43.7-64.6)  66.0 (55.5-75.4)  
Toffart (2011) 103  87.4 (79.4-93.1)    
 Mortality at one year was reported in five studies and ranged from 35.9% to 
88.0% and a single study by Bissell reported 62.8% survival at five years [122]. 
Figure 2-3 provides summary mortality estimates at all follow-up periods. 
Generally, mortality increases from the ICU admission period to the first six 
months after admission. Thereafter, there is little further increase in mortality 
reported by these studies. However, each time point describes different patient 
populations and in some cases a single study, so caution is required in making 
conclusions about mortality over time. 
 
Figure 2-3  Pooled mortality by length of follow-up among ICU patients with solid tumours. 
Modified from “Survival in solid cancer patients following intensive care unit admission” 
Puxty et al. Intensive Care Med (2014) with permission. 
 
2.3.5 Predictors of survival 
When the effects of risk factors associated with survival have been found to be 
statistically significant in multivariable analyses these have been described along 
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with the magnitude of effect (odds ratios unless otherwise stated) in Tables 2-3, 
2-4 and 2-5.  
Author Prognostic factors for ICU mortality 
Adam (2008) Vasopressors 8.7 (2.8 – 27) 
>2 Organ failures 40.8 (5.1 – 328.3) 
Andréjak 
(2011) 
IMV 6.61 (1.44 – 30.5) 
Vasopressors 6.81 (1.77 – 26.26) 
Platelet count <100000/mm3 5.13 (1.17-22.5);  
Admission for complication of cancer management 0.206 
(0.058-0.738) 
de Almedia 
(2012) 
APACHE II score 1.15 (1.05-1.26) 
LIS score 2.23 (1.29-3.87)  
Positive fluid balance >1100ml/24h 5.14 (1.45-18.24) 
Kopterides 
(2011)  
Model I 
APACHE II score 1.16 (1.07-1.26) 
PS 3-4 6.70 (2.18-20.60) 
Septic shock 5.51 (1.16-26.10) 
Kopterides 
(2011)  
Model II 
SOFA score 1.2 (1.05-1.38)  
Medical admission 3.84 (1.14-12.92) 
PS 3-4 3.88 (1.22-12.39) 
Infection on admission 3.9 (1.17-13.05) 
Kopterides 
(2011)  
Model III 
SAPS II score 1.04 (1.01-1.08) 
PS 3-4 6.67 (2.12-21.00) 
Septic shock 4.75 (1.00-22.73) 
Anaemia on admission 4.06 (1.30-12.65) 
Mourad* 
(2013) 
SOFA score 1.35 (1.05-1.75) 
IMV 16.6 (3.60-77.15) 
Diastolic dysfunction (e'≤8cm/s) 16.6 (3.28-84.6) 
Namendys-
Silva (2010) 
APACHE II score 1.92 (1.43-2.58) 
Vasopressors 22.66 (6.09-84.22) 
Song (2011) SOFA score >10 9.66 (1.43-65.47) 
IMV 6.26 (1.12-34.95) 
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Zuber (2012) SAPS II score 1.04 (1.03-1.04) 
Medical admission 1.73 (1.29-2.32) 
IMV 5.52 (4.04-7.54) 
RRT 1.74 (1.30-2.33 
Fungal infection 1.95 (1.18-3.21) 
Unknown microorganism 1.64 (1.27-2.11) 
Admission to high vs. low volume unit 0.63 (0.46-0.87)  
Table 2-3  Prognostic factors associated with ICU mortality with corresponding odds ratios. 
*includes haematological malignancies. Modified from “Survival in solid cancer patients 
following intensive care unit admission” Puxty et al. Intensive Care Med (2014) with 
permission. 
 
Author             Prognostic factors for hospital mortality 
Azoulay* 
(2004) 
Vasopressors 3.19 (1.28-7.95)  
NIMV followed by conventional IMV 17.46 (5.04-60.52)  
First-line conventional IMV 8.75 (2.35-32.54) 
Late NIMV failure 10.64 (1.05-107.83) 
Congestive heart failure 0.16 (0.03-0.72) 
Invasive aspergillosis 3.78 (1.05-14.24)  
No definite diagnosis 3.85 (1.26-11.70) 
Bonomi 
(2012) 
Sepsis 5.06 (3.04-8.43) 
IMV 4.69 (3.02-7.30)  
Renal failure 2.28 (1.02-5.10) 
Admission related to respiratory conditions 2.34 (1.43-3.82) 
Caruso (2009) SAPS II 1.09 (1.01-1.18) 
Thrombocytopenia 26.2 (2.6-267.9) 
Christodoulou 
(2007) 
PS 3-4 5.44 (1.48-19.99) 
Chou (2012) SOFA score 1.360 (1.038-1.782) 
Lecuyer 
(2007) 
No significant independent predictors of hospital mortality 
Libório (2011) SAPS II score 1.05 (1.02-1.08) 
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SOFA score 1.69 (1.37-2.09)  
APACHE II 1.65 (1.34-2.03) 
RIFLE score 4.86 (1.68-14.06) 
Maccariello 
(2010) 
Medical admission 6.55 (2.29–18.73) 
Associated organ dysfunction 2.14 (1.25-3.65) 
ICU days until start of RRT 1.42 (0.97-2.09) 
Mendoza 
(2008) 
Vasopressors (value not given) 
Metastatic disease (value not given) 
Namendys-
Silva (2013) 
APACHE II score 1.43 (1.01-2.09) 
Vasopressors 8.6 (2.05-36) 
Park (2009) IMV 1.24 (1.03-1.50) 
Age: 60-69 1.68 (1.07-2.63); 70-79 2.64 (1.69-4.15); ≥80 3.84 
(2.14-6.87) [Reference group <50 years) 
P/F ratio: <10 3.7 (1.7-8.07); 10-19 2.65 (1.49-4.69); 20-29 
2.04 (1.17-3.55); 30-39 1.9 (1.08-3.33) [Reference group 50-
59kPa] 
Serum urea ≥14.4 2.49 (1.37-4.53) [Reference group 
<6.3mmoll-1] 
Serum creatinine ≥150 2.01 (1.32-3.06) [Reference group 50-
99micromoll-1] 
Serum albumin: <15 2.58 (1.87-3.55); 15-19.9 1.73 (1.31-2.29) 
[Reference group 25-29.9gl-1] 
Lowest arterial pH: <7.15 1.85 (1.13-3.01); 7.15-7.24 2.0 (1.49-
2.68); 7.25-7.29 1.42 (1.11-1.84) [Reference group 7.3-7.34] 
Roques (2009) PS 3-4 3.6 (1.5-8.7) 
Acute respiratory failure 3.5 (1.5-8.4) 
Slatore (2012) IMV 6.95 (6.89-7.01) 
Soares 2007) PS 3-4 5.17 (1.84–14.53) 
Number of acute organ failures 2.87 (1.83–4.50) 
Stage IV disease 3.80 (1.28–11.28) 
Soares (2007) Number of organ failures 1.95 (1.16-3.28) 
Age 1.08 (1.02-1.15) 
Uncontrolled recurrence/ progression of cancer 8.81 (1.56-
49.67)  
Airway obstruction by cancer 3.55 (1.02-12.32) 
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Soares (2010) SOFA score 1.25 (1.17-1.34) 
Medical admission 5.66 (3.43-9.33) 
PS ≥2 3.40 (2.19-5.26) 
IMV 2.42 (1.51-3.87) 
Emergency surgical 2.46 (1.28-4.73) 
Hospital stay 1.18 (1.01-1.37) 
Newly diagnosed cancer 2.75 (1.19-6.32) 
Recurrence/ progression of cancer 2.42 (1.51-3.87) 
Song (2007) APACHE III ≥50 12.100 (2.859–51.206) 
RRT 3.611 (1.096–11.895) 
Duration of ventilation ≥5 days 7.859 (2.375–26.006) 
Song* (2012) SOFA score 1.18 (1.03-1.35) 
MET criteria (3+) 3.09 (1.32-7.23) 
Time to intervention by MET (hours) 1.45 (1.22-1.72) 
Souza-Dantas 
(2011) 
Model I 
SAPS 1.06 (1.03-1.09) 
Medical admission 7.82 (1.75-34.88) 
PS ≥2 2.43 (1.03-5.70) 
Severe sepsis/ septic shock 4 (1.37-11.73) 
Chemo before admission 0.19 (0.05-0.78) 
Hospital days before ICU admission 1.50 (1.08-2.07) 
Souza-Dantas 
(2011) 
Model II 
SOFA score 1.19 (1.06-1.33) 
Medical admission 7.06 (1.68-29.63) 
PS ≥2 2.84  (1.26-6.40) 
Severe sepsis/ septic shock 3.53 (1.20-10.33) 
Hospital days before ICU admission 1.49 (1.09-2.04) 
Taccone 
(2009) 
SAPS II score 1.07 (1.05-1.08) 
Sepsis 2.1 (1.2-3.7) 
IMV 2.4 (1.2-4.7) 
ARDS 2.5 (1.2-5.3) 
Table 2-4 Prognostic factors associated with hospital mortality with corresponding odds 
ratios. *includes haematological malignancies. Modified from “Survival in solid cancer 
patients following intensive care unit admission” Puxty et al. Intensive Care Med (2014) with 
permission. 
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Author Prognostic factor 
            30 day Mortality 
Darmon 
(2005) 
IMV 6.36 (1.76-22.94) 
Vasopressors 6.01 (1.86-19.4) 
Liver failure 7.76 (1.25-48.27) 
            90 day Mortality 
Namendys-
Silva† (2011) 
SOFA 1.11† (1.02-1.19) 
PS 3-4 1.84† (1.03-3.29) 
Toffart (2011) 
Model I 
SAPS 1.03† (1.02-1.05) 
PS 3-4 1.96† (1.11-3.46) 
Toffart (2011) 
Model II 
LOD, per point 1.19† (1.08-1.32) 
PS 3-4 2.65† (1.43-4.88) 
Metastasis at ICU admission 1.90† (1.08-3.33) 
Roques (2009) IMV 3.6 (1.35-9.4) 
Cancer progression 6.1 (2.2-17) 
Slatore (2012) IMV 1.21 (1.16-1.26) 
           6 month Mortality 
Soares (2005) IMV 1.34 (1.00-1.78); 
No. of organ failures: 1–2 1.77 (1.29–2.43); >2 3.89 (2.73-5.53) 
Age: 40-70 1.66 (1.24–2.23); >70 years 2.07 (1.49–2.88)  
Surgical patient 0.69 (0.55–0.86) 
Cancer status: Newly-diagnosed 1.46 (1.11–1.91); Recurrence/ 
progression 2.20 (1.72–2.82) 
        Mortality after discharge 
Namendys-
Silva (2010) 
Vasopressors 2.79† (1.06-7.33) 
Length of stay in ICU 1.10† (1.007-1.02) 
CCI>2 5.81† (1.35-25.03) 
Bissell (2013) RRT 5.63† (4.0-7.2) 
Age 1.05† (1.01-1.09) 
Table 2-5 Prognostic factors associated with longer-term mortality with corresponding odds 
ratios. †Hazard ratios. Modified from “Survival in solid cancer patients following intensive 
care unit admission” Puxty et al. Intensive Care Med (2014) with permission. 
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Several studies reported an association between measures of severity of illness 
and short-term survival. Increasing severity of illness scores such as APACHE, 
SAPS and SOFA were associated with greater risks of mortality. Renal failure, as 
assessed by RIFLE score, was associated with mortality when assessed in 
Liborio’s study. The number of organ failures has also been associated with 
survival and this is likely a surrogate marker for severity of illness. The 
relationship between higher severity of illness score and increased mortality was 
reported up to 90 days after admission and was of a similar magnitude to its 
effect on shorter-term mortality. However, beyond 90 days, severity of illness 
scores were not assessed for impact upon mortality.  
Features associated with organ failure such as specific organ support were also 
associated with short-term mortality. Invasive mechanical ventilation increased 
ICU mortality by around six-fold in most studies. The study by Mourad et al 
reported a much higher figure of a nearly 17-fold increase in ICU mortality for 
IMV, however, this analysis included haematological patients and the confidence 
interval around the estimate was wide [133]. Use of vasopressors increased the 
risks of both ICU and in-hospital mortality. The increased ICU mortality was 
nearly nine-fold in the paper by Adam [118] and 22-fold in the cohort by 
Namendys-Silva [134]. Hospital mortality was increased three to eight-fold by 
the requirement for vasopressors. The increased mortality at 30 days reported 
by Darmon was of a similar magnitude to that reported in hospital by several 
authors [103]. This similarity may reflect the duration of hospitalisation in 
patients with critical illness. Renal replacement therapy had a smaller impact on 
ICU mortality in the study by Zuber et al with OR 1.74 [149]. Hospital mortality 
was increased three-fold by RRT in Song’s 2007 study [143] and hazard ratio was 
5.63 in ICU cancer patients with RRT in the Bissell study [122]. Sepsis increased 
ICU mortality by five-fold and in-hospital mortality between two- and five-fold. 
ICU admission type has an impact upon short-term outcomes in cancer patients 
with medical admissions (as opposed to surgical) associated with a two- to four-
fold increased risk of ICU mortality; and increased risk of in-hospital mortality of 
between six and eight-fold. In the study by Bos et al [95] this effect was 
particularly pronounced in the cancer population in comparison to the non-
cancer population with in-hospital mortality of medical cancer patients 44.6% vs. 
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23.7% medical non-cancer patients and 17.4% surgical cancer patients vs. 14.6% 
surgical non-cancer patients. 
WHO Performance Status, which is used to quantify cancer patients’ general 
health and functioning, was associated with survival. Generally, papers 
compared patients with scores of 3 and 4 (from capable of only limited self-care 
to completely disabled and confined to bed or chair) with those of 0, 1 and 2. 
Poorer Performance Status was associated with increased ICU mortality of 
between four and seven-fold and increased mortality by two to three-fold at 90 
days after ICU admission.  
The impact of cancer stage has been inconsistently associated with mortality. 
The study of 147 patients with mixed solid tumours by Mendoza et al found 
metastatic disease to be independently predictive of hospital mortality on 
multivariate analysis [107]. Soares’ study of patients with head and neck cancer 
identified that those with stage IV disease had a higher risk of in-hospital death 
with OR 3.8 (95% CI 1.28 – 11.28) [102]. A further study by Soares of cancer 
patients receiving >24 hours of invasive mechanical ventilation found that 
hospital mortality increased in patients with recurrence/ progression of cancer 
status (OR 3.43, 95% CI 1.81 – 6.53 compared with controlled cancer) and when 
airway/ pulmonary involvement by the tumour was the reason for ventilation 
(OR 5.73 CI 1.92 – 17.08) [109]. However, an additional three papers did not find 
an association between metastatic disease and short-term outcomes such as ICU 
or hospital mortality [87, 101, 105]. The impact of leukopenia and neutropenia 
has been assessed in many of the studies and has not been found to be 
associated with short-term mortality [87, 97, 99, 103, 106].  
Studies varied widely in their mean acute illness scores (Appendix 1) and 
reported mortality (Tables 2-1 and 2-2). Figure 2-4 plots ICU mortality for each 
study by its acute illness score (APACHE II, SOFA and SAPS II, respectively). 
Circle sizes are proportionate to sample sizes. In general, studies with higher 
acute illness scores reported higher ICU mortality. However, there was some 
variation in mortality between studies with similar acute illness scores. This is 
likely to be a reflection of differences in other patient characteristics within the 
cohorts, particularly cancer site. 
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Figure 2-4 Mortality by mean/ median severity of illness score (APACHE II, SOFA and SAPS 
II, respectively). Modified from “Survival in solid cancer patients following intensive care 
unit admission” Puxty et al. Intensive Care Med (2014) with permission. 
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2.3.6 Tumour specific survival 
Table 2-6 and Figure 2-5 summarises short-term mortality where this has been 
described for specific tumour sites, indicating the site-specific average and 
overall pooled mortality.  
 
Tumour type  Pooled ICU mortality % 
(95% CI) 
Pooled hospital 
mortality % (95% CI) 
Lung  40.1% (28.6 – 52.2) 46.9% (39.9 – 54.0) 
Oesophageal  14.7% (2.5 – 34.6) 19.9% (3.6 – 44.8) 
Upper GI  12.3% (10.6 – 14.1) 20.9% (18.8 – 23.2) 
Colorectal  19.2% (0 – 62.3) 35.0% (13.7 – 60.2) 
Breast  33.3% (10.3 – 59.0) 57.7% (42.1 – 72.7) 
Head and neck  34.2% (24.6 -44.6) 54.7% (24.9 – 82.8) 
Pancreatic  0% (0 – 70.8) 30.8% (0.4 – 80.5) 
Gynaecological  12.0% (4.6 – 22.4) 16.4% (6.7 – 29.3) 
Gastrointestinal  15.4% (8.2 – 25.3) - 
Urological  36.4% (24.9 – 49.2) - 
Stomach  0% (0 – 97.5) 50.1% (2.3 – 97.7) 
Melanoma  - 100% (48.4 – 100) 
Prostate  - 80% (28.4 – 99.5) 
Table 2-6 ICU and hospital mortality by tumour type. Modified from “Survival in solid cancer 
patients following intensive care unit admission” Puxty et al. Intensive Care Med (2014) with 
permission. 
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Figure 2-5 Short-term mortality by specific tumour type. Modified from “Survival in solid 
cancer patients following intensive care unit admission” Puxty et al. Intensive Care Med 
(2014) with permission. 
 
It is apparent from Figure 2-5 that survival varies between studies on the same 
cancer site and between different cancer sites. Precision of estimates varied 
considerably between studies. Generally, mortality was high for patients with 
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lung cancers with pooled ICU and hospital mortality of 40.1% (95% CI 28.6 – 52.2) 
and 46.9% (95% CI 39.9 – 54). Hospital mortality was higher in patients with 
breast cancer at 57.7% (95% CI 42.1 – 72.7) and head and neck cancer at 54.7% 
(95% CI) 24.9 – 82.8) but numbers were low in these groups and as a result 
confidence intervals were high. There were large number of patients included 
with oesophageal cancer and this group of patients tended towards lower 
mortality with 14.7% (95% CI 2.5 – 34.6) ICU and 19.9% (3.6 – 44.8) hospital. It is 
likely this is due to the large proportion of post-operative patients within this 
group. Colorectal cancer was the third largest group reported on with pooled ICU 
and hospital mortality of 19.2% (95% CI 0 – 62.3) and 35% (95% CI 13.7 – 60.2).  
 
2.3.7 Quality of life in cancer patients after ICU  
Quality of life (QoL) was not routinely measured in the majority of the 47 
included studies. The paper by Cense et al reported QoL as measured by the 
generic Medical Outcome Studies Short Form-20 (MOS SF-20) and Rotterdam 
Symptoms Check List (RSCL) in patients admitted to ICU following elective 
oesophagectomy for cancer. They compared scores for those patients who had a 
short ICU stay versus those who had a long ICU stay. They compared ≤5 days with 
≥6 days and ≤2 days with ≥14 days. From a preoperative baseline there was a 
significant decline in QoL measures immediately postoperatively that slowly 
recovered to baseline. When comparing ICU stay ≤5 days with ≥6 days there was 
no significant difference in MOS SF-20 scores. However, RSCL outcomes were 
worse for the group with ICU stay ≥6 days as scores were lower after five weeks 
and three months in the overall QoL domain and after three months in the 
physical symptoms and activities of daily living domains. When comparing ICU 
stay ≤2 days with ≥14 days the MOS SF-20 scores revealed that the prolonged 
admission group had significantly worse physical and social functioning than the 
short stay group. RSCL revealed lower scores for activities of daily living in the 
long stay group at three months and less of an improvement in overall QoL at 
two years. However, pain scores after one year as assessed by MOS SF-20 were 
more favourable in the long stay group. 
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Oeyen et al measured QoL using Medical Outcomes Study 36-item Short Form 
Health Survey and the EuroQoL-5D in a mixed population of ICU cancer patients. 
QoL measures were found to decrease after ICU admission as compared to 
baseline and improved in most areas after one year. Exceptions were mobility 
and anxiety, which remained lower than baseline. 
While Toffart et al did not formally assess QoL they did describe the effect on 
life after ICU discharge for a population of patients with non-resectable lung 
cancer in terms of time spent at home. They found that 52% patients were 
discharged alive from hospital. Of these 11% never returned home, 74% spent 
more than half of the follow-up time at home with 61% spending more than 
three quarters of the follow-up time at home.  
 
2.4 Discussion 
2.4.1 Summary of findings 
This systematic literature review identified a set of studies that describe 
contemporary outcomes in patients with solid tumours after admission to ICU. 
The 47 papers that reported on solid cancers were characterised by a wide range 
of case-mix variables both in terms of critical illness and in tumour types. The 
broad range of observed outcomes, with ICU mortality ranging from 4.5% to 85%, 
reflects the heterogeneity of patients described in the available literature. By 
pooling all available data the average mortality was calculated for 25,339 
patients where ICU outcome was known and for 74,061 patients where hospital 
outcome was known. Average mortality across all included studies demonstrated 
an ICU mortality of 31.2% and hospital mortality of 38.2%. This is considerably 
lower than that which has been historically reported for the ICU cancer 
population [79-81]. Cancer patients should therefore not be excluded from ICU 
exclusively based on having an underlying malignancy as has previously been 
suggested and instead those factors that are known to be associated with 
survival should be taken into account. 
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2.4.2 Factors associated with survival 
A number of studies reported factors that were associated with survival. Poorer 
physiological status was associated with poorer short-term survival including ICU 
and hospital survival. However, the range of different severity of illness scoring 
systems employed, and the absence of any measure from some studies makes 
summary estimates difficult in this patient group. The total number of organ 
failures present has also been linked to mortality and it is likely that this is also 
a reflection of severity of illness. All types of organ failure were associated with 
a poorer outcome. However, of these, requirement for invasive mechanical 
ventilation had the strongest effect on mortality. In addition, poor chronic 
health or limited functional status has been demonstrated to be associated with 
poorer survival. These findings are consistent with those seen in the general ICU 
population and are not specific to cancer patients. When compared to surgical 
admissions to ICU, patients that have a medical admission have an increased risk 
of short-term mortality. This effect has been demonstrated in the non-cancer 
population in the past but the paper by Bos et al [95] suggests that it may be 
exaggerated in patients with cancer. When describing outcomes for cancer vs. 
non-cancer patients in the surgical population they report ICU mortality of 9% vs. 
8.9% (p = 0.8) and hospital mortality of 17.4% vs. 14.6% (p <0.001). This 
compares to the medical patients with an ICU mortality of 30.4% vs. 16.2% (p 
<0.001) and hospital mortality of 44.6% vs. 23.7% (p <0.001). 
Whilst tumour type was not demonstrated to be associated with mortality in any 
of the individual studies, the average mortality by tumour types described in this 
systematic review varies widely. This may suggest that there is variation in 
outcome depending on tumour or may be reflective of the different population 
that make up each tumour group. For example, the ICU population of upper GI 
cancers are often elective post-operative patients compared with a larger 
proportion of medical admissions within the lung cancer group. The impact of 
disease stage and presence of metastasis has been inconsistently associated with 
mortality and the exact role these factors play is uncertain. Thus, despite 
around 15% of ICU admissions being for patients with known malignancies [87], 
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current literature is unable to predict likely survival of the individual cancer 
patient after ICU admission. 
Bos et al noted that many studies which report on prognostic factors mainly 
involve specialised oncological ICUs, making it difficult to extrapolate to general 
ICUs where the mixture of tumour types and expertise is different [95]. They 
suggested that their own study was most appropriately compared to papers by 
Taconne et al and Soares et al [86, 87]. Even in this limited comparison there 
were important differences in terms of study size, duration, and discrimination 
of emergency admissions, medical and surgical patients. Given the paucity and 
variability of the published literature, to restrict the inclusion criteria for this 
review further would have been even less informative as more than half of the 
published data would have been lost with no increase in precision. This is 
important because although this review summarises the distribution of reported 
mortality using the average mortality with 95% confidence intervals, the 
mortality reference range of published studies is justifiably very wide.  
 
2.4.3 Longer-term outcomes 
Longer-term outcomes for ICU cancer patients are only reported in 12 of the 47 
included studies. Six month mortality is low for the group in Cense’s study of 
patients following elective oesophagectomy at 17.4% [124], however, in the six 
other studies that report it this varies at 48.2 – 77.1%. Mortality in the study by 
Cense increased with time to 39.4%, 56% and 68.8% at one, two and three years.  
Oeyen et al described a group that comprised of a large proportion of elective 
post-operative patients [111]. One-year mortality for this group was 35.9% and is 
at the lower end of the range due to the nature of admission and likely pre-
operative selection of patients with little co-morbidity and potentially curative 
disease.  
The longer-term outcomes reported by Song et al in their 2007 paper pertain to 
a group patients undergoing major thoracic surgery for either lung or 
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oesophageal cancer who had been readmitted to ICU during the same 
hospitalisation [143]. While readmission is a major adverse event for this patient 
group, they will have almost certainly been subject to selection bias in terms of 
fitness for major surgery and will have had potentially curative disease. In spite 
of this, one-year mortality was 54.3% and three year mortality 66% for this 
group.  
The study by Caruso et al reported on patients with metastatic disease at 
presentation to ICU [113]. Longer-term outcomes in this group were particularly 
poor with one and two year mortality rates of 88% and 97.6% respectively. 
Toffart et al studied a group of non-resectable lung cancer patients [146] and 
described one year mortality of 87.4%, similar to Caruso’s group of patients with 
metastatic disease.  
Bissell et al reported longer-term outcomes for their group of patients 
undergoing elective oesophagectomy that were readmitted to ICU [122]. None of 
their patients had metastatic disease and again were likely to have the same 
selection biases as described before for patients undergoing major thoracic 
surgery. One-year mortality for this group was 58.1% and five-year mortality 
62.8%.  
The number of patients included in these longer-term follow up studies were low 
and it remains difficult to make any generalisable summations as the groups 
were so disparate. Those with advanced disease such as that described by Caruso 
and Toffart had very poor outcomes in the longer term. It is difficult to know if 
this was due to the underlying cancer or was in any way attributable to the 
critical illness. However, even those patients undergoing elective surgical 
interventions (presumably with curative intent) and pre-operative selection bias 
had a significant risk of mortality at one, three and even five years. 
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2.4.4 Conclusions 
This systematic review identified 47 papers that reported survival outcomes for 
cancer patients with solid tumours. The pooled mortality across the published 
literature was 31.2% ICU mortality and 38.2% hospital mortality. Outcomes 
appear to vary significantly depending upon underlying tumour types. While 
several studies identified performance status and cancer stage as impacting 
upon ICU and hospital mortality the factors associated with short-term outcomes 
are more commonly related to the critical illness such as severity of illness 
scores, organ support, medical admissions and sepsis. Current evidence on 
outcomes in cancer patients after admission to ICU would be improved with 
additional clinical details, reporting outcomes in clearly defined groups and 
producing further prognostic information on those factors that are associated 
with poorer survival.  
Whilst oncological ICUs provide a large patient population in which to study 
these patients, they may not be representative of the general ICU cancer 
population and therefore additional studies require to be performed on both 
groups. Where patients are admitted to general ICUs, there is value in reporting 
comparative outcomes for non-cancer patients to allow calculation of the 
additional risk posed by having cancer both in the short and longer-term. In 
addition to describing survival over the short, medium and longer terms, 
research is needed to describe which cancer patients are likely to require ICU 
care.  
 
2.4.5 Strengths and weaknesses 
This systematic review and meta-analysis has summarised the literature on 
outcomes for patients with a solid tumour that are admitted to ICU. The findings 
show heterogeneity in reported mortality reflecting differences in case-mix, 
patient selection criteria and international ICU bed availability and practices. 
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This study has a number of strengths including being the first systematic review 
on outcomes among cancer patients admitted to ICU. It consolidates and 
summarises a large volume of information form multiple primary published 
sources. Generalising the findings of individual studies to a local population is 
problematic for a number of reasons. There are international variations in the 
definition of ICUs and in the case-mix of patients they treat with corresponding 
variability in outcomes. Within the same country outcomes may vary between 
hospitals, particularly where specialised tertiary units are concerned such as 
oncological, neurosurgical or cardiothoracics. Furthermore, individual studies 
often focused on a specific population whether that be tumour type, grade or 
management. By generating pooled mortality for ICU cancer patients this study 
gives an estimate of the average mortality across the globe but may not reflect 
what is seen within an individual unit. 
The principal weakness of this study is that including all studies within this field 
has resulted in a heterogeneous population. Studies were included whether the 
focus was on the general ICU cancer population or a subgroup such as those with 
sepsis, a specific organ failure or an individual tumour type. The differences in 
terms of patient population, types of cancer, or type of patients (surgical vs. 
non-surgical) are selection biases that contribute towards the heterogeneity we 
report. As a result there are large differences between the study populations of 
the included papers, which is reflected in the distribution of mortality rates that 
they report. Outcomes are worse for medical admission versus surgical 
admissions to ICU and this effect seems to be exaggerated within the oncological 
population. For example, the three studies with the lowest mortality [111, 130, 
137] include mainly elective surgical patients. In contrast, the studies with 
higher mortality [92, 97, 105, 113] included only a few surgical patients and 
instead selected patients based on their severity (mechanical ventilation and at 
least one additional organ failure) [92]; only patients requiring renal 
replacement therapy [105], the extent of the underlying disease [113] or both. 
The difference in reported mortality is therefore to be expected. 
While the systematic review excluded publications that reported on ICU 
populations that entirely pre-dated 1st January 2000, there were 15 of the 47 
included studies that consisted of a population that partially pre-date the year 
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2000. The decision was taken to include these studies although it is possible that 
in doing so this has introduced a small proportion of patients who were managed 
in ICU with historical practices. 
 
2.4.6 New literature published since performing the systematic 
review 
Since performing the systematic review in 2014, there have been a number of 
publications pertaining to outcome of cancer patients in ICU. Twelve of the most 
relevant studies have been summarised in table 7-1. Mortality for a group of 
mixed solid tumours was reported in papers by Wohlfarth, Champigneulle, Lee, 
Xia, Fischer, Auclin, Ostermann and Ha [112, 152-158]. ICU mortality varied from 
14.9% to 75.3% and hospital mortality from 26.4% to 57.1% suggestive of 
significant differences in the studied populations. Mortality by specific tumour 
types were reported by Bos (lung, head and neck, colorectal, pancreatic, 
oesophageal, urinary tract, breast and prostate) [159], Hawari (lung, 
gynaecological, breast, gastrointestinal and genitourinary) [160], Soares (lung) 
[161] and Destrebecq (breast) [162]. 
 
Wohlfarth et al describe a population of cancer patients receiving chemotherapy 
in the ICU [152]. Their cohort was predominantly made up of patients with 
haematological malignancies. However, they do describe a hospital mortality of 
57.1% in the seven solid tumour patients in their cohort.  
Champigneulle et al describe a mixed cohort of cancer patients admitted to ICU 
after cardiac arrest [153]. Among the 81 patients with a solid tumour only 24.7% 
survived ICU. While the authors advocate for the admission of cancer patients to 
ICU following cardiac arrest, this should only be undertaken in the context of 
alternative positive prognostic factors as the outcomes for this group have been 
demonstrated to be particularly poor. 
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Author ICU features Cancer features ICU  Hospital  Six 
month  
One 
year  
Two 
year 
Wohlfarth (2014) Single centre oncological ICU Mixed tumours receiving 
chemotherapy in ICU 
- 57.1% - - - 
Champigneulle 
(2015) 
Multi-centre general ICUs. 
Patients post cardiac arrest 
Mixed solid tumours 75.3% - - - - 
Lee (2015) Oncological ICU Mixed solid tumours - - - 26.5% - 
Xia (2016) Single centre oncological ICU Metastatic solid tumours 14.9% 29.8% - - - 
Fisher (2016) Single centre oncological ICU, 
low severity of illness 
Mixed solid tumours (42.7% lung 
cancer) with metastatic disease in 
33.3% 
- 31% 52.2% - - 
Auclin (2017) Age over 64 years. High 
severity of illness scores 
Mixed solid tumours 33.6% 43.9% - - - 
Ostermann 
(2017) 
General ICUs included in 
ICNARC 
Mixed solid tumours 17.1% 26.4% - - - 
Ha (2017) Single centre oncological ICU Metastatic solid tumours - 35% - 77% - 
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Author ICU features Cancer features ICU  Hospital  Six 
month  
One 
year  
Two 
year 
Bos (2015) Multi-centre general ICUs Lung 
Head and neck 
Colorectal 
Pancreatic 
Oesophageal 
Urinary tract 
Breast 
Prostate 
- - 36% 
42% 
38% 
44% 
28% 
43% 
36% 
20% 
47% 
49% 
51% 
53% 
40% 
58% 
43% 
25% 
 
Hawari (2016) Single centre oncological ICU Lung 
Gyn 
Breast 
GI 
GU 
41.6% 
41.4% 
36.6% 
36.0% 
31.3% 
- - - - 
Soares (2014) Multi-centre general ICUs. 
Low use of IMV 
Lung cancer (41% with metastatic 
disease) 
28% 39% 55% - - 
Destrebecq 
(2016) 
Single centre oncological ICU. 
Low severity of illness scores 
Breast cancer 15% 28% - - - 
Table 2-7 Mortality reported for solid tumour patients after an ICU admission in publications since April 2014 
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The study by Lee et al described a population of cancer patients admitted to an 
oncological ICU after medical emergency team activation [154]. The majority of 
their results are for a mixed population of haematological and solid tumours but 
they do report one-year survival for the group with solid tumours at 26.5%. This 
is poorer than the 65.6% one year survival described in this thesis, however, the 
population is likely to differ in terms of oncological versus general ICU in 
addition to the bias introduced by only including those patients that had 
deteriorated on a ward such that the emergency team were activated. 
Xia et al in 2016 reported on 141 patients with metastatic solid tumours 
admitted to an oncological ICU between 2012 and 2015 in China [155]. Severity 
of illness scores were reported with median APACHE II 21 and SOFA 9 on 
admission, suggesting a moderate severity of illness. In this cohort ICU mortality 
was 14.9%, hospital mortality was 29.8% and median overall survival was 17 
months. While these measures of short-term mortality are similar to that 
described in this thesis the authors do not report any longer-term survival which 
might be expected to be poor given the underlying metastatic disease. 
The study by Fisher et al reported results for patients with a solid tumour from a 
single centre London oncological ICU [112]. This population had a large 
proportion of lung cancer patients (42.7%) and one third of all patients had 
metastatic disease. Of note, the burden of critical illness was low and 37.3% of 
patients did not have any organ failures at ICU admission. Consistent with this is 
the relatively low use of organ support reported (20% vasopressors, 8% RRT, 18% 
IMV). In spite of these favourable features associated with critical illness 
hospital mortality was 31% with six-month mortality 52.2%. This may represent 
differences in the selection criteria of patients admitted to oncological ICUs 
compared with that in general ICUs. 
An older ICU cancer population is described by Auclin et al who have reported 
outcomes for ICU patients with solid tumours that are aged 65 years or older at 
ICU admission [156]. Severity of illness was high with a mean SAPS II score of 
61.9. Mortality was described at 33.6% for ICU, 43.9% for hospital and 51.9% for 
90-days. In addition, post-ICU anticancer therapy was described, with only 52.7% 
of patients with indications for post-ICU treatment receiving it. 
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In the UK, Ostermann et al have performed a review of the ICNARC database and 
identified almost 40,000 patients with a solid tumour and admission to general 
ICUs between 2009 and 2013 [158]. Metastatic disease was present in over one 
fifth of patients. Median APACHE II score was 17 and less than half of the 
population received level three support during the first 24 hours. Of all the 
studies published in this field, the population in this paper most closely 
resembles the ICU cancer population described in this thesis, being both based in 
the UK and within general ICUs. It is therefore unsurprising that ICU and hospital 
mortality is similar (17.1% and 26.4% respectively) to that described in the West 
of Scotland population (14.7% and 25.7%). However, the study was limited to 
that information held within the ICNARC database. This dataset was not linked 
to any cancer registry and the quality of the cancer data may be questionable. 
Furthermore, the lack of data linkage limits the survival analysis to hospital 
mortality and longer-term survival is unknown.  
In a published abstract by Ha et al survival up to one year was described in a 
population of 101 ICU patients with metastatic malignancy [157]. This study 
demonstrated hospital mortality at 35%, comparable with that found in the 
meta-analysis in addition to one-year mortality of 77%. There is little additional 
data provided in the abstract in terms of describing the nature of the critical 
illness and therefore it is unclear whether this cohort is similar to ICU cancer 
populations previously described. 
Bos et al made a further publication in 2015 on their previously described 
population of the rate of ICU cancer patients in the Netherlands between 2006 
and 2011 [159]. This study described the ICU admission rate among cancer 
patients in addition to tumour specific one and two year survival. This included 
lung (64% one-year survival and 53% two-year survival), head and neck (58% and 
51%), colorectal cancer (62% and 49%), pancreatic (56% and 47%), oesophageal 
(72% and 60%), urinary tract (57% and 42%), breast (64% and 57%) and prostate 
cancer (80% and 75%). 
Tumour specific ICU mortality was also described in the study by Hawari et al 
[160]. Their study was based in a single centre oncological ICU in Jordan and also 
noted that one in five patients with solid tumours admitted to their hospital 
  
115 
required ICU admission. ICU mortality varied by cancer type and was reported 
for lung (41.6%), gynaecological (41.4%), breast (36.6%), GI (36.0%) and 
genitourinary tumours (31.3%). 
In 2014 Soares et al published a multi-centre international study of lung cancer 
patients in ICUs admitted during 2011 [161]. They identified 449 patients (88% 
NSCLC) or which 41% had metastatic disease. Just over half of the group 
received ventilatory support at admission to ICU and mean SAPS II score was 
46.1. Outcomes were described as: ICU mortality 28%, hospital mortality 39%, 
30-day mortality 41% and six-month mortality 55%. This survival was more 
favourable than that described in the majority of previous lung cancer studies or 
in the average mortality in this meta-analysis. However, the low requirement for 
ventilatory support may have impacted on the outcomes for this group of 
patients. 
Breast cancer patients admitted to an oncological ICU in Belgium between 2009 
and 2014 were described in a study by Destrebecq et al [162]. Median SAPS II 
score of 34 and median SOFA score of 2 suggest that this cohort had a relatively 
low burden of critical illness. They reported an ICU mortality of 15% and hospital 
mortality 28% for their group of 175 patients. While this is lower than that 
previously reported for breast cancer ICU patients, it is the likely that this 
reflects the mild severity of illness seen in this group. However, it is worth 
noting that this is the largest group of breast cancer patients described in the 
literature and may be reflective of the severity of illness and outcomes seen for 
this population. 
This group of newer publications continue to demonstrate significant variation in 
outcomes dependent on the population being studied. There is still a tendency 
to describe outcomes for a mixed group of cancer patients and in spite of clear 
evidence that survival varies by underlying tumour type. Furthermore, there are 
differences in the populations studied in terms of ICU and critical illness features 
including admission criteria, general/ oncological ICUs, severity of illness and 
organ support utilisation. In addition, some studies are restricted to a subgroup 
of the ICU cancer population such as those patients aged over 64 years, patients 
admitted following cardiac arrest, patients with metastatic disease or patients 
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that receive chemotherapy during their ICU stay. These variations in case mix 
and inclusion criteria make comparisons between studies unhelpful. 
 
 
2.5 Key points 
 Outcomes vary significantly across studies demonstrating differences in 
international and hospital specific case-mix and illness severity, in addition 
to targeted population analyses. 
 Pooled estimate of mortality across all reporting studies found mortality 
within ICU was 31.2% and hospital mortality was 38.2%. 
 Factors associated with ICU and hospital mortality were most commonly 
related to the critical illness such as severity of illness scores, organ support, 
medical admissions and sepsis. 
 Longer-term mortality was rarely reported making pooled estimates 
unhelpful due to the small numbers. 
 ICU and hospital mortality appears to vary by underlying tumour type and 
generally patients with lung cancer seem to have higher mortality rates than 
that reported for other tumour types.  
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Chapter 3 Methods 
In a systematic review of the literature on outcomes in cancer patients admitted 
to ICU, the need for more up-to-date UK-based literature was identified. Given 
the variation in outcomes based upon case-mix future studies should detail 
outcomes for subgroups within the study population. In this large retrospective 
observational study I identified patients resident in the West of Scotland region 
who had a diagnosis of a solid cancer on the Scottish Cancer Registry between 1st 
January 2000 and 31st December 2009. I then determined whether they had been 
admitted to one of the 16 general ICUs located in the region within two years 
following the date of cancer incidence. I then compared the clinical and 
demographic features of this group to those ICU patients who did not have a 
diagnosis of cancer. Finally, long-term survival was assessed in ICU survivors and 
the degree to which this was affected by a diagnosis of cancer. 
 
 
3.1 Setting 
The West of Scotland region, UK, has a population of 2.4 million and comprises 
approximately half of the Scottish population. This region was chosen because it 
is the area that I work within and therefore have links with the ICUs included. It 
is predominantly urban with the majority of the population living in large towns 
or within the city of Glasgow, however, it does have a mix of urban and rural 
population and a good range of socio-economic backgrounds. Scotland has a high 
incidence rate for cancer. Cancer survival within the UK does not compare 
favourably with the rest of Europe [163] and cancer is the commonest cause of 
death within the Scottish population [164]. 
There were 16 general ICUs in the area during the study period. Some functioned 
as combined ICU/HDUs for some or all of the period. The total number of funded 
beds within the West of Scotland ICUs varied during the study period from 77 to 
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104.25 [165]. Throughout this time the number of funded HDU beds within 
combined units also varied although was consistently lower than the number of 
ICU beds funded (Figure 3-1). 
 
Figure 3-1 Total number of funded beds across the West of Scotland ICU’s during the study 
period by ICU and HDU support. 
 
The participating hospitals comprised of Ayr Hospital, Crosshouse Hospital, 
Dumfries and Galloway Royal Infirmary, Falkirk and District Royal Infirmary, 
Forth Valley Royal Hospital, Glasgow Royal Infirmary, Hairmyres Hospital, 
Inverclyde Royal Hospital, Monklands Hospital, Royal Alexandra Hospital, Stirling 
Royal Infirmary, Southern General Hospital, Stobhill Hospital, Victoria Infirmary, 
Western Infirmary and Wishaw General Hospital.  
Glasgow Royal Infirmary, Southern General Hospital, Stobhill Hospital, Victoria 
Infirmary and the Western Infirmary were all city centre teaching hospitals. The 
remaining hospitals were district general hospitals within the area. Hairmyres 
Hospital functioned as a combined ICU/ HDU throughout the study period. The 
unit in Wishaw General Hospital was a combined unit from 2002 – 2008 and the 
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unit in the Western Infirmary was combined from 2002 - 2010. Falkirk and 
District Royal Infirmary was a combined unit that transferred to Stirling Royal 
Infirmary. The HDU beds transferred in 2004 followed by ICU beds in 2005. 
Stirling Royal Infirmary subsequently transferred to a new site at Forth Valley 
Royal Hospital in 2011 which functioned as a combined ICU/ HDU. Stobhill 
hospital closed in 2011 and transferred its ICU beds to Glasgow Royal Infirmary. 
The new critical care unit at Glasgow Royal Infirmary, which opened in 2011 
with the transfer of Stobhill Hospital, also included funding for HDU beds and 
therefore functioned as a combined unit from that point. 
In 2010 the Golden Jubilee National Hospital (GJNH) opened in the West of 
Scotland and all cardiothoracic procedures including lung resection for cancer 
were centralised at this time. During the study period the GJNH did not utilise 
Wardwatcher for collection of ICU data and therefore has not been included in 
this analysis. 
 
 
3.2 Approval for data analysis 
Permission to use Wardwatcher ICU data was obtained from each of the audit 
lead Consultants from the ICUs involved in addition to the West of Scotland 
Critical Care Research Network and the Scottish Intensive Care Society Audit 
Group (SICSAG) who own the Wardwatcher data. 
Use of the West of Scotland Cancer Registry data was authorised by Dr David S 
Morrison, Director, West of Scotland Cancer Surveillance Unit as data controller 
of the West of Scotland extract of the cancer registry. Dr Morrison has previously 
obtained authorisation from all Caldicott Guardians of the West of Scotland 
Health Boards for use of their cancer registry data for the purposes of improving 
the quality of cancer services in the NHS. 
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Ethics approval was sought and granted to create a research database from the 
local research ethics committee using the Integrated Research Application 
System, REC reference 12/WS/0075 (Chapter 8-2 Appendices).  
The SMR linkage, consistent with other routine NHS hospital care and cancer 
registration systems, does not require expressed consent from patients, as it is a 
clinical administration (rather than principally research) system. Any benefits 
from obtaining patient consent were felt to be outweighed by the potential 
harms (including contacting deceased patients’ relatives). Due to the 
retrospective nature of the data analysis it was very unlikely that any patient 
harm was possible.  
Following ethics approval an application was made to the Privacy Advisory 
Committee (PAC) for release of ISD data. This involved completion of PAC 
application to use personal health information for health research or audit form. 
The application for this data release was granted from the privacy advisory 
committee. The requested data was provided and formed the initial dataset that 
was used for analysis. 
 
 
3.3 Data sources 
The data used for analysis were linked data from four large Scottish datasets: 
the Scottish Cancer Registry, Scottish Morbidity Record 01 (SMR01), National 
Records of Scotland death records, and the Scottish Intensive Care Society Audit 
Group (SICSAG) Wardwatcher ICU database. Information Services Division (ISD) of 
NHS National Services Scotland collects the data from each of these sources and 
links them using Community Health Index (CHI) numbers and probabilistic linkage 
procedures. Every patient in Scotland has a unique ten-digit CHI number that is 
allocated on first registration and can be used to identify individuals. This 
linkage of datasets by CHI numbers occurs routinely within ISD.  
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3.3.1 Scottish Cancer Registry dataset 
The Scottish Cancer Registry (SMR06) collects information on all new cases of 
cancer including primary malignant neoplasms, carcinoma in situ, neoplasms of 
uncertain behaviour and benign brain and spinal cord tumours. Cancer diagnoses 
are coded to the International Classification of Diseases 10th revision (ICD-10). 
The registry began in 1958 collecting personal, demographic and diagnostic 
information (such as site, histology, behaviour, histological confirmation and 
hospital of diagnosis) from cancer patients. In 1997, a new electronic cancer 
recording system was launched as part of a centralisation process at ISD. At this 
point the registry was extended to include extra information on tumour stage 
(for breast, cervical and colorectal cancer), tumour grade and treatment 
information such as surgical interventions, radiotherapy, chemotherapy and 
hormone therapy. Cancer incidence is dated as the earliest point that the cancer 
is likely to have existed. This may predate pathological diagnosis if there were 
symptoms, signs or radiological suggestion of tumour prior to pathological 
diagnosis. It is possible for patients with a cancer diagnosis only confirmed after 
death to be entered into the registry if, for example, the patient undergoes 
laparotomy with resection of tumour but dies prior to pathological result or 
where the patient has been symptomatic but the diagnosis is only confirmed at 
post mortem examination. 
A wide variety of geographical data is also included in the dataset including 
Scottish Index of Multiple Deprivation (SIMD), census output area, NHS Board, 
Electoral Ward and Parliamentary constituency. Each cancer diagnosis 
constitutes an entry and a patient can have more than one Cancer Registry 
entries if they have more than one cancer diagnosis. Over 50,000 records of 
primary invasive and non-invasive cancers are added each year. 
Completeness of the patient Community Health Index (CHI) number influences 
the ability to link data to other indexed datasets deterministically. In the most 
recent few years completeness is over 99%, and has been over 90% since 2005. 
Prior to this CHI could not be relied upon for linkage (only present for 56% of 
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cases in 2000) and patients were linked on probabilistic methods. This involved 
linkage of two records based on the likelihood of the records being for the same 
patient. The probability was determined by comparison of other patient 
identifiers including name, date of birth and postcode. 
The West of Scotland cancer registry is a subset of SMR06 held by the West of 
Scotland Cancer Surveillance Unit pertaining to all of those patients resident in 
the West of Scotland. This was used for identifying the cancer patients that were 
not admitted to ICU cohort. 
 
3.3.2 Scottish Morbidity Record 01 dataset 
The General/ Acute and Inpatient Day Case dataset (SMR01) has collected 
episode level data on hospital inpatient and day case admissions from acute 
specialities in Scottish hospitals since 1961. The dataset contains patient 
identifiers, demographic data (including age, sex and SIMD) and data pertaining 
to the clinical episode such as hospital, ward type, admission type, diagnosis (as 
classified under the international statistical classification of diseases and related 
health problems version 10 (ICD-10)), operative interventions, and discharge 
location. Each patient hospitalisation generates a new record and therefore 
patients may have multiple SMR01 records. Approximately 1.4 million records 
are added to the SMR01 dataset annually. Multiple episodes can constitute a 
single admission to hospital as an episode is created when any of the following 
occur: inpatient/ day case admission to NHS hospital, change in specialty, 
transfer to another hospital, transfer to another consultant, change in significant 
facility (including ICU or HDU) or return to hospital after being on pass for 
greater than five days. The main data fields in the SMR01 database used in this 
project were patient demographics, dates of admission and discharge and types 
of admission. 
The SMR01 dataset utilises a patient’s CHI number to link data deterministically 
to the other indexed datasets and the CHI number is then attached by ISD to 
historical records retrospectively to improve linkage. In recent years SMR01 data 
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has been demonstrated to be 98 – 99% complete and external validation checks 
are in place within ISD. 
 
3.3.3 National Records of Scotland Death Records dataset 
National Records of Scotland (NRS) records all deaths registered in Scotland in a 
database that has been established since 1974. The dataset includes information 
pertaining to cause of death, date of death, age at death and place of death. 
The NRS undergoes regular quality assurance checks to ensure data accuracy and 
the quality of data is of a high standard. This NRS is linked to the ISD datasets 
and for patients on the Cancer Registry additional confirmatory checks are made 
on death data by the Cancer Registry team. 
 
3.3.4 SICSAG Wardwatcher dataset 
The SICSAG has maintained a national database of patients admitted to adult 
general ICUs in Scotland since 1995. The SICSAG Wardwatcher audit system is in 
place in all general adult ICUs throughout Scotland. It collects data on patient 
demographic details, admitting specialty, admission diagnosis, patient’s prior 
location, co-morbidities and type of organ support for all ICU admissions. Audit 
data is collected prospectively and is completed by individuals within the 
participating unit such as clinicians, nursing staff and clerical staff. It has been 
routinely linked to ISD data, including SMR01, since 2006 and historically back to 
1998. All patients recorded in the SICSAG database should have SMR01 records 
relating to the same hospital stay. From 1998 to 2014, 96% of all SICSAG episodes 
were matched to an SMR01 stay.  
The data is collected within each unit and directly inputted into the 
Wardwatcher data collection form and stored on the hospital computer system. 
With each ICU admission, a form is created with a specific key number for that 
admission. If a patient has multiple admissions to ICU then they will also have 
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multiple key numbers thus the key number identifies an ICU admission rather 
than a patient. For each ICU admission, data is collected pertaining to patient 
identity and demographics, hospital admission type and source, circumstances of 
ICU admission, past medical history, diagnosis, severity of illness, organ support 
and discharge details. The demographic details are collected on an admission 
page (Figure 3-2).  
 
Figure 3-2 SICSAG Wardwatcher admission data entry screen 
 
Separate data entry pages are used for admission circumstances, co-morbidities 
and diagnosis. Comorbidities recorded on the history section of the Wardwatcher 
system are strictly defined as per the APACHE definitions. Diagnostic information 
is collected as a selection from a potential list of 212 APACHE pre determined 
diagnoses. In addition there is also a section for the SICS diagnostic coding which 
allows for a larger range of diagnoses in addition to free text options. 
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The severity of illness section collects data required for the calculation of an 
APACHE II score. This data may be entered manually or automatically 
transferred from a clinical computer system if in use. 
The Augmented Care Period (ACP) data is collected on a daily basis and records 
the highest level of care for that period based on the support of five organ 
systems. This data includes information pertaining to organ support including 
mechanical ventilation, cardiovascular support (with vasoactive drugs) and renal 
replacement therapy. Additional information from ACP includes neurological 
monitoring, nutritional support and requirement for complex dressings. 
On ICU discharge the final data entry screen is completed with information on 
whether the patient is alive or dead at ICU discharge, discharge destination and 
expected hospital outcome. 
SICSAG and Wardwatcher have a number of processes to ensure data quality. At 
the point of data entry, Wardwatcher has been programmed to query data 
entries that are incongruous or unexpected. For example, if the ICU discharge 
date is input for a date prior to ICU admission then the system will query this. In 
addition, case note validations are undertaken periodically throughout the year 
by Quality Assurance managers and Co-ordinators during site visits. Finally 
central validation takes place where missing data fields are queried with the 
local co-ordinator and age and length of stay are validated against that 
documented in the SMR01 dataset. 
SICSAG episodes were matched to SMR01 stays using the dates of hospital and 
ICU admission and discharge. This allowed identification of type of hospital 
admission, admitting specialty and discharge date. All SICSAG records should be 
represented in the SMR01 dataset as an in-patient stay. However, a small 
proportion of SICSAG records were unable to be linked to the SMR01 dataset 
because they fell below the linkage threshold for probabilistic matching. This 
may be due to inaccuracies with data entry within the patient identifier section. 
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3.4 Inclusion criteria 
3.4.1 Cancer patients 
Patients were included in the cancer population if they were aged 16 or older, 
resident in the West of Scotland, and had a diagnosis of a solid tumour as 
defined by ICD-10 codes (C00-C76, excluding non-melanoma skin cancer C44 and 
CNS neoplasms C69-C72) in the Scottish Cancer Registry between 1st January 
2000 and 31st December 2009. Patients were excluded if they had a diagnosis of 
haematological malignancy (ICD-10 codes C81-C96, D45-D47) because there has 
been a separate series of significant changes in guidance for treatment and 
support of patients with haematological malignancies over the study period. 
Patients with CNS neoplasms (ICD-10 codes C71-72, D32-33, D35.2-35.4, D42-
D43, D44,3-D44.5)) were excluded because they are more likely to be admitted 
to a specialised ICU. For simplicity, patients who had more than one cancer were 
grouped separately under the label “Multiple cancers”. The incidence date of 
the earliest diagnosed tumour was used in cases of multiple cancers.  
 
3.4.2 ICU patients 
The ICU population was defined as having an admission to one of the 16 general 
adult ICUs in the West of Scotland between 1st January 2000 and 31st December 
2011 as identified by the Wardwatcher database. If a patient had more than one 
ICU admission we used the date and outcome of the first ICU admission. Patients 
that were admitted to a combined unit during this time were considered to be 
an ICU patient. 
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3.4.3 ICU Cancer population 
Patients that were identified as having a solid tumour between 1st January 2000 
and 31st December 2011 and had an ICU admission up to two years after the date 
of cancer incidence were defined as the ICU cancer group. This time period was 
chosen so that the cancer population were likely to have either active disease or 
be undergoing treatment for their cancer at the time of ICU admission. 
 
3.4.4 ICU Non-Cancer population 
The ICU non-cancer population were those patients within the ICU population 
who do not appear on the Cancer registry at any point. Patients with a diagnosis 
of cancer after their ICU admission were excluded from this group and included 
in the “Cancer Non-ICU population”. This was to ensure that ICU admissions due 
to an undiagnosed cancer were not included and to guarantee that cancer did 
not impact upon survival of patients in the non-cancer group.  
 
3.4.5 Cancer Non-ICU population 
Patients with cancer confirmed on the West of Scotland cancer registry (SMR06) 
that are not admitted to ICU at any point after 1st January 2000 were considered 
to be the cancer non-ICU population. No restrictions were made on cancer 
patients that had been admitted to ICU prior to cancer diagnosis. 
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3.5 Definition of variables 
3.5.1 ICU Diagnosis 
Within the diagnosis screen of Wardwatcher there are several options for 
defining the diagnosis that are used for different purposes. These include the 
APACHE diagnosis, the SICS hospital admission diagnosis and the SICS ICU 
admission diagnosis. 
The APACHE diagnosis pertains to ICU diagnosis and is required to calculate the 
predicted mortality from the APACHE score. The APACHE diagnosis is a broad 
classification designed to divide patients into groups whose reason for admission 
has a similar impact or mortality probability. There are a limited number of 
options that are determined by whether the patient was admitted from theatre/ 
recovery (limited to 94 surgical diagnoses) or not (limited to 118 medical 
diagnoses). In some circumstances patients may be admitted to ICU for medical 
reasons following surgery (e.g. dysrhythmias during routine surgery). In this case 
the APACHE diagnosis would be the surgery that the patient underwent. In other 
circumstances, patients may be admitted to the unit from a ward within hours of 
undergoing surgery. In this situation the diagnosis would be the medical 
condition that precipitated admission not the surgical diagnosis. This strict 
criterion stems from the APACHE methodology and can be misleading when used 
for descriptive studies.  
In addition to APACHE diagnosis, Wardwatcher also collects data from SICS 
diagnostic coding. This is a list of diagnoses created by the Scottish Intensive 
Care Society that groups patients into categories that are more useful 
descriptors of the types of patients being admitted to Scottish units. Within the 
SICS diagnostic coding there are entries for “Diagnosis requiring hospital 
admission” and “Diagnosis requiring unit admission” and these options are not 
limited by whether the patient was admitted from theatre or another source. In 
addition to the available diagnoses there are options for free text to allow 
additional details to be provided. 
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As fewer restrictions are placed on the SICS diagnostic coding this was used as 
the principle source of ICU diagnosis. Different diagnoses were categorised into 
diagnostic groups to allow broad descriptions to be made. Details of these 
categories are listed in Appendix table 8-3. 
 
3.5.2 Admission type 
3.5.2.1  Hospital admission specialty 
Patients were considered to be surgical or medical hospitalisation depending on 
the admission sub-specialty documented at hospital admission in the SMR01 
dataset. The SMR01 further documents whether the hospitalisation during which 
the ICU admission occurred was emergency or elective in nature. This allowed 
categorisation of hospital admission type into elective surgical, emergency 
surgical, elective medical or emergency medical. 
 
3.5.2.2  ICU admission specialty 
ICU admission specialty was taken from the Wardwatcher database using the 
data collected on the history screen under admission specialty. It is not 
documented whether the admission to ICU was planned (elective) or emergency 
in nature. 
 
3.5.3 Organ support 
The ACP section of Wardwatcher was used to determine delivery of organ 
support. Organ support was defined as the patient receiving any of mechanical 
ventilation via endotracheal tube or tracheostomy, vasoactive support (single or 
multiple) or renal replacement therapy of any modality, during their ICU stay. 
Additional information on organ support was available but not utilised. 
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Neurological support such as intra-cranial pressure monitoring would not 
routinely be provided in a general ICU and within the West of Scotland and is 
only available at the specialist Neuro-ICU. Gastrointestinal support was defined 
on Wardwatcher as receipt of artificial nutrition. However, this would be 
considered routine practice on a general ward outwith an ICU, as is 
dermatological support in the form of significant skin dressings. For this reason 
gastrointestinal support and dermatological support were not considered to be 
organ support for the purpose of this work.  
 
3.5.4 Socioeconomic circumstances 
Socioeconomic circumstances were measured using the Scottish Index of Multiple 
Deprivation 2006 (SIMD). This was available through linkage to the SMR01 
database. It provides an area-based measure of socioeconomic circumstance, 
based on the postcode of residence. There are 6505 geographical small areas or 
data zones across Scotland each containing approximately 750 people. The SIMD 
score provides a relative ranking of these 6505 areas from the most to the least 
deprived, based on detailed information on seven key subject areas including: 
(1) income and benefits (2) employment in working age population (3) health 
and healthcare utilisation (4) educational attainment, skills and training (5) 
access to services and transport (6) recorded crime rates and (7) housing quality 
and overcrowding. The score generated for each key subject area (weighted 
towards income, employment and education) is ultimately combined to create 
an overall SIMD score for each data zone. Overall, SIMD 2006 scores are 
presented as quintiles, with 1 representing the least deprived and 5 representing 
the most deprived; each representing 20% of the Scottish population. Individual 
SIMD scores can then be assigned to the population, based on the postcode of 
residence.  
Area-based measures of deprivation such as this one can incorporate data about 
individual living standards, along with broader issues such as crime, the physical 
environment, access to services or social capital. However, the system only 
allows a measure of relative deprivation within Scotland and not absolute 
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deprivation. Nor is it possible to compare different levels of deprivation in one 
area across different points in time. However, the primary disadvantage of an 
area-based measure is that it is not able to provide information about 
individuals. This is known as the ecological fallacy where conclusions are made 
about individuals based only on analyses of group data from which that 
individual belongs. Within each area it does not specify the number of 
individuals within each deprivation group or the form of deprivation experienced 
by any individual or groups. The practical reality is that the data is not currently 
available to produce an individual measure with the same detail and 
comprehensiveness as SIMD and that this is the best available system for making 
these measurements. 
 
3.5.5 Survival data 
Date of death was taken from NRS dataset as this is the most valid basis of 
identifying a death record. Place of death was defined as occurring in ICU if this 
had been recorded in WardWatcher as such. Death in hospital was determined 
when death had not occurred in ICU as per Wardwatcher but had occurred prior 
to or at the discharge date recorded on the corresponding SMR01 data entry. For 
patients without a corresponding SMR01 record, Wardwatcher hospital outcome 
was used to determine hospital survival. 
 
 
3.6 Missing data 
3.6.1 Organ support/ ACP 
Data pertaining to organ support was collected daily on the Augmented Care 
Period (ACP) form within Wardwatcher. The ACP uses the organ support data to 
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determine the level of care received by the patient on a daily basis and 
differentiates ICU and HDU patients. 
The Wardwatcher data collection form for ACP was changed in 2004. ISD did not 
collect the ACP data prior to 2004 and this was unavailable on the initial linked 
dataset. However, the original data pertaining to organ support was still 
available on the Wardwatcher computers within each hospital site. To ensure 
the maximum amount of data was available each of the 16 included hospital 
sites were visited and the Wardwatcher computer interrogated for the pre 2005 
ACP data. This data was collected from these original sources and added to the 
full dataset by means of deterministic matching based on CHI, name, date of 
birth and postcode. This allowed the dataset to be as complete as possible, 
however, a proportion of missing data remained.  Receipt of organ support could 
not be fully ascertained for 15% of patients prior to 2005 mainly because of 
incomplete renal support data. The number who received organ support prior to 
2005 is therefore underestimated. However the proportion of patients who 
received renal support only is small (0.8% of patients admitted after 2004) and 
thus it is unlikely that the missing organ support data would substantially bias 
the findings. 
When describing or analysing the effects of a specific mode of organ support 
patients with missing data for that organ support were dealt with separately. 
When calculating the numbers of organ supported, patients were categorised as 
not having received the particular organ support if the data was missing for that 
particular modality. For example, if a patient was known to receive mechanical 
ventilation and vasoactive drugs but data regarding renal replacement therapy 
was missing then they were categorised as have received two organ support. 
Patients with missing data for all three types of organ support were analysed 
separately as an unknown group. 
Level of care data prior to 2005 was unreliable and poorly completed. It was 
therefore not possible to identify which patients admitted to combined units 
were ICU patients and which were HDU patients using the ACP level of care data. 
  
133 
 
3.6.2 APACHE II 
Certain groups of patients are excluded from APACHE scoring including patients 
aged less than 16 year of age; ICU stay less than 8 hours; readmissions to ICU 
during the same hospital stay; and primary diagnosis for which the system was 
not developed of validated (e.g. burns, coronary artery bypass graft, and liver 
transplant). In addition, clinicians within the individual units could opt out of 
APACHE scoring of selected patients at their own discretion. As a result there 
are a significant number of ICU admissions without a corresponding APACHE 
score. For the purposes of analysis, the group with a missing APACHE score was 
analysed separately. 
 
3.6.3 Survival data 
Not all patients that featured on the Wardwatcher ICU database had a 
corresponding SMR01 entry. Of the 41,689 ICU admissions 40,585 (97.4%) had a 
SMR01 record corresponding to the ICU admission. If the patient did not have a 
SMR01 entry then this could not be used to determine whether the patient died 
prior to or after discharge. The Wardwatcher dataset documents death in ICU or 
hospital and this has been used to determine in-hospital mortality for those 
patients without a corresponding SMR01 entry. 
For the ICU admission cohort, follow up time started on the day of ICU 
admission. All patients were followed up until the date of death, or when four 
years of follow up was completed. Complete follow up was available for all 
patients.  
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3.7 Statistical analysis 
Statistical analyses were performed using Stata software (version 14, StataCorp 
2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). 
  
3.7.1  Descriptive analysis 
Descriptive analysis involved documenting a cumulative count of numbers 
followed by a percentage of the studied cohort. Unless otherwise stated, median 
and inter-quartile ranges were used to summarise continuous variables, and 
Wilcoxon rank sum test (Mann Whitney) to test for differences in median values. 
Median values were chosen, as the data was not normally distributed. Pearson’s 
chi-square test and exact 95% confidence intervals were used to compare 
proportions. A significance level of 5% was accepted. 
Wilcoxon rank sum test is a non-parametric test that can be used to determine 
whether two dependent samples were selected from populations having the 
same distribution [166]. The variable of interest is ordered and the sum of the 
ranks for each population is then calculated. Where the population is of differing 
sizes this is accounted for. The smallest value of the sum of the ranks is then 
compared with a critical value that represents the smallest value that could be 
expected if the null hypothesis was true. If it is less than the critical value then 
the null hypothesis is rejected.  
Pearson’s chi-squared test is applied to sets of categorical data to evaluate how 
likely it is that any observed difference between the sets arose by chance [167]. 
This calculates the difference between an observed frequency and expected 
frequency, squares this value (to ensure a positive value) and divides it by the 
expected frequency. This is performed for each of the outcome variables and 
then summed to give a chi-square value. This value, in addition to the degrees of 
freedom of the dataset (a measure of the number of variables and potential 
outcomes that determines the potential for variation within the dataset) is then 
used to calculate a p-value. The chi-squared test has a number of assumptions. 
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It requires that the sample data is a random sampling from a fixed population 
where every member of the population has an equal probability of selection. 
Furthermore the observations are assumed to be independent of each other and 
each subject can only contribute to one outcome for one variable. A sample with 
a sufficiently large size is required to avoid committing a type II error (i.e. 
Incorrectly accepting a false null hypothesis). A minimum number of 20 subjects 
has been suggested to avoid this or the use of a correction where the expected 
frequency of events for any given cell is less than five. 
 
3.7.2  Survival analysis 
Survival was described in terms of ICU, hospital and time-defined survival. In 
addition, Kaplan-Meier survival graphs were plotted for specific subgroups using 
the log-rank test for equality of survivor functions to calculate a p-value. The 
log-rank test is a non-parametric test of the null hypothesis that no difference 
between the population survival curves exists [168]. For each event, the 
observed number of deaths in each group and the number of deaths expected if 
there were no differences between the groups is calculated. These calculations 
are performed each time an event occurs. From the calculations, the number of 
expected and observed deaths are totalled in each group. This is then used for a 
x2 test of the null hypothesis where the observed minus expected value is 
squared then divided by the expected value for each group. The sum of these 
values gives the test statistic. The test statistic and the degrees of freedom are 
compared with a table of x2 distribution to give a p value. The log-rank test is 
most likely to detect a difference when the risk of an event is consistently 
greater for one group than another and is unlikely to detect a difference when 
survival curves cross. Therefore, when analysing survival data, the survival 
curves were always plotted. 
When assessing factors associated with mortality risk after ICU, hazard ratios 
were calculated using Cox proportional hazard models. The hazard ratio is the 
ratio of hazards between two groups. The hazard represents the probability that 
an individual would experience an event at a particular given point in time. For 
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the purposes of survival analysis the event is death. The hazard ratio is the odds 
that an individual in a group with the higher HR reaches the endpoint first. 
Hazard ratios differ from relative risks (RR) or odds ratios (OR) in that the RRs 
and ORs are cumulative over an entire study, using a defined end point, while 
HRs represent instantaneous risk over the study time period. 
Univariate analysis describes the difference between groups when only the single 
variable concerned is accounted for while ignoring the impact of any others. 
Multivariable analysis allows the impact of a variable to be evaluated following 
adjustment for all other variables that may also potentially affect the outcome.  
Cox proportional hazards regression is a method of multivariable analysis that is 
used for investigating differences in survival due to independent variables and 
distinguishes the individual contributions of covariates on survival [169].  
The Cox model is expressed by the hazard function denoted by h(t). The hazard 
function is the risk of dying at time t and can be represented by [170]: 
h(t) = h0(t) x exp(b1x1 + b2x2 + …+ bpxp) 
Where t represents the survival time and h(t) is the hazard function determined 
by a set of p covariates (x1, x2,…,xp). The coefficients (b1,b2,…,bp) measure the 
impact of the covariates. The baseline hazard (h0(t)) is the baseline hazard when 
all the covariates are equal to zero (i.e. exp(0) = 1). 
When comparing two groups and calculating a hazard ratio it is assumed that the 
ratio of the hazard between the groups remains constant over time. This applies 
even if the magnitude of the hazards varies over time and the constant ratio is 
known as the hazard ratio. Thus the mortality rate might be different between 
the two groups but the pattern of mortality remains the same. It is important to 
verify that the covariates satisfy the assumption of the proportionality as if this 
assumption is violated, the Cox model is invalid and more sophisticated analyses 
are required. 
The proportional hazards (PH) assumption can be checked using statistical tests 
and geographical diagnostics. Using Schoenfeld residuals involves calculating the 
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observed rate minus the predicted rate for each covariate over time [171]. This 
difference between observed and expected for each covariate should remain 
constant over time and is considered to be a zero slope. If the residuals vary 
with time then there is a non-zero slope which is an indication of a violation of 
the proportional hazard assumption. Statistical software plots the Schoenfeld 
residuals and reports p-values for likelihood of any PH violations. 
The assumption that the proportional hazards remains constant with time can be 
visually assessed using a graph that demonstrates the logarithm of the estimated 
cumulative hazard function over time (log –log plots) [172]. The assumption is 
equivalent to assuming that the difference between the logarithms of the 
hazards for the two groups does not change with time and therefore the 
difference between the logarithms of the cumulative hazard functions is 
constant. The PH assumption is supported by parallel lines between groups and 
refuted by lines that cross or nearly cross. 
 
 
3.8 Data handling and storage 
Data received from ISD was stored on a password-protected encrypted file server 
at the West of Scotland Cancer Surveillance Unit, 1 Lilybank Gardens, Glasgow 
G12 8RZ. This file server was located in a locked office within a department that 
requires an entry code to gain access. Outwith office hours the building was 
locked and alarmed. The file server was backed up in a locked fire safe in a 
locked basement room.  
A user account and password was created for each individual involved with data 
analysis to allow access to a single PC to work on the data. Passwords were 
alphanumeric and a minimum of 8 characters long. Password-protected screen 
savers were activated on all PCs after 5 minutes of inactivity. All patient-
identifiable information was removed from the combined dataset prior to data 
analysis. No identifiable data was released for off-site working and when non-
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identifiable data was taken off-site it was transported using an NHS-approved 
encrypted USB drive. 
In accordance with good research practice [173], data will be kept securely in 
password-protected, encrypted electronic format for at least 10 years after 
publications have been completed. 
 
 
3.9 Key points 
 ICU data was collected from the 16 West of Scotland ICUs which included a 
small proportion of HDU patients from those combined units. 
 ISD provided data linked between the Wardwatcher ICU database, the 
hospitalisation database (SMR01), the cancer database (SMR06) and death 
records (NRS). 
 Data was optimised by adding information retrieved from the individual ICU 
sites. 
 Patients groups by whether they had cancer and whether they were admitted 
to ICU to create three cohorts: 
o Cancer patients that have been admitted to ICU 
o Cancer patients that have not been admitted to ICU 
o ICU patients without cancer 
 Approval was sought and granted from individual ICUs, the West of Scotland 
Critical Care Research Network, the Scottish Intensive Care Society Audit 
Group, the West of Scotland Cancer Surveillance Unit, the local Ethics 
committee and the Privacy Advisory Committee (ISD).  
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Chapter 4 What proportions of cancer patients 
are admitted to ICU and what are the features 
associated with admission? 
4.1 Introduction 
Development of a critical illness requiring ICU support is an important clinical 
event for a cancer patient and is likely to impact upon survival. There may be 
certain features that increase a cancer patient’s risk of developing critical 
illness, however, this has not been previously explored. If the factors associated 
with ICU admission were better understood, then clinicians may be better placed 
to monitor patients at higher risk in an attempt to minimise morbidity and 
mortality. The aim of this study was to describe the factors associated with 
critical illness resulting in ICU admission among patients with solid tumours.  
 
 
4.2 Study questions 
4.2.1 What proportions of patients diagnosed with a solid tumour 
are admitted to ICU? 
I will describe the overall proportion of cancer patients that are admitted to ICU 
in the first two years following diagnosis and how this varies by patient age, sex, 
hospital admitting specialty, and socioeconomic status. Overall, the total 
number of patients admitted to ICU will be examined in addition to the number 
admitted to ICU that subsequently received organ support.  
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4.2.2 At what point does the ICU admission occur after cancer 
diagnosis? 
Cancer patients may present to ICU at different points during their illness. The 
ICU admission may be associated with the initial cancer diagnosis, as a direct 
consequence of surgery or chemotherapy, due to long-term complications 
associated with the cancer or its treatment, or due to an unrelated illness. I will 
describe the time from cancer incidence date to the date of ICU admission up to 
two years following cancer incidence. 
 
4.2.3 Do rates of ICU admission vary according to underlying 
tumour types? 
It might be expected that different tumour types and their specific treatments 
may result in different requirements for ICU. I will therefore describe the 
proportion of patients admitted to ICU for each underlying tumour type and 
describe them in terms of timing of ICU admission, hospital admission type and 
receipt of organ support. 
 
4.2.4 Which features are associated with ICU and hospital 
mortality? 
I will report ICU and hospital mortality for all patients admitted to ICU in 
addition to the following subgroups; hospital admission features, receipt of 
organ support during ICU, underlying tumour type and socioeconomic status.  
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4.3 Methods 
Cancer patients’ and rate of ICU admission was initially calculated using a 
cumulative count of numbers of ICU admission expressed as a percentage of the 
incident cancer population. This was described for different age groups, sex, and 
cancer types. The population was then described in terms of time from cancer 
diagnosis to ICU admission. Those cancer patients that were admitted to ICU 
were then described in more detail in terms of hospital admission type (during 
same inpatient stay as ICU admission) described as emergency or elective, 
hospital admitting specialty (dichotomised as medical or surgical) and by receipt 
of organ support. Organ support was used to identify those patients admitted to 
combined units for routine post-operative care or monitoring. Patients that did 
not receive organ support during their ICU stay may be regarded as level 2 or 
HDU patients. Organ support was defined as one of mechanical ventilation, 
vasoactive drugs or renal replacement therapy. 
 
 
4.4 Results 
In the West of Scotland between 2000 and 2009, 118,541 patients were 
diagnosed with a solid tumour. Within 2 years of cancer diagnosis 6,116 (5.2%, 
95% CI 5.0-5.3%) of these patients experienced a critical illness resulting in 
admission to ICU. 
 
4.4.1 Cancer patients demographics at admission to ICU 
The median age of all cancer patients was 69 (IQR 59-77) and 61,607 (52%) were 
women. Those aged 60 years and older accounted for three quarters (74.8%) of 
the cancer population (Table 4-1). Of those cancer patients admitted to ICU the 
median age was 68 (IQR 60-75) and 2,542 (42%) were women. Admission to ICU 
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increased with increasing age, rising from 2.2% at ages 16-29 to a maximum of 
6.3% between the ages of 60 and 69 and declined thereafter to a low of 1.6% in 
the 90 years and over age group. A similar pattern was observed in the group of 
patients who received organ support in ICU. Of the cancer patients aged 16 to 29 
years, only 1.4% were admitted to ICU for organ support. This proportion 
increased with increasing age up to a maximum of 3.7% for those cancer patients 
aged 60 to 69 years. Following this the proportion falls with increasing age to a 
low of 0.9% in the 90 years and over age group. 
Age Group 
(years) 
All 
cancer 
patients, 
N  
Admitted to 
ICU, N (%) 
Received organ 
support, N (%) 
Proportion of 
cancer 
population 
admitted to ICU 
for organ 
support 
16-29 1163 26 (2.2) 17  (65.4) 1.4% 
30-39 3128 90 (2.9) 48  (53.3) 1.5% 
40-49 7844 371 (4.7) 206  (55.5) 2.6% 
50-59 17690 985 (5.6) 618  (62.7) 3.5% 
60-69 30749 1945 (6.3) 1151  (59.2) 3.7% 
70-79 35423 1938 (5.5) 1159  (59.8) 3.3% 
80-89 19557 712 (3.6) 397  (55.8) 2% 
90+ 2987 49 (1.6) 28  (57.1) 0.9% 
All cancer 
patients 
118,541 6116 (5.2) 3624  (59.3) 3.1% 
Table 4-1 Incident cancers by age group with proportion admitted to ICU (and receive organ 
support) within 2 years of diagnosis. Modified from “Risk of critical illness among patients 
with solid tumours.” Puxty et al. JAMA Oncology (2015) with permission. 
 
Hospital admission data from the same hospitalisation as ICU admission was 
available for 6040 patients (98.8%). Most ICU admissions followed a surgical 
hospitalisation with 83.2% (95% CI 82.3-84.1%) versus 15.5% (95% CI 14.6-16.4%) 
for medical hospitalisations. Admission to ICU occurred followed an emergency 
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hospitalisation for 43% of patients. Organ support was received by 59.3% of 
cancer patients admitted to ICU, or 3.1% (95% CI 3.0-3.2%) of all cancer patients. 
Among patients who received organ support, 18.9% (95% CI 17.6-20.2%) had been 
admitted to a medical specialty at hospital admission (Table 4-2). The 
proportion admitted to a medical specialty was higher at younger ages than at 
older ages with the exception of those aged 90 years and older. 
Age group Medical n (%) Surgical n (%) 
16-29  4  (23.5) 13  (76.5) 
30-39  12  (25) 36  (75) 
40-49  48  (23.3) 156  (75.7) 
50-59  117  (18.9) 494  (79.9) 
60-69  216  (18.8) 921  (80) 
70-79  210  (18.1) 936  (80.8) 
80-89  71  (17.9) 322  (81.1) 
90+ 7  (25) 21  (75) 
All cancer patients  685  (18.9) 2899  (80) 
Table 4-2  Admitting specialty of patients who receive organ support in ICU by age group 
(percentages do not sum to 100% because some ICU patients could not be matched to a 
hospital admission record). Modified from “Risk of critical illness among patients with solid 
tumours.” Puxty et al. JAMA Oncology (2015) with permission. 
 
The incidence of critical illness was higher in men than in women for all age 
groups (Figure 4-1). For men, the highest risk of ICU admission occurred in the 
age 40-49 years group. The peak incidence for women occurred at 60-69 years. 
These trends are similar to that for ICU admission with organ support and are 
represented in Figure 4-1 by dashed lines. 
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Figure 4-1  Percentage of cancer patients admitted to ICU within 2 years of cancer incidence 
by sex and age. Modified from “Risk of critical illness among patients with solid tumours.” 
Puxty et al. JAMA Oncology (2015) with permission. 
 
4.4.2 Timing of ICU admission following cancer diagnosis 
The time from cancer diagnosis to ICU admission is demonstrated in Figure 4-2. 
There was an initial sharp increase in the cumulative incidence of ICU admission 
following cancer diagnosis. By 100 days post diagnosis 3.7% (95% CI 3.6-3.9%) of 
cancer patients had been admitted to ICU. There was then a slower increase 
reaching 4.5% (95% CI 4.4-4.6%) by 200 days after diagnosis. Following this there 
was then a slow but steady climb in the cumulative incidence and at 2 years 
5.2% (95% CI 5.0-5.3%) of patients diagnosed with a solid tumour had been 
admitted to an ICU. 
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Figure 4-2 Cumulative incidence of admission to ICU by time since cancer incidence date. 
Shaded areas represent 95% CI. Modified from “Risk of critical illness among patients with 
solid tumours.” Puxty et al. JAMA Oncology (2015) with permission. 
 
Year of cancer incidence had an impact on the rate of admission to ICU. From 
2000 to 2009 there was a decline in the proportions of solid tumour patients 
diagnosed who developed a critical illness and were admitted to ICU (Figure 4-
3). This decline was predominantly among patients who did not receive organ 
support; there were smaller reductions in ICU admissions for patients who 
required organ support. This change was similar for both of the sexes and is 
likely to reflect changes within the ICUs during this time period or in patient 
management. 
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Figure 4-3 Trends in the percentage of cancer patients admitted to ICU by year of incidence. 
Modified from “Risk of critical illness among patients with solid tumours.” Puxty et al. JAMA 
Oncology (2015) with permission. 
 
 
4.4.3 Tumour type and risk of ICU admission 
For specific solid tumour types the cumulative incidence of critical illness and 
ICU admission varied (Table 4-3). During 2000-2009 the most frequently 
diagnosed solid cancers were lung, breast and colorectal malignancies making up 
19.8%, 14.8% and 13.1% of all solid tumour diagnoses respectively. However, the 
pattern of those admitted to ICU did not reflect cancer incidence rates.  
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Cancer type,            
N = Incident number 
of cancers 2000-2009 
Admitted to 
ICU,          
N (%) 
Emergency 
hospital 
admission,     
N (%) 
Received 
organ 
support,     
N (%) 
Proportion 
admitted to 
ICU for organ 
support 
Colorectal N=15,535 2561 (16.5) 1167 (45.6) 1225 (47.8) 7.9% 
Head & neck N=4958 636 (12.8) 164 (25.8) 582 (91.5) 11.7% 
Stomach N=4045 456 (11.3) 129 (28.3) 234 (51.3) 5.8% 
Oesophagus N=3815 389 (10.2) 74 (19.0) 255 (65.6) 6.7% 
Lung N=23,443 381 (1.6) 230 (60.4) 285 (74.8) 1.2% 
Kidney N=3054 249 (8.2) 63 (25.3) 137 (55) 4.5% 
Bladder N=3523 182 (5.2) 68 (37.4) 115 (63.2) 3.3% 
Breast N=17,591 149 (0.8) 94 (63.1) 93 (62.4) 0.5% 
Ovary N=2910 138 (4.7) 84 (60.9) 68 (49.3) 2.3% 
Prostate N=11,337 136 (1.2) 71 (52.2) 85 (62.5) 7.5% 
Cervix & corpus uteri 
N=3721 
113 (3) 58 (51.3) 65 (57.5) 1.7% 
Unknown N=5722 121 (2.1) 103 (85.1) 88 (72.7) 1.5% 
Pancreas N=2920 81 (2.8) 61 (75.3) 56 (69.1) 1.9% 
Liver N=2291 67 (2.9) 43 (64.2) 50 (74.6) 2.2% 
Small intestine 
N=319 
55 (17.2) 43 (78.2) 33 (60) 10.3% 
Thyroid N=700 28 (4) 11 (39.3) 18 (64.3) 2.6% 
Testis N=1018 26 (2.6) 14 (53.8) 21 (80.8) 2.1% 
Melanoma of skin 
N=4070 
18 (0.4) 13 (72.2) 14 (77.8) 0.3% 
Mesothelioma 
N=1029 
18 (1.7) 12 (66.7) 13 (72.2) 1.3% 
Other N=3163 106 (3.4) 53 (50.0) 59 (55.7) 1.9% 
Multiple N=3377 206 (6.1) 74 (35.9) 128 (62.1) 3.8% 
Total N=118,541 6116 (5.2) 2629 (43.0) 3624 (59.3) 3.1% 
Table 4-3  ICU admissions within 2 years of cancer incidence by cancer type. Modified from 
“Risk of critical illness among patients with solid tumours.” Puxty et al. JAMA Oncology 
(2015) with permission. 
  
148 
 
The rate of admission to ICU was greatest for small intestinal and colorectal 
malignancies (17.2%, 95% CI 13.3-21.8%, and 16.5%, 15.9-17.1%, respectively). 
Other tumour types that had a high rate of admission were those that are likely 
to require peri-operative critical care support for tumour resection surgery such 
as head and neck cancers (12.8%, 95% CI 11.9-13.8%), stomach cancer (11.3%, 
95% CI 10.3-12.3%) and oesophageal cancer (10.2%, 95% CI 9.2-11.2%). Although 
breast cancer had a high incidence, the risk of critical illness and ICU admission 
was among the lowest of all malignancies at 0.8% (95% CI 0.7 - 1.0%). 
Patients with colorectal cancer made up the largest proportion of ICU cancer 
patients (41.9%). Cancer stage was not recorded for most cancer sites but was 
available for 77.7% (12071/15535) of colorectal cancers. The ICU admission rate 
was higher among Dukes stage B and C colorectal patients (22.9%, 95% CI  21.6-
24.3% of patients with Dukes B and 23.8%, 95% CI 22.4-25.3% of patients with 
Dukes C) compared to Dukes A or D (15.8%, 95% CI 14.1-17.6% of Dukes A 
patients and 9.6%, 95% CI 8.6-10.7% of Dukes D patients). 
While lung cancer was the fifth most frequent cancer type admitted to ICU (6.2% 
of ICU cancer admissions) this under represents the lung cancer population, as 
this was the most frequently diagnosed tumour type during this time period.  
The majority of cancer patients (57%) were admitted to ICU after an elective 
admission to hospital. The proportion of admissions to ICU which occurred during 
an emergency hospital admission varied from a low of 25% for kidney and head & 
neck cancers, to 78% and 85% of patients with cancers of the small intestine and 
unknown primary, respectively.  
Organ support was provided to 59.3% of all solid tumour patients admitted to 
ICU, corresponding to 3.1% (95% CI 3.0-3.2%) of all patients with solid tumours. 
Receipt of organ support varied by cancer type and was lowest for colorectal 
cancer patients (47.8%, 95% CI 45.9-49.8%). Patients with head and neck cancer 
had the highest frequency of organ support at 91.5% (95% CI 89.1-93.6%) and this 
is likely to represent ventilation via tracheostomy in this patient subgroup.  
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The majority (80.0%) of cancer patients who received organ support were 
surgical patients but there was substantial variation by cancer type (Table 4-4). 
Over 85% of colorectal, head and neck, stomach, bladder, kidney and 
oesophageal cancer patients were admitted with a surgical diagnosis. In 
contrast, over 40% of lung, melanoma, ovarian, cervical and cancers of unknown 
origin were medical admissions. 
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Cancer type Received 
organ 
support, N  
Medical admission,          
N (%) 
Surgical admission,          
N (%) 
Colorectal  1225  134  (10.9) 1074  (87.7) 
Head & neck  582  47  (8.1) 533  (91.6) 
Stomach  234  34  (14.5) 199  (85) 
Oesophagus  255  21  (8.2) 231  (90.6) 
Lung  285  138  (48.4) 145  (50.9) 
Kidney  137  14  (10.2) 120  (87.6) 
Bladder  115  13  (11.3) 101  (87.8) 
Breast  93  37  (39.8) 53  (57) 
Ovary  68  42  (61.8) 26  (38.2) 
Prostate  85  25  (29.4) 58  (68.2) 
Cervix & corpus uteri  65  44 (67.7) 20  (30.8) 
Unknown  88  43  (48.9) 45  (51.1) 
Pancreas  56  10  (17.9) 45  (80.4) 
Liver  50  19  (38) 31  (62) 
Small intestine  33  12  (36.4) 21  (63.6) 
Thyroid  18  5  (27.8)  13  (72.2) 
Testis  21  7  (33.3) 14  (66.7) 
Melanoma of skin  14  6  (42.9) 8  (57.1) 
Mesothelioma  13  5  (38.5) 7  (53.8) 
Other  59  18  (30.5) 40  (67.8) 
Multiple  128 11  (8.6) 115  (89.8) 
Total  3624  685  (18.9) 2899  (80) 
Table 4-4 Admitting specialty of cancer patients admitted to ICU for organ support by 
cancer type. Modified from “Risk of critical illness among patients with solid tumours.” 
Puxty et al. JAMA Oncology (2015) with permission. 
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4.4.4 Timing of ICU admission by cancer type 
Of those cancer patients admitted to ICU 70% were admitted within three 
months of the date of cancer incidence (Table 4-5). Notable exceptions include 
breast, bladder, prostate cancer and testicular cancer when over two thirds of 
patients in each group were admitted later than three months from diagnosis. 
The highest proportions of early ICU admissions (within three months of cancer 
diagnosis) were seen with lung cancer (75.6%), colorectal cancer (77.1%), small 
intestinal cancer (77.2%), liver cancer (77.6%), ovarian cancer (87.6%) and 
pancreatic cancer (87.7%). With the exception of colorectal and intestinal 
malignancy these cancer types are those that are associated with poorer survival 
and thus are less likely to be admitted at a later point. 
 
 Time from cancer incidence to admission to ICU % (N)  
Cancer type ≤14 days 15 days – ≤3 
months 
3 months – 
≤6 months 
>6 months 
Colorectal 
N=2561 
32.0% (820) 45.1% (1155) 13.3% (340) 9.6% (246) 
Head & neck 
N=636 
11.0% (70) 67.3% (428) 8.8% (56) 12.9% (82) 
Stomach 
N=456 
17.1% (78) 54.6% (249) 20.8% (95) 7.5% (34) 
Oesophagus 
N=389 
7.7% (30) 44.7% (174) 39.3% (153) 8.2% (32) 
Lung N=381 37.8% (144) 37.8% (144) 11.0% (42) 13.4% (51) 
Kidney N=249 25.3% (63) 47.0% (117) 14.5% (36) 13.3% (33) 
Bladder 
N=182 
13.2% (24) 23.6% (43) 26.4% (48) 36.8% (67) 
Breast N=149 10.7% (16) 24.8% (37) 8.7% (13) 55.7% (83) 
Ovary N=138 54.3% (75) 33.3% (46) 2.9% (4) 9.4% (13) 
Prostate 
N=136 
9.6% (13) 18.4% (25) 22.8% (31) 49.3% (67) 
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 Time from cancer incidence to admission to ICU % (N)  
Cancer type ≤14 days 15 days – ≤3 
months 
3 months – 
≤6 months 
>6 months 
Cervix & 
corpus uteri 
N=113 
11.5% (13) 49.6% (56) 10.6% (12) 28.3% (32) 
Unknown 
N=121 
61.2% (74) 25.6% (31) 7.4% (9) 5.8% (7) 
Pancreas 
N=81 
45.7% (37) 42.0% (34) 6.2% (5) 6.2% (5) 
Liver N=67 34.3% (23) 43.3% (29) 9.0% (6) 13.4% (9) 
Small 
intestine 
N=55 
50.9% (28) 27.3% (15) 9.1% (5) 12.7% (7) 
Thyroid N=28 25.0% (7) 39.3% (11) 14.3% (4) 21.4% (6) 
Testis N=26 19.2% (5) 11.5% (3) 26.9% (7) 42.3% (11) 
Melanoma of 
skin N=18 
0.0% (0) 33.3% (6) 22.2% (4) 44.4% (8) 
Mesothelioma 
N=18 
27.8% (5) 44.4% (8) 16.7% (3) 11.1% (2) 
Other N=106 25.5% (27) 32.1% (34) 17.9% (19) 24.5% (26) 
Multiple 
N=206 
9.2% (19) 35.9% (74) 14.6% (30) 40.3% (83) 
Total N=6116 25.7% (1571) 44.5% (2719) 15.1% (922) 14.8% (904) 
Medical 
patients 
N=949 
38.6% (366) 31.3% (297) 10.1% (96) 20.0% (190) 
Surgical 
patients 
N=5091 
23.2% (1182) 47.0% (2393) 15.9% (811) 13.8% (705) 
Table 4-5 Time from cancer incidence to ICU admission by cancer type. Data are described 
as percentages (with total numbers). Modified from “Risk of critical illness among patients 
with solid tumours.” Puxty et al. JAMA Oncology (2015) with permission. 
 
  
153 
While patients were most commonly admitted between two weeks and three 
months (44.5%), there were some patients that were admitted within two weeks 
of diagnosis (25.7%). This is likely to be where patients were admitted at the 
time of diagnosis or during the same continuous inpatient stay. Patients 
admitted to ICU with a medical diagnosis were more likely to be admitted to ICU 
within two weeks of cancer incidence compared to patients admitted to surgical 
specialties (38.6% compared to 23.2%, p<0.001). 
 
4.4.5 Mortality  
ICU mortality for all solid tumour patients admitted to ICU was 14.7% (95% CI 
13.8-15.6%). Mortality varied by type of hospital admission, admitting specialty 
and provision of organ support (Table 4-6).  
 ICU Mortality % 
(95% CI) 
Hospital Mortality % 
(95% CI) 
Surgical Medical  Surgical Medical 
 
Elective 
admission 
No organ 
support * 
1.7% 
(1.1–2.5) 
6.3% 
(2.1–14.2) 
4.9% 
(3.8–6.1) 
13.9% 
(7.2–23.5) 
Organ 
support 
14.5% 
(12.9–16.3) 
21.1% 
(13.9–30.0) 
22.1% 
(20.2–24.1) 
40.4% 
(31.1–50.2) 
 
Emergency 
admission 
No organ 
support * 
5.0% 
(3.5–6.8) 
8.6% 
(5.0-13.7) 
15.3% 
(12.8–18.1) 
33.0% 
(26.3–40.3) 
Organ 
support 
24.6% 
(22.1-27.2) 
41.7% 
(37.6–45.8) 
41.2% 
(38.3–44.1) 
59.2% 
(55.1–63.2) 
Table 4-6 ICU and hospital mortality by hospital admission type, specialty and organ 
support. *Includes patients with organ support not known. Data are percentages with 95% 
confidence intervals 
 
Patients that received organ support had an ICU mortality rate that was six-
times higher than that observed in patients who did not receive organ support 
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(22.3%, 95% CI 21.0-23.7% compared to 3.7%, 95% CI 3.0-4.5%). Deaths among 
medical patients who received organ support (38.4%, 95% CI 34.7-42.2%) were 
twice that experienced by the patients admitted from a surgical specialty 
(18.4%, 95% CI 17.0-19.9%). The lowest ICU mortality of 1.7% (95% CI 1.1-2.5%) 
occurred among patients who were elective surgical admissions that did not 
receive organ support. This is likely to represent routine post-operative care in a 
high-dependency setting. In contrast, 41.7% (95% CI 37.6-45.8%) of patients who 
were emergency medical admissions with organ support during their stay died in 
ICU.   
A further 10.5% of cancer patients admitted to ICU died prior to hospital 
discharge giving a crude hospital mortality of 25.7% (95% CI 24.6-26.8%). The 
proportion of ICU cancer patients who died in hospital was higher among those 
who received organ support (35.3%, 95% CI 33.8-36.9%) compared to those who 
had not (11.8%, 95% CI 10.5-13.1%). Following discharge from ICU, hospital 
deaths among surgical patients who received organ support increased by 11.1% 
to 29.5% (95% CI 27.8-31.2%) and among medical patients by 17.8% to 56.2% (95% 
CI 52.4-60.0%). Hospital mortality was lowest in the group of patients who were 
admitted as an elective surgical patient and did not require organ support (4.9% 
95% CI 3.8–6.1%). In contrast, 59.2% (95% CI 55.1-63.2%) of patients who were 
emergency medical admissions to ICU that received organ support died prior to 
hospital discharge. 
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Cancer type 
All patients N=6116 Emergency hospital 
admission N=2629 
Received organ 
support N=3624 
Emergency admission + 
received organ support 
N=1700 
Colorectal N=2561 21.8% (20.2-23.4) 28.0% (25.4-30.7) 35.6% (32.9-38.3) 40.3% (36.5-44.1) 
Head & neck N=636 12.3% (9.8-15.1) 23.2% (16.9-30.4) 12.5% (10.0-15.5) 25.0% (18.1-33.0) 
Stomach   N=456 23.9% (20.1-28.1) 39.5% (31.0-48.5) 38.5% (32.2-45.0) 53.8% (42.2-65.0) 
Lung         N=381 60.6% (55.5-65.6) 67.4% (60.9-73.4) 68.8% (63.0-74.1) 71.1% (63.9-77.6) 
Oesophagus N=389 20.8% (16.9-25.2) 35.1% (24.4-47.1) 26.7% (21.3-32.5) 42.6% (29.2-56.8) 
Kidney     N=249 16.5% (12.1-21.7) 28.6% (17.9-41.3) 25.5% (18.5-33.7) 39.5% (25.0-55.6) 
Bladder    N=182 27.5% (21.1-34.6) 51.5% (39.0-63.8) 32.2% (23.8-41.5) 54.8% (38.7-70.2) 
Breast     N=149 32.2% (24.8-40.4) 42.6% (32.4-53.2) 45.1% (34.8-55.5) 53.7% (41.1-66.0) 
Ovary      N=138 29.7% (22.2-38.1) 34.5% (24.5-45.7) 39.7% (28.0-52.3) 46.5% (31.2-62.3) 
Prostate  N=136 28.7% (21.3-37.1) 42.3% (30.6-54.6) 37.6% (27.4-48.8) 48.1%(34.3-62.2) 
Cervix & corpus uteri  N=113 18.6% (11.9-27.0) 25.9% (15.3-39.0) 29.2% (18.6-41.8) 33.3% (19.1-50.2) 
Unknown N=121 72.7% (63.9-80.4) 78.6% (69.5-86.1) 76.1% (65.9-84.6) 82.9% (72.5-90.6) 
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Cancer type 
All patients N=6116 Emergency hospital 
admission N=2629 
Received organ 
support N=3624 
Emergency admission + 
received organ support 
N=1700 
Pancreas    N=81 46.9% (35.7-58.3) 47.5% (34.6-60.7) 55.4% (41.5-68.7) 56.8% (41.0-71.7) 
Liver         N=67 53.7% (41.1-66.0) 62.8% (46.7-77.0) 58.0% (43.2-71.8) 66.7% (47.2-82.7) 
Small intestine N=55 32.7% (20.7-46.7) 30.2% (17.2-46.1) 42.5% (28.1-63.6) 42.3%(23.4-63.1) 
Thyroid      N=28 10.7% (2.3-28.2) 27.3% (6.0-61.0) 5.6% (1.4-27.3) 12.5% (3.2-52.7) 
Testis         N=26 42.3% (23.4-63.1) 71.4% (41.9-91.6) 47.6% (25.7-70.2) 75.0% (42.8-94.5) 
Melanoma of skin   N=18 27.8% (9.7-53.5) 30.8% (9.1-61.4) 35.7% (12.8-64.9) 36.4% (10.9-69.2) 
Mesothelioma N=18 50.0% (26.0-74.0) 58.3% (27.7-84.8) 61.5% (31.6-86.1) 70.0% (34.8-93.3) 
Other       N=106 27.4% (19.1-36.9) 35.8% (23.1-50.2) 40.7% (28.1-54.3) 46.9% (29.1-65.3) 
Multiple   N=206 18.9% (13.8-25.0) 29.7% (19.7-41.5) 27.3 (19.8-35.9) 39.2 (25.8-53.9) 
All N=6116 25.7%(24.6-26.8) 37.2% (35.4-39.1) 35.3% (33.8-36.9) 47.3% (44.9-49.7) 
Table 4-7 Hospital mortality by cancer site. Numbers are percentages (with 95% CI) of patients who died during the hospital stay in which they were 
admitted to ICU. 
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Hospital mortality varied by cancer type (Table 4-7) and was highest for patients 
with cancers of unknown primary (72.7%, 95% CI 64.7-80.8%), lung (60.6%, 95% CI 
55.7-65.6%) and liver (53.7%, 95% CI 41.5-66.0%). The lowest hospital mortalities 
were observed in patients with thyroid cancer (10.7%, 95% CI -1.5-22.9%), head 
& neck cancers (12.2%, 95% CI 9.7-14.8%) and kidney cancer (16.5%, 95% CI 11.8-
21.1%). For most cancers, hospital mortality was substantially higher among 
patients who were admitted as an emergency patient or had received organ 
support. Mortality was higher still among those patients admitted to medical 
compared to surgical specialties (Table 4-8). 
 Cancer type Total                
N=1700 
Surgical                   
N=1124 
Medical          
N=576 
Colorectal  40.3% 
(36.5-44.0) 
37.8% 
(33.7-42.1) 
51.7% 
(42.3-61.1) 
Head & neck  25.0% 
(18.1-33.0) 
20.2% 
(13.0-29.2) 
38.9% 
(23.1-56.5) 
Stomach  53.8% 
(42.2-65.0) 
48.9% 
(34.1-63.9) 
60.6%  
(42.1-77.1) 
Lung  71.1% 
(63.9-77.6) 
62.0% 
(47.2-75.3) 
74.6%  
(66.2-81.8) 
Oesophagus 42.6% 
(29.2-56.8) 
27.8% 
(14.2-45.2) 
72.2%  
(46.5-90.3) 
Kidney  39.5% 
(25.0-55.6) 
44.8% 
(26.4-64.3) 
28.6%  
(8.4-58.1) 
Bladder  54.8% 
(38.7-70.2) 
55.2% 
(35.7-73.6) 
53.8%  
(25.1-80.8) 
Breast  53.7% 
(41.1-66.0) 
45.2% 
(27.3-64.0) 
61.1%  
(43.5-76.9) 
Ovary   46.5% 
(31.2-62.3) 
36.4% 
(17.2-59.3) 
57.1%  
(34.0-78.2) 
Prostate  48.1% 
(34.3-62.2) 
40.6% 
(23.7-59.4) 
59.1%  
(36.4-79.3) 
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 Cancer type Total                
N=1700 
Surgical                   
N=1124 
Medical          
N=576 
Cervix & corpus 
uteri  
33.3% 
(19.1-50.2) 
36.8% 
(16.3-61.6) 
30.0% 
(11.9-54.3) 
Unknown  82.9% 
(72.5-91.0) 
83.3% 
(67.2-93.6) 
82.5%  
(67.2-92.3) 
Pancreas  56.8% 
(41.0-71.7) 
58.8% 
(40.7-75.4) 
50.0%  
(18.7-81.3) 
Liver     66.7% 
(47.2 -82.7) 
78.6% 
(49.2-95.3) 
56.3%  
(29.9-80.2) 
Small intestine  42.3% 
(23.4-63.1) 
41.2% 
(18.4-67.1) 
44.4%  
(13.7-78.8) 
Thyroid  12.5% 
(3.2-52.7) 
25.0% 
(0.6-80.6) 
0%  
(0-60.2) 
Testis  75.0% 
(42.8-94.5) 
40.0% 
(5.3-85.3) 
100%  
(59.0-100) 
Melanoma of skin 36.4% 
(10.9-69.2) 
40.0% 
(5.3-85.3) 
33.3%  
(-20.9-87.5) 
Mesothelioma  70.0% 
(34.8-93.3) 
60.0% 
(14.7-94.7) 
80.0%  
(28.4-99.5) 
Other 46.9% 
(29.1-65.3) 
52.4% 
(29.8-74.3) 
36.4%  
(10.9-69.2) 
Multiple 39.2% 
(25.8-53.9) 
35.7% 
(21.6-52.0) 
55.6%  
(21.2-86.3) 
All  47.3% 
(44.9-49.7) 
41.2% 
(38.3-44.1) 
59.2% 
(55.1-63.2) 
Table 4-8 Hospital mortality by cancer site for emergency admissions that received organ 
support. Numbers are percentages (with 95% CI) of patients who died during the hospital 
stay in which they were admitted to ICU. 
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4.4.6 Socioeconomic trends 
More than half (55.6%) of the West of Scotland cancer population are from a 
deprived area (SIMD quintiles 1 or 2) and this is likely to represent the general 
population of the West of Scotland. There was no clear trend in the proportions 
of cancer patients admitted to ICU when examined by socio-economic 
deprivation (Table 4-9).  
SIMD 
quintile 
Total cancer 
patients* N (%) 
ICU admission 
N (%) 
Emergency 
hospital 
admission N (%) 
Number with 
organ support 
N (%) 
Most 
deprived 
37,333 (31.5) 1,842 (4.9) 859 (46.6) 1,261 (68.5) 
2 28,550 (24.1) 1,650 (5.8) 708 (42.9) 916 (55.5) 
3 21,000 (17.7) 1,134 (5.4) 471 (41.5) 609 (53.7) 
4 16,384 (13.8) 806 (4.9) 310 (38.5) 440 (54.6) 
Most 
affluent 
15,272 (12.9) 684 (4.5) 281 (41.1) 398 (58.2) 
All 118,539  6,116 (5.2) 2,629 (43.0) 3,624 (59.3) 
Table 4-9 Cancer incidence and critical illness requiring ICU admission and organ support 
by socio-economic circumstances. *Missing SIMD data for 2 patients. Modified from “Risk 
of critical illness among patients with solid tumours.” Puxty et al. JAMA Oncology (2015) 
with permission. 
 
The most deprived SIMD quintile had a higher proportion of patients who were 
emergency hospital admissions (46.6%, (95% CI 44.3-48.9%)) and that had 
received organ support (68.5% (95% CI 66.3-70.6%)), compared to the least 
deprived quintile (41.1%, (95% CI 37.4-44.9%), p=0.0127, and 58.2%, (95% CI 
54.4-61.9%), p<0.001 respectively). This corresponded to higher hospital 
mortality among patients admitted from the most deprived areas (30.1%, 95% CI 
28.0-32.3%) when compared to those who lived in the most affluent areas 
(23.1%, 95% CI 20.0-26.4%), p<0.001 (Table 4-10). 
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SIMD quintile Hospital mortality 
% (95% CI) 
Most deprived 30.1 (28.0–32.3) 
2 25.3 (23.2–27.5) 
3 22.5 (20.1-25.0) 
4 23.2 (20.3–26.3) 
Most affluent 23.1 (20.0-26.4) 
All 25.7 (24.6-26.8) 
Table 4-10 Crude hospital mortality of ICU cancer patients by socio-economic 
circumstances.  
 
 
4.5 Discussion 
This study has demonstrated that one in twenty patients with a solid tumour 
developed a critical illness that required admission to an ICU within two years of 
cancer diagnosis. Requirement for organ support suggests an increased severity 
of illness and receipt of level 3 care and this was received by 3.1% of all cancer 
patients in this study. Within the solid tumour population, admission to ICU 
tends to happen early after cancer incidence with 3.7% of cancer patients 
admitted to ICU within 100 days of diagnosis. It is likely that the critical illness is 
therefore linked to the cancer either in terms of directly leading to the illness or 
following surgical intervention or treatment. This would be consistent with 
previous studies that have demonstrated that cancer-related hospital activity is 
highest in the first year following diagnosis [174]. 
Bos et al performed a similar study in the Netherlands where patients with a 
cancer diagnosis between 2006 and 2011 were analysed for any ICU admissions 
during the study period [159]. Similar to the observations made by this study 
they found that 6.4% of their population were admitted to ICU, although their 
study included both solid and haematological cancer. 
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4.5.1 Features associated with ICU admission 
The rate of ICU admission increased with age up to 70 years after which there 
was a decrease in the rate of ICU admission. This pattern may be explained by 
the increasing prevalence of co-morbidities with increasing age countered by 
less invasive or aggressive treatment regimens as patients get beyond 70 years 
old. Cancer patients aged over 90 years were the least likely to be admitted to 
ICU and this may also reflect a reluctance to admit by the ICU clinical teams due 
to concern regarding the burden of care. 
Within the cohort of cancer patients admitted to ICU, the majority were surgical 
admissions (83%) and following elective hospitalisation (57%). Peri-operative 
critical care is often offered to elective patients undergoing major surgical 
intervention or to those with co-morbidities who are at higher risk of post-
operative complications. Enhanced monitoring and management of analgesia 
such as epidural care means that many patients benefit from a brief post-
operative period in ICU/ HDU. Elective cancer surgery therefore contributes a 
large proportion of the cancer ICU cohort. In addition, there are a group of 
patients who are admitted to ICU after a complication of elective cancer surgery 
either at the time of operation or in the post-operative period. While these 
patients have been admitted to hospital electively, their ICU admission has been 
unplanned. Emergency surgical admissions contribute the second largest group 
of ICU cancer patients. These patients often undergo unplanned surgical 
intervention and therefore have no opportunity for pre-operative optimisation. 
Many of these patients will have critical illness on admission to hospital due to 
the underlying condition. Admission may be required as a result of presenting 
illness, surgical intervention or underlying co-morbidity. 
Patients from the most deprived areas had similar rates of ICU admission to 
other socio-economic groups; however, there was a higher rate of emergency 
admissions and receipt of organ support within this group. It has been previously 
established that deprivation is associated with poor uptake in cancer 
surveillance programmes [175, 176]. This may partly explain patients from 
poorer socio-economic groups presenting later as an emergency and 
consequently having a greater requirement for organ support. 
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There was a modest decline in the rate of ICU admission during the study period 
although this was predominantly seen among patients that did not receive organ 
support. During the study period there were changes within the ICU’s in terms of 
total number of beds and proportion of level 2 and level 3 provision, in addition 
to centralisation of cardiothoracic services to a hospital outwith this dataset. It 
is likely that the changes in rate of ICU admission relate to these service changes 
rather than any real change in the treatment of cancer patients.  
 
4.5.2 Impact of underlying cancer type and rate of ICU admission 
During the study period the commonest incident cancers were lung, breast and 
colorectal cancer. However, the pattern of those admitted to ICU was not 
reflective of these incidence rates. Colorectal cancer was the most frequently 
admitted cancer type to ICU with 16.5% of all colorectal patients admitted to 
ICU. Due to the high incidence of colorectal cancer and the high rate of ICU 
admission, this patient group made up over two fifths of all ICU cancer patients. 
Colorectal cancer patients had the lowest requirement for organ support (47.8%) 
and were predominantly made up of surgical admissions (87.7% of those that 
received organ support). This reflects the large proportion of surgical level 2 
patients that require a brief period of post-operative monitoring only following 
colorectal cancer resection surgery. Other tumour types that require 
perioperative critical care support for tumour resection surgery such as head and 
neck cancers, stomach cancer and oesophageal cancer all had ICU admission 
rates greater than ten percent. 
In contrast to colorectal cancer, only a small proportion of lung and breast 
cancer patients are admitted to ICU (1.6% and 0.8% respectively). Poor long-
term survival in patients with lung cancer is likely to influence the ICU physician 
against admitting these patients and it is possible that this contributes to the 
low rates of ICU admission. For breast cancer the surgical interventions tend to 
be minimally invasive and therefore patients are less likely to develop a critical 
illness at the time of surgery compared with other tumour resections. 
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4.5.3 Mortality of cancer patients admitted to ICU 
Mortality was high, with one in four of all cancer patients that developed a 
critical illness dying during the same hospital stay. Mortality was observed to be 
lowest for elective surgical patients. Their outcomes might be expected to be 
favourable as they have been selected for potentially curative treatment and 
have benefitted from a period of pre-operative optimisation. Emergency 
admissions associated with a cancer diagnosis have poorer outcomes than 
elective, and medical admissions have poorer outcomes than surgical. Again, 
these observations partly reflect a group of surgical patients for whom the 
critical illness is likely to have been related to a discrete peri-operative insult 
rather than an on-going inflammatory process that often occurs with medical 
patients. Cancer patients admitted to ICU with a medical diagnosis comprise a 
mixture of those who are suffering from the side effects of treatment, such as 
sepsis or tumour lysis syndrome, and those suffering from progression of their 
cancer. While a direct comparison cannot be made with other studies because of 
differences in case mix, the observation that medical admissions have higher 
mortality than emergency and elective surgery, respectively, has been made by 
Soares and others [86]. This is a consistent finding seen in ICU patients 
regardless of comorbidity and is often accounted for when using ICU mortality 
prediction scores [22, 28]. 
Patients that received organ support during their ICU stay had higher mortality 
rates compared with those who did not receive organ support regardless of 
whether they were medical/ surgical or elective/ emergency admissions. 
Receipt of organ support is a coarse reflection of the presence of organ failure 
and will be associated with an increased severity of illness. It is expected that 
those patients with organ failure and higher severity of illness would also have a 
higher mortality. 
Mortality by tumour type varied considerably, with hospital mortality ranging 
from 10.7% of thyroid cancers to 72.7% of cancers of unknown primary. In 
general, those tumour types that are associated with poor outcomes such as 
lung, liver, mesothelioma and pancreatic had high hospital mortality after 
admission to ICU. This may be due to late clinical presentation, limited 
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treatment options, advanced cancer stage, physician nihilism or a combination 
of the above. While general survival associated with oesophageal cancer tends to 
be poor, it is worth noting that in this dataset hospital mortality for those that 
are admitted to ICU was lower than the average at 20.8%. Those patients with 
oesophageal cancer that were admitted to ICU were predominantly surgical and 
are likely to be those who have undergone curative oesophageal resection. This 
procedure is a major operative intervention and prior to its undertaking the 
patients undergo extensive investigation and optimisation. There will therefore 
be a significant selection bias applied to those oesophageal cancer patients who 
undergo surgical resection compared to those who do not. It is likely that this is 
reflected in the low hospital mortality within this cohort. This selection bias is 
amplified by the fact that mortality for oesophageal cancer is very high and pre-
operative optimisation prior to surgery is comprehensive. It should be expected 
that within the elective surgical population this selection bias will be present to 
a varying extent within each of the tumour type sub-categories.  
Survival from most cancers has improved over time but international variations 
exist, with poorer survival in the UK than other developed countries. Variations 
in outcomes manifest soon after diagnosis. For example, socio-economic 
variations in survival from colorectal cancers are largely confined to excess 
mortality in the postoperative period [177] and international variations in breast 
cancer survival are most pronounced in the first month and year after diagnosis 
[178]. However, it remains unclear what mediates better survival. It has been 
suggested that quality of healthcare may explain international variations in 
cancer outcomes [163]. While this is often considered in terms of availability and 
effectiveness of therapeutic interventions, the role of supportive care to prevent 
or ameliorate critical illness among cancer patients should not be overlooked.  
The United Kingdom has considerably lower provision of ICU beds, at 3.5 per 
100,000 population, than other European countries, North America and 
Australasia [179]. Among the EUROCARE countries, those with consistently better 
survival, such as France and Belgium, have between three and six times greater 
numbers of ICU beds per head of population than the UK [163, 179]. The UK has 
both poorer cancer outcomes and considerably lower provision of ICU beds than 
most other developed countries. From these results I cannot say whether greater 
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provision of ICU beds would contribute to improvements in cancer survival in the 
UK. However, it might be hypothesised that if ICUs are effective in reducing 
mortality following a critical illness, increased surveillance for early signs of 
critical illness and greater capacity to offer ICU to cancer patients might be 
beneficial. Studies are needed in which ICU is provided to cancer patients who 
would not normally be admitted to ICU under current UK provision and outcomes 
in this group compared to a similar group of cancer patients who did not receive 
ICU care.  
Critical illness may therefore play an important role in determining overall 
cancer outcomes and may help to explain variations in cancer survival. 
 
4.5.4 Strengths and weaknesses 
This study describes the proportion of patients with solid cancers that develop a 
critical illness necessitating ICU admission, with a comprehensive coverage of 
tumour types. Patient groups are described in detail by cancer type, admission 
type and receipt of organ support. The large sample size and reliability of cancer 
registration and ICU admission data would suggest that this population is 
representative of the overall population of solid tumour patients that are 
admitted to ICU in the UK.  
The principal limitation is that patients with critical illness who were not 
admitted to ICU could not be identified. A further limitation is the inability to 
clearly differentiate high dependency patients from intensive care patients in 
combined units. To overcome this issue we described the population of patients 
that received organ support in an attempt to exclude those HDU patients who 
were receiving monitoring only. Although there was significant variation in 
mortality between centres it is likely that this reflects differences in case mix. A 
prospective study is needed in which a range of physiological and functional 
measures is included to determine outcomes among cancer patients whose 
critical illnesses do, and do not, result in ICU admission. This study was carried 
out in one region of the UK and while it is unlikely that admission policies are 
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significantly different to other parts of the UK, further work to repeat this 
methodology on other geographic areas is needed.   
 
 
4.6 Conclusions 
The development of a critical illness requiring support in an ICU has received 
relatively little attention for cancer patients, yet this study demonstrates that 
one in twenty cancer patients will be admitted to ICU. Those admitted to ICU 
had high mortality rates with increased risk in those admitted as an emergency, 
with a medical diagnosis or in those that received organ support. It remains 
unknown whether the persisting effects of critical illness and ICU care interferes 
with planned cancer treatment and impacts upon longer term outcomes. 
Development of a critical illness requiring ICU support may be an important 
clinical event that contributes to poorer overall survival in patients with 
malignancy. 
 
 
4.7 Key points 
• 5.2% of patients diagnosed with a solid tumour diagnosed between 2000 and 
2009 developed a critical illness necessitating ICU admission within 2 years of 
diagnosis with 3.1% of patients requiring organ support. 
• The rate of ICU admission increased with increasing age up to 70 years after 
which there was a decline in the rate of admission. 
• The majority of ICU admissions in patients with a solid tumour are the result of 
a surgical hospitalisation (83.2%). 
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• ICU admission tends to occur soon after cancer diagnosis with 3.7% of solid 
tumour patients admitted to ICU within 100 days of diagnosis and 4.5% within 
200 days. 
• The rate of ICU admission was greatest for bowel malignancies and for those 
tumours that require peri-operative support for tumour resection surgery such as 
head and neck cancers, stomach cancer and oesophageal cancer. 
• Patients with colorectal cancer made up the largest proportion of ICU cancer 
patients. 
• Although lung and breast cancer were the two most commonly diagnosed 
cancers during the study period, the rate of admission to ICU was low at 1.6% 
and 0.8% respectively. 
• Patients with solid tumours admitted to ICU had an ICU mortality of 14.7% and 
hospital mortality of 25.7%. 
• Mortality varied by cancer type and was higher in emergency admissions, 
medical admissions and in patients that received organ support. 
• Deprivation was not associated with an increased rate of ICU admission, 
however, the most deprived population were more likely to be admitted as an 
emergency and receive organ support and this group had a corresponding higher 
mortality. 
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Chapter 5 What proportions of patients admitted 
to ICU have a diagnosis of cancer and how do 
they differ from the non-cancer population? 
 
5.1 Introduction 
The previous chapter established that over 5% of patients with a solid tumour 
were admitted to ICU within 2 years of diagnosis. To appreciate the impact this 
might have on ICU work, it is necessary to understand these patients in the 
context of other ICU patients. A comparison of baseline characteristics and 
outcomes of solid tumour patients and patients without cancer admitted to 
general ICUs was therefore made. 
 
 
5.2 Study questions 
5.2.1 What proportions of patients admitted to ICU have a 
diagnosis of cancer? 
In the first instance I will describe the general ICU population in terms of those 
with and without a diagnosis of cancer as a proportion of the total number of 
admissions. Because the nature of illness and outcomes vary by whether patients 
are admitted as a surgical or medical admission I will look at these groups 
separately and describe the proportion of cancer patients within each subgroup. 
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5.2.2 Are the features associated with critical illness different in 
patients with an underlying cancer when compared to the 
non-cancer population? 
I will describe the differences in demographic and clinical features of the ICU 
cancer group compared with the ICU group without cancer. Patients with cancer 
may present to ICU with different types of critical illness and may vary in terms 
of their severity of illness and requirement for organ support. This may be 
different again depending on whether the ICU admission was medical or surgical 
in nature and I will therefore analyse these groups separately. Finally, I will 
describe the differences in features in the subgroup of patients who received 
organ support during their ICU stay. 
 
5.2.3 Do the ICU features vary according to underlying tumour 
types? 
It might be expected that different tumour types and their specific treatments 
may result in different presentations to ICU. It is therefore important to analyse 
the features associated with ICU admission grouped by the type of underlying 
cancer for surgical and medical admissions separately. 
 
5.2.4 Do ICU outcomes differ between those patients with and 
without an underlying cancer? 
I will report ICU and hospital mortality for patients with and without cancer 
admitted to ICU in addition to those admitted as medical or surgical ICU 
admissions and by whether organ support was received in ICU. Longer-term 
survival of all patients will be described up to four years following ICU 
admission. 
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5.3 Methods 
Statistical analyses were performed using Stata software (version 14, StataCorp 
2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP).  
Hospital admission type was described for the cancer group and the non-cancer 
group. This was then compared with ICU admission type. 
Descriptive analysis was initially completed for all ICU patients and documented 
as a percentage of the cohort. ICU patients were separated into those admitted 
to ICU under a surgical admitting team or a medical admitting team. Further 
subgroup analysis was performed within these groupings on those patients that 
had received organ support during their ICU stay. This was to exclude those 
patients admitted to combined units for routine post-operative care or 
monitoring. Organ support was defined as one of mechanical ventilation, 
vasoactive drugs or renal replacement therapy. 
Additional descriptive analysis was performed on surgical and medical admissions 
depending on the underlying tumour type. The most frequently admitted tumour 
types were explored in more detail. 
Unless otherwise stated, median and inter-quartile ranges were used to 
summarise continuous variables, and Wilcoxon rank test (Mann Whitney) to test 
for differences in median values. Pearson chi-square test and exact 95% 
confidence intervals were used to compare proportions. A significance level of 
5% was accepted. Survival was described in terms of ICU, hospital and time-
defined survival up to four years following ICU admission. In addition, Kaplan-
Meier survival graphs were plotted for specific subgroups using the log-rank test 
for equality of survivor functions to calculate a p-value.  
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5.4 Results 
During the study period 1st January 2000 – 31st December 2011 there were 41,689 
patients admitted to general ICUs in the West of Scotland. Of these 6116 (14.7%) 
had a diagnosis of solid tumour within 2 years prior to admission and 35,573 did 
not have a cancer diagnosis.  
 
5.4.1 Admission types 
Of the 41,689 patients admitted to ICU on Wardwatcher there was corresponding 
SMR01 hospital admission data available for 40,585 patients (97.4%) including 
data on emergency/ elective hospitalisation and medical/ surgical hospital 
admission type data (Table 5-1). 
                All ICU admissions 
Hospital admission type Patients without cancer 
N=35,573 
Patients with cancer 
N=6116 
Elective medical 498 (1.4%) 188 (3.1%) 
Emergency medical 12,636 (35.5%) 761 (12.4%) 
Elective surgical 3550 (10.0%) 3223 (52.7%) 
Emergency surgical 17,861 (50.2%) 1868 (30.5%) 
Unknown 1028 (2.9%) 76 (1.2%) 
Table 5-1 Hospital admission type by patients with and without cancer 
 
Patients without cancer were predominantly admitted to hospital as an 
emergency (88.3% (95% CI 87.9 – 88.6). Half of the ICU non-cancer population 
had been admitted to hospital as an emergency surgical patient with an 
additional 10% admitted as an elective surgical patient. Emergency medical 
hospitalisations contribute over a third to ICU patients without cancer with very 
few patients admitted to ICU after an elective medical hospitalisation (1.4%). 
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Patients with cancer were less commonly emergency hospitalisations (43.5% (95% 
CI 42.3 – 44.8). More than half of the ICU cancer population had been admitted 
to hospital as an elective surgical patient and a further 30.5% admitted as an 
emergency surgical hospitalisation. Emergency medical admissions to hospital 
were less common at 12.4% of all ICU admissions in the cancer population. The 
proportions of ICU cancer patients admitted after an elective medical 
hospitalisation was slightly higher at 3.1% and this likely reflects investigation 
and inpatient management of the underlying cancer. 
ICU admission type data was available for all 6116 patients in the cancer group 
and 35,573 patients (99.7%) in the non-cancer group. Compared to the non-
cancer population, patients with cancer were more likely to be admitted to ICU 
with a surgical diagnosis (89.3% (95% CI 88.5 – 90.1) vs. 55.0% (95% CI 54.5 – 55.5) 
p<0.001) as demonstrated in Figure 5-1.  
 
Figure 5-1 ICU admission type by patients with and without cancer 
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ICU admission type and hospital admission type for patients with and without 
cancer can be seen compared in Table 5-2. This demonstrates that the original 
cause of hospitalisation may not be the cause of ICU admission.   
 ICU Medical admissions ICU Surgical admissions 
Hospital 
admission type 
Non Cancer 
N=16,018 
Cancer 
N=654 
Non Cancer 
N=19,555 
Cancer 
N=5462 
Elective 
medical N=686 
153 (1.0%) 28 (4.3%) 345 (1.8%) 160 (2.9%) 
Emergency 
medical 
N=13,397 
10007 (62.5%) 344 (52.6%) 2629 (13.4%) 417 (7.6%) 
Elective 
surgical N=6773 
141 (8.8%) 122 (18.7%) 3409 (17.4%) 3101 (56.8%) 
Emergency 
surgical 
N=19,729 
5265 (32.9%) 157 (24.0%) 12596 (64.4%) 1711 (31.3%) 
Unknown 
N=1197 
452 (2.8%) 3 (0.5%) 576 (2.9%) 73 (1.3%) 
Table 5-2 ICU admission type compared with hospitalisation type by patients with and 
without cancer 
 
Of all ICU patients with an elective surgical hospitalisation, 96.1% are admitted 
to ICU as surgical patients. Emergency surgical hospitalisations are 
predominantly admitted to ICU due to a surgical diagnosis although 27.5% have a 
medical ICU admission. However, within the ICU cancer population 91.6% of 
emergency surgical hospitalisations are surgical ICU admissions. Within the 
general ICU population, most patients that were admitted to hospital as an 
elective medical admission have a surgical ICU admission (73.6%) and this is 
more pronounced within the cancer population (85.1%). ICU patients with an 
emergency medical hospitalisation tend to have a medical ICU admission, 
however, this is less common within the ICU cancer population when compared 
with the ICU non-cancer population (45.2% vs. 79.2% p<0.001). 
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5.4.2 Demographic and clinical features 
Comparative patient demographics for those with and without cancer can be 
seen in Table 5-3. There were a slightly higher proportion of males within the 
ICU cancer population compared with the non-cancer population (58.4% vs. 
54.5%, p<0.001) in keeping with the higher incidence rates of cancer in males. 
The median age of cancer patients was 68 years (IQR 60 – 75). ICU patients 
without a cancer diagnosis were younger (median age 59 years (IQR 43 – 71)). 
Admission related to underlying malignancy was the commonest reason for 
admission in the cancer group (39.4%). Of note, 216 patients in the non-cancer 
group (0.7%) had an ICU admission relating to a malignancy. This may be 
accounted for by incorrect admission diagnosis (either due to mistaken diagnosis 
or user error) or by patients with cancer diagnosed outwith Scotland being 
admitted to a west of Scotland ICU. Within the non-cancer group sepsis was the 
most frequent admitting diagnosis and this was the third most common diagnosis 
within the cancer group. Gastrointestinal and Liver disease was a common 
reason for admission within both groups. 
 
Severity of illness scoring by APACHE II was recorded for 83.8% of non-cancer ICU 
patients and 70% of cancer ICU patients. Median APACHE II score was lower for 
cancer patients (17 vs. 19, p <0.0001). This was also reflected in lower use of 
organ support with 59.3% of cancer patients receiving support compared with 
74.6% of non-cancer patients (p<0.001). Each type of organ support was utilised 
less often within the cancer group compared with the non-cancer group. Multi-
organ support was utilised less frequently in the cancer group with two or more 
organ support provided in 27.2% compared with 38.9% of the non-cancer group (p 
<0.001). ICU length of stay was similar for both groups. Overall mortality was 
higher for the non-cancer group with ICU mortality of 22.9% vs. 14.7% (p<0.001) 
and in-hospital mortality of 34.2% vs. 25.7% (p <0.001). 
 ICU Non-cancer 
patients     
N=35,573 
ICU Cancer 
patients      
N=6116  
P value 
Men 19,393 
54.5% (54.0 – 55.0) 
3573 
58.4% (57.2 – 59.7) 
<0.001 
Median Age (IQR) years 59 (43 – 71) 68 (60 – 75) <0.0001 
Surgical admission to 
ICU 
19,555 
55.0% (54.5 – 55.5) 
5462 
89.3% (88.5 – 90.1) 
<0.001 
Emergency 
hospitalisation 
30,497 / 34,545 
88.3% (87.9 – 88.6) 
3411 / 6040 
43.5% (42.3 – 44.8) 
<0.001 
Reason for admission 
Malignancy 
Gastrointestinal/ Liver 
Sepsis 
Surgical complication 
Respiratory disorder 
Haemorrhage 
Vascular 
Drug related 
Trauma 
Cardiovascular 
Post cardiac arrest 
Renal 
Neurological 
 
261 
5212 
8020 
931 
3102 
1714 
2426 
2262 
1776 
1622 
1848 
603 
3359 
 
0.7% 
14.7% 
22.5% 
2.6% 
8.7% 
4.8% 
6.8% 
6.4% 
5.0% 
4.6% 
5.2% 
1.7% 
9.4% 
 
2408 
1106 
819 
384 
310 
223 
57 
15 
30 
215 
84 
100 
84 
 
39.4% 
18.1% 
13.4% 
6.3% 
5.1% 
3.7% 
0.9% 
0.2% 
0.5% 
3.5% 
1.4% 
1.6% 
1.4% 
<0.001 
Median APACHE II (IQR) 
 
Not recorded 
19 (13 – 25) 
 
5759  16.2% 
17 (13 – 22) 
 
1837  30.0% 
<0.001 
 
<0.001 
Organ support type: 
Respiratory support 
 
 
Unknown 
 
25,166 / 35,089 
71.7% (71.2 – 72.2) 
  
484  1.4% 
 
3344 / 5939 
56.3% (55.0 – 57.6) 
 
177  2.9% 
 
 
<0.001 
 
<0.001 
Cardiovascular support  
 
14,546 / 34,783 
41.8% (41.3 – 42.3) 
1879 / 5923 
31.7% (30.5 – 32.9) 
 
<0.001 
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Unknown 
 
790  2.2% 
 
193  3.2% 
 
<0.001 
Renal support 
 
                   
 Unknown 
3573 / 31,496 
11.3% (1.0 – 11.7) 
4077  11.5% 
306 / 5228 
5.9% (5.2 – 6.5) 
 
888  14.5% 
 
<0.001 
 
<0.001 
Organ support 
             0 
1 
2 
3 
Unknown for all modes 
 
8564 
12,714 
10,921 
2910 
464 
 
24.1% 
35.7% 
30.7% 
8.2% 
1.3% 
 
2321 
1958 
1427 
239 
171 
 
37.9% 
32.0% 
23.3% 
3.9% 
2.8% 
<0.001 
 
 
 
 
<0.001 
ICU length of stay (IQR) 
Unknown 
2 (1 – 5) days 
80          0.2% 
2 (1 – 5) days 
35         0.6% 
<0.0001 
ICU mortality 22.9% (22.5 – 23.3)  14.7% (13.8 – 15.6) <0.001 
Hospital mortality 34.2% (33.7 – 34.9) 25.7% (24.6 – 26.8) <0.001 
Table 5-3 Patient demographics for ICU patients with and without cancer. Numbers are 
cumulative total followed by percentages (with 95% confidence intervals) unless otherwise 
specified. 
 
5.4.2.1  Patients receiving organ support in ICU 
Among all ICU patients there were 10,885 patients (26.1%) that did not receive 
organ support during their ICU stay and a further 635 patients (1.5%) for whom 
all three types of organ support were unknown. The remaining 30,169 patients 
received respiratory (94.5%), vasoactive (54.4%) or renal support (12.9%). These 
patients were analysed separately as a group that received organ support in ICU.  
Among patients receiving organ support 3624 (12.0%) had a solid tumour 
diagnosis. Of these 3,165 patients (87.3%) were admitted to ICU with a surgical 
diagnosis. This compares with 49.2% of non-cancer patients admitted with a 
surgical diagnosis. Cancer patients were more likely to be admitted to ICU after 
  
177 
an elective hospitalisation compared with non-cancer patients (52.6% vs. 7.8% 
p<0.0001).  
 
5.4.3 Surgical admissions to ICU 
There were 25,017 ICU surgical admissions of which 5,462 (21.8%) were patients 
with cancer. Table 5-4 gives patient characteristics for surgical admission to ICU 
with and without a diagnosis of cancer.    
Surgical ICU cancer patients tended to be older than non-cancer patients and 
there are a slightly higher proportion of male patients within the cancer group. 
The majority of the cancer population had been admitted to hospital electively 
compared to the non-cancer group (60.5% vs. 19.8% p<0.001). ICU admission was 
directly related to underlying malignancy for 42.0% of the cancer group and in 
1.2% of the non-cancer group. The most frequent diagnostic groups were similar 
between the cancer and non-cancer groups with sepsis, gastrointestinal/ liver 
disease and surgical complications as common causes for admission. Vascular 
disease and trauma occurred significantly more frequently in the non-cancer 
group. 
APACHE II score was available for 79.2% of non-cancer patients and 69.6% of 
cancer patients with similar median value for both groups (17 vs. 17, p= 0.1161) 
although organ support was provided less frequently in the cancer group 
compared with the non-cancer group (57.9% vs. 66.7%, p<0.001). Single organ 
support did not differ between the two groups but the provision of multi-organ 
support was less for the cancer group (25.4% vs. 33.8%, p<0.001). ICU and 
hospital mortality was lower for the cancer population compared with the non-
cancer population at 12.2% vs. 16.8% (p<0.001) and 22.9% vs. 28.1% (p<0.001) 
respectively.  
  
ICU Non-cancer 
patients     
N=19,555  
ICU Cancer 
patients      
N=5462  
P value 
Men 10,696 
54.7% (54.0 – 55.4) 
3201 
58.6% (57.3 – 59.9) 
<0.001 
Median Age (IQR) 62 (45 – 74) 68 (60 – 76) <0.0001 
Emergency 
hospitalisation 
15,255 / 18,979 
80.2% (79.6 – 80.8) 
2128 / 5389 
39.5% (38.2 – 40.8) 
<0.001 
Reason for admission 
Malignancy 
Gastrointestinal/ Liver 
Sepsis 
Surgical complication 
Respiratory disorder 
Haemorrhage 
Vascular 
Trauma 
Cardiovascular 
Renal 
 
244 
4778 
3089 
893 
1174 
1377 
2392 
1702 
769 
308 
 
1.2% 
24.4% 
15.8% 
4.6% 
6.0% 
7.0% 
12.2% 
8.7% 
3.9% 
1.6% 
 
2294 
1020 
610 
376 
244 
206 
56 
30 
180 
84 
 
42.0% 
18.7% 
11.2% 
6.9% 
4.5% 
3.8% 
1.0% 
0.6% 
3.3% 
1.5% 
<0.001 
Median APACHE II (IQR) 
 
Not recorded 
17 (12 – 22) 
 
4073  20.8% 
17 (13 – 21) 
 
1659  30.4% 
0.1161 
 
<0.001 
Organ support type: 
Respiratory support 
 
 
Unknown 
 
12,300 / 19220 
64.0% (63.3 – 64.7) 
 
335  1.7% 
 
2919 / 5306 
55.0% (53.7 – 56.4) 
 
156  2.9% 
 
<0.001 
 
 
<0.001 
Cardiovascular support 
 
    
Unknown 
7103 / 19,080 
37.2% (36.4 -37.9) 
475  2.4% 
1584 / 5291 
29.9% (28.7 – 31.2) 
 
171  3.1% 
<0.001 
 
 
0.004 
Renal support 
 
                   
1557 / 16,882 
9.2% (8.8 – 9.7) 
237 / 4674 
5.1% (4.5 – 5.7) 
 
<0.001 
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Unknown 2673  13.7% 788  14.4% 0.152 
Organ support              
0 
1 
2 
3 
Unknown for all modes 
 
6186 
6438 
5302 
1306 
323 
 
31.6% 
32.9% 
27.1% 
6.7% 
1.7% 
 
2146 
1779 
1197 
189 
151 
 
39.2% 
32.6% 
21.9% 
3.5% 
2.8% 
<0.001 
 
 
 
 
<0.001 
ICU length of stay (IQR) 
Unknown 
2 (1 – 5) days 
69  0.4% 
2 (1 – 4) days 
34  0.6% 
<0.0001 
ICU mortality 16.8% (16.3 – 17.4)  12.2% (11.3 – 13.1) <0.001 
Hospital mortality 28.1% (27.4 – 28.7) 22.9% (21.8 – 24.1) <0.001 
Table 5-4 Surgical admissions to ICU with and without cancer. Numbers are cumulative total 
followed by percentages (with 95% confidence intervals) unless otherwise specified. 
 
 
5.4.3.1  Surgical ICU admissions with organ support 
There were 16,211 surgical patients that were admitted to ICU and received 
organ support during the study period. Of these 3165 (19.5%) had a solid tumour 
diagnosis (Table 5-5). Compared with the surgical population without cancer, the 
surgical ICU cancer group had a higher proportion of men (61.3% vs. 56.0%, 
p<0.001) and tended to be older (median age 68 years vs. 63 years, p<0.0001). 
Elective admission to hospital prior to ICU occurred more frequently in the 
cancer group with 58.5% vs. 14.1%, p<0.001. Admission to ICU was directly 
related to the malignancy in 30.4% of patients with cancer. Common causes for 
ICU admission in both cancer and non-cancer patients included sepsis (17.5% and 
20.1%), gastrointestinal/ liver disease (17.1% and 22.6%), surgical complication 
(9.4% and 5.3%), non-infectious respiratory disorder (6.3% and 6.6%) and 
haemorrhage (5.3% and 7.6%). Other frequent reasons for admission to ICU in the 
non-cancer population included vascular disease (10.5%) and trauma (8.5%). 
However, these were less frequent in the ICU cancer population at 1.0% and 0.6% 
respectively. 
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 ICU Non-cancer 
patients     
N=13,046  
ICU Cancer 
patients      
N=3165  
P value 
Men 7312 
56.0% (55.2 – 56.9) 
1941 
61.3% (59.6 – 63.0) 
<0.001 
Median Age (IQR) 63 (46 – 74) 68 (60 – 76) <0.0001 
Emergency 
hospitalisation 
10,892 / 12,680 
85.9% (85.3- 86.5) 
1299 / 3128 
41.5% (39.8 – 43.3) 
<0.001 
Reason for admission 
Malignancy 
Sepsis 
Gastrointestinal/ Liver 
Surgical complication 
Respiratory disorder 
Haemorrhage 
Vascular 
Trauma 
Cardiovascular 
Neurological 
 
80 
2624 
2949 
689 
863 
992 
1368 
1103 
393 
794 
 
0.6% 
20.1% 
22.6% 
5.3% 
6.6% 
7.6% 
10.5% 
8.5% 
3.0% 
6.1% 
 
961 
555 
540 
297 
198 
168 
31 
18 
99 
33 
 
30.4% 
17.5% 
17.1% 
9.4% 
6.3% 
5.3% 
1.0% 
0.6% 
3.1% 
1.0% 
<0.001 
Median APACHE II (IQR) 
 
Not recorded 
18 (14 – 24) 
 
1040  8.0% 
18 (14 – 23) 
 
293  9.3% 
0.177 
 
0.018 
Organ support type: 
Respiratory support 
 
     
 Unknown 
 
12,300 
94.3% (93.9 – 94.7) 
1  0.0% 
 
2919 
92.2% (91.2 – 93.1) 
 
0  0%  
 
<0.001 
 
 
0.622 
Cardiovascular support 
 
    
Unknown 
7103 
54.6% (53.7 – 55.4) 
33  0.3% 
1584 
50.1% (48.4 – 51.9) 
 
4  0.1% 
<0.001 
 
 
0.181 
Renal support 
 
1557 
13.3% (12.7 – 14.0) 
237 
8.3% (7.3 – 9.3) 
<0.001 
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Unknown 1365  10.5% 
 
301  9.5% 
 
0.113 
Organ support             1 
2 
3 
6438 
5302 
1306 
49.4% 
40.6% 
10.0% 
1779 
1197 
189 
56.2% 
37.8% 
6.0% 
<0.001 
ICU length of stay (IQR) 3 (1 – 7) days 2 (1 – 5) days 0.0001 
ICU mortality 23.5% (22.8 – 24.2) 18.6% (17.2 – 19.9) <0.001 
Hospital mortality 36.0% (35.1 – 36.8) 31.4% (29.8 – 22.0) <0.001 
Table 5-5 Surgical admissions to ICU that received organ support. Numbers are cumulative 
total followed by percentages (with 95% confidence intervals) unless otherwise specified. 
 
APACHE II score was available for 92% of ICU non-cancer patients and 90.7% of 
ICU cancer patients and median value was 18 for both groups. Within this group 
of patients defined as surgical ICU admissions that had received organ support, 
respiratory support was the commonest mode of support within both the cancer 
and non-cancer groups at 92.2% and 94.3% respectively. Cardiovascular support 
was provided to half of the cancer group (50.1%) and 54.6% of the non-cancer 
group. Data pertaining to provision of renal replacement therapy (RRT) was 
missing in 10.5% of non-cancer patients and 9.5% of cancer patients. RRT was not 
commonly provided in either group but those patients in the cancer group had a 
lower prevalence of RRT when compared to the non-cancer group (8.3% (95% CI 
7.3 – 9.3) vs. 13.3% (95% CI 12.7 – 14.0)). Single organ support was more common 
in the cancer group with 56.2% of patients compared with 49.4% in the non-
cancer group.  
ICU length of stay was shorter for the cancer group with a median value of 2 
days versus 3 days in the non-cancer group (p <0.0001). Mortality was lower in 
the cancer group with ICU mortality 18.6% versus 23.5% (p <0.001) and hospital 
mortality 31.4% versus 36.0% (p <0.001). 
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5.4.3.2  Features of ICU surgical admissions by underlying tumour type 
Table 5-6 lists all tumour types in ICU during the study period along with ICU and 
hospital mortality. Short-term mortality varied considerably between different 
cancer types. To explore this further the ICU clinical features were analysed. As 
expected the clinical features varied by the underlying tumour type and the four 
commonest tumours admitted to ICU as a surgical admission are described in 
Table 5-7 (colorectal, head and neck, stomach and oesophageal cancer). 
 
 
Cancer type Number 
of 
patients 
Percent of 
surgical 
ICU cohort 
ICU mortality Hospital mortality 
Colorectal 2414 44.2% 11.6% (10.3 – 12.9) 21.9% (20.2 – 23.6) 
Head & Neck 610 11.2% 5.6% (3.9 – 7.7) 11.0% (8.6 – 13.7) 
Stomach 419 7.7% 10.7% (7.9 – 14.1) 22.0% (18.1 – 26.2) 
Oesophagus 355 6.5% 8.5% (5.8 – 11.8) 17.7% (13.9 – 22.1) 
Kidney 230 4.2% 9.6% (6.1 – 14.1) 15.2% (10.8 – 20.5) 
Lung 220 4.0% 35.9% (29.6 – 42.6) 51.4% (44.6 – 58.1) 
Bladder 172 3.1% 7.0% (3.7 – 11.9) 26.7% (20.3 – 34.0) 
Ovary 130 2.4% 14.6% (9.0 – 21.9) 29.2% (21.6 – 37.8) 
Prostate 102 1.9% 8.8% (4.1 – 16.1) 21.6% (14.0 – 30.8) 
Uterus 102 1.9% 10.8% (5.5 – 18.5) 16.7% (10.0 – 25.3) 
Breast 99 1.8% 15.2% (8.7 – 23.8) 22.2% (14.5 – 31.7) 
Pancreas 72 1.3% 25.0% (15.5 – 36.6) 47.2% (35.3 – 59.3) 
Liver 56 1.0% 32.1 (20.3 – 46.0) 58.9% (45.0 – 71.9) 
Small 
intestine 
50 0.9% 14.0% (5.8 – 26.7) 32.0% (19.5 – 26.7) 
Thyroid 24 0.4% 4.2% (1.1 – 21.1) 8.3% (1.0 – 27.0) 
Testis 16 0.3% 18.8% (4.0 – 45.6) 18.8% (4.0 – 45.6) 
Mesothelioma 13 0.2% 23.1% (5.0 – 53.8) 46.2% (19.2 – 74.9) 
Melanoma 11 0.2% 0% (0 – 28.5)* 18.2% (2.3 – 51.8) 
Other 95 1.7% 12.6% (6.7 – 21.0) 25.3% (16.9 – 35.2) 
Unknown 82 1.5% 39.0% (28.4 – 50.4) 68.3% (57.1 – 78.1) 
Multiple 190 3.5% 8.9% (5.3 – 13.9) 17.4% (12.3 – 23.5) 
Total 5462 100% 12.2% (11.3 – 13.1) 22.9% (21.8 – 24.1) 
Table 5-6 Frequency of specific tumour types in the surgical ICU population and short-term 
mortality. Numbers are cumulative total followed by percentages (with 95% confidence 
intervals) unless otherwise specified. *One sided 97.5% confidence interval 
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ICU Features Colorectal 
N=2414 
Head & Neck  
N=610 
Stomach 
N=419 
Oesophagus 
N=355 
Median age (IQR) 71 (63 – 78) 62 (55 – 69) 69 (61 – 76) 64 (57 – 71) 
Emergency 
hospital 
admission  
1089 / 2372 
45.9%  
(43.9 – 47.9) 
142 / 608 
23.4%  
(20.0 – 26.9) 
109 /  417 
26.1%  
(22.0 – 30.6) 
54 /  352 
15.3%  
(11.7 – 19.5) 
Sepsis 10.5% 7.9% 10.0% 9.3% 
Median APACHE II  
(IQR) 
 
Not recorded 
18 (14 – 22) 
 
908  37.6% 
15 (12 – 19) 
 
61  10% 
16 (12 – 21) 
 
125  29.8% 
14 (11 – 19) 
 
52  14.6% 
Organ support 
Respiratory 
support 
 
     
 Unknown 
 
1014 / 2350 
44.3%  
(42.3 – 46.3) 
 
64  2.7% 
 
558 / 598 
93.3%  
(91.0 – 95.2) 
 
12  2.0%  
 
193 /  401 
48.1%  
(43.1 – 53.1) 
 
18  4.3% 
 
199 / 151 
56.9%  
(51.5 – 62.1) 
 
5  1.4% 
CVS support 
 
 
    
Unknown 
733 /  2343  
31.3%  
(29.4 – 33.2) 
71  2.9% 
100 / 598 
14.4%  
(11.7 – 17.5) 
 
12  2.0% 
209 /  398  
27.4%  
(23.1 – 32.1) 
 
21  5.0% 
112 / 350 
32.0%  
(27.1 – 37.2) 
 
5  1.4% 
Renal support 
 
 
                   
Unknown 
90 / 2037 
4.4%  
(3.6 –   5.4) 
377   15.6% 
16 / 570  
2.8%  
(1.6 – 4.5)  
 
40   6.6% 
16 / 338 
4.7%     
(2.7 – 7.6) 
 
81   19.3% 
15 / 313 
4.8%  
(2.7 – 7.8) 
 
42 11.8% 
Organ support 
0 
1 
2 
3 
Unknown for all 
modes 
 
1181 
553 
540 
77 
63 
 
48.9% 
22.9% 
22.4% 
3.2% 
2.6% 
 
40 
467 
83 
9 
11 
 
6.6% 
76.6% 
13.6% 
1.5% 
1.8% 
 
189 
117 
84 
11 
18 
 
45.1% 
27.9% 
20.0% 
2.6% 
4.3% 
 
124 
141 
70 
15 
5 
 
34.9% 
39.7% 
19.7% 
4.2% 
1.4% 
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ICU Features Colorectal 
N=2414 
Head & Neck  
N=610 
Stomach 
N=419 
Oesophagus 
N=355 
ICU mortality 11.6%  
(10.3 – 12.9) 
5.6%  
(3.9 – 7.7) 
10.7%  
(7.9 – 14.1) 
8.5%  
(5.8 – 11.8) 
Hospital mortality 21.9%  
(20.2 – 23.6) 
11.0%  
(8.6 – 13.7) 
22.0%  
(18.1 – 26.2) 
17.8%  
(13.9 – 22.1) 
Table 5-7 ICU features by commonest surgical tumour types. Numbers are cumulative total 
followed by percentages (with 95% confidence intervals) unless otherwise specified.  
 
Colorectal cancer was the commonest tumour type admitted to ICU as a surgical 
admission (44.2%). Other common tumours included head and neck tumours 
(11.2%) and upper gastrointestinal tumours (stomach 7.7%, oesophageal 6.5%). 
Colorectal cancer had the highest rate of emergency hospitalisation at 45.9% and 
median APACHE II scores were correspondingly higher. Organ support showed 
some variation by underlying tumour type. Notably, single organ support was 
more common in surgical patients with head and neck cancer (76.6%) compared 
with that seen in other common tumour types (22.9% in colorectal cancer 
patients to 39.7% oesophageal cancer patients). This was largely accounted for 
by the high rate of mechanical ventilation for patients with head and neck 
cancer. There was a high proportion of patients receiving no organ support in 
the groups with colorectal cancer and stomach cancer (48.9% and 45.1% 
respectively). These groups also had a larger proportion of patients with missing 
APACHE II scores. ICU and hospital mortality were lowest for the group of 
patients with head and neck cancer.  
 
5.4.4 Medical admissions to ICU 
During the study period there were 16,672 medical admissions to ICU. Of these 
654 patients (3.9%) had a solid tumour diagnosis. Clinical features of those 
medical patients admitted to ICU with and without a diagnosis of cancer are 
demonstrated in Table 5-8. 
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 ICU Non-cancer 
patients      
N=16,018 
ICU Cancer 
patients         
N=654  
P value 
Men 8679 
54.3% (53.5 – 55.1) 
372 
56.9% (53.0 – 60.7) 
0.194 
Median Age (IQR) 55 (41 – 68) 67 (59 – 74) <0.0001 
Emergency 
hospitalisation 
15,272 / 15,566 
98.1% (97.9 – 98.3) 
501 / 651 
77.0% (73.5 – 80.1) 
<0.001 
Reason for admission 
Sepsis 
Malignancy 
Gastrointestinal/ Liver 
Respiratory disorder 
Neurological 
Post cardiac arrest 
Cardiovascular 
Haemorrhage 
Drug related 
Endocrine/ Metabolic 
 
4931 
17 
434 
1928 
2451 
1593 
849 
337 
2164 
415 
 
30.8% 
0.1% 
2.7% 
12.0% 
15.3% 
9.9% 
5.3% 
2.1% 
13.5% 
2.6% 
 
209 
114 
86 
66 
44 
41 
28 
17 
9 
6 
 
32.0% 
17.4% 
13.1% 
10.1% 
6.7% 
6.3% 
4.3% 
2.6% 
1.4% 
0.9% 
 
<0.001 
Median APACHE II (IQR) 
 
Not recorded 
21 (15 – 27) 
 
1686  10.5% 
22 (17 – 27) 
 
178  27.2% 
0.0002 
 
<0.001 
Organ support type: 
Respiratory support 
 
     
Unknown 
 
12,866 / 15,869 
81.1% (80.5 – 81.7) 
149  0.9% 
 
425 / 633 
67.1% (63.3 – 70.8) 
 
21  3.2% 
 
<0.001 
 
 
<0.001 
Cardiovascular support  
 
   
Unknown 
7444 / 15,703  
47.4% (46.6 – 48.2) 
 
315  2.0% 
295 / 632 
46.7% (42.7 – 50.7) 
 
22  3.4% 
0.719 
 
 
0.013 
Renal support 
 
2016 / 14,614  
13.8% (13.2 – 14.4) 
69 / 554 
12.5% (9.8 – 15.5) 
0.369 
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Unknown 1404  8.9% 
 
100  15.3% 
 
<0.001 
Organ support               0 
1 
2 
3 
 Unknown for all modes 
2016 
6276 
5619 
1604 
503 
12.6% 
39.2% 
35.1% 
10.0% 
3.1% 
129 
179 
230 
50 
66 
19.7% 
27.4% 
35.2% 
7.6% 
10.1% 
<0.001 
 
 
 
<0.001 
ICU length of stay (IQR) 2 (1 – 6) days 3 (1 – 6) days 0.004 
ICU mortality 30.3% (29.6 – 31.0) 35.8% (32.1 – 39.6) 0.003 
Hospital mortality 41.7% (40.9 – 42.4) 49.1% (45.2 – 53.0) <0.001 
Table 5-8 Medical admissions to ICU with and without cancer. Numbers are cumulative total 
followed by percentages (with 95% confidence intervals) unless otherwise specified. 
 
Median age at the time of ICU admission was higher in the cancer group at 67 
years compared with 55 years in the non-cancer group (p<0.001). 77.0% of 
hospitalisations were emergency in nature within the ICU cancer group 
compared with 98.1% in the non-cancer group (p<0.001). Sepsis was the 
commonest reason for admission affecting 32.0% of cancer patients and 30.8% 
non-cancer patients. Within the ICU cancer group other reasons for admission 
included malignancy (17.4%), gastrointestinal/ liver disease (13.1%), non-
infectious respiratory disorder (10.1%), neurological conditions (6.7%) and post 
cardiac arrest (6.3%). Those ICU patients without cancer were admitted with 
neurological conditions (15.3%), drug related (13.5%), non-infectious respiratory 
disorder (12.0%) and post cardiac arrest (9.9%).  
There was not a clinically significant difference in median APACHE II score 
although there were a larger proportion of cancer patients with missing APACHE 
II scores than the non-cancer group (27.2% vs. 10.5%, p<0.001). Respiratory 
support was provided less frequently in the cancer group compared to the non-
cancer group (67.1% vs. 81.1%, p<0.001). Support with vasoactive drugs and 
renal replacement therapy was similar between both groups. A larger proportion 
of cancer patients received no organ support during their time in ICU when 
compared to the non-cancer patients (19.7% vs. 12.6%, p<0.001). However, 
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multi-organ support was provided to a similar proportion within each groups 
(42.8% vs. 45.1% p=0.251). 
ICU length of stay was slightly longer for cancer patients when compared with 
non-cancer patients (median duration 3 days vs. 2 days, p=0.004). Mortality was 
high for both groups but was consistently higher in the ICU cancer population 
with ICU mortality of 35.8% (95% CI 32.1 – 39.6) vs. 30.3% (95% CI 29.6 – 31.0), 
p=0.003, and hospital mortality of 49.1% (95% CI 45.2 – 53.0) vs. 41.7% (95% CI 
40.9 – 42.4), p<0.001. 
 
5.4.4.1  Medical ICU admissions with organ support 
There were 13,958 medical admissions that received organ support during the 
study period. Only 459 patients (3.3%) had a solid tumour diagnosis (Table 5-9). 
Compared with the medical population without cancer, the medical ICU cancer 
group tended to be older (median age 66 years vs. 56 years, p<0.0001). The 
majority of patients in both groups were admitted to ICU after emergency 
admission to hospital. The proportion was slightly less for the cancer group at 
87.9% (95% CI 84.6 – 90.8) compared with 98.3% (95% CI 981. – 98.5) of the non-
cancer group. 
The commonest reason for admission in both groups was due to sepsis. This 
contributed 40.3% of medical ICU cancer admissions and 33.0% of medical ICU 
non-cancer admissions. Common causes for ICU admission in both cancer and 
non-cancer patients included non-infectious respiratory disorders (12.2% and 
10.6%), neurological disorders (9.3% and 16.3%), post cardiac arrest (8.7% and 
11.5%), and gastrointestinal/ liver disease (5.7% and 2.1%). Malignancy was the 
direct cause for ICU admission in 9.2% of the ICU cancer population. Drug related 
admissions accounted for 12.9% of the non-cancer ICU medical admissions but 
only 1.7% in the cancer group.  
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 ICU Non-cancer 
patients N=13,499 
(%) 
ICU Cancer 
patients N=459 
(%) 
P value 
Men 7427 
55.0% (54.2 – 55.9) 
259 
56.4% (51.8 – 61.0) 
0.553 
Median Age (IQR) 56 (42 – 68) 66 (59 – 73) <0.0001 
Emergency 
hospitalisation 
12,890 / 13,108 
98.3% (98.1 – 98.5) 
401 / 456 
87.9% (84.6 – 90.8) 
<0.001 
Reason for admission 
Sepsis 
Respiratory disorder 
Neurological 
Malignancy 
Post cardiac arrest 
Gastrointestinal/ Liver 
Cardiovascular 
Haemorrhage 
Drug related 
Endocrine/ Metabolic 
 
4451 
9 
281 
1425 
2200 
1551 
766 
251 
1743 
241 
 
33.0% 
10.6% 
16.3% 
0.1% 
11.5% 
2.1% 
5.7% 
1.9% 
12.9% 
1.8% 
 
185 
42 
26 
56 
43 
40 
24 
8 
8 
3 
 
40.3% 
12.2% 
9.3% 
9.2% 
8.7% 
5.7% 
5.2% 
1.7% 
1.7% 
0.7% 
<0.001 
Median APACHE II (IQR) 
 
Not recorded 
22 (16 – 28) 
 
1014  7.5% 
23 (18 – 28) 
 
44  9.6% 
0.004 
 
0.099 
Organ support type: 
Respiratory support 
 
     
Unknown 
 
12,866 / 12,864 
95.2% (95.0 – 95.7) 
2  0.0% 
 
425 
92.6% (89.8 – 94.8) 
 
0  0%  
 
0.007 
 
 
0.794 
Cardiovascular support    
 
 
Unknown 
7444 / 7401 
55.3% (54.5 – 56.2) 
 
43  0.3% 
295 
64.3% (59.7 – 68.7) 
 
0  0% 
<0.001 
 
 
0.226 
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Renal support                   
 
 
Unknown 
2016 / 12,466 
16.2% (15.5 – 16.8) 
 
1033  7.7% 
69 / 423 
16.3% (12.9 – 20.2) 
 
36  7.8% 
0.939 
 
 
0.880 
Organ support             1 
2 
3 
6276 
5619 
1604 
46.5% 
41.6% 
11.9% 
179 
230 
50 
39.0% 
50.1% 
10.9% 
0.001 
ICU length of stay (IQR) 2 (1 – 7) days 3 (1 – 6) days 0.893 
ICU mortality 34.5% (33.7 – 35.4) 48.4% (43.7 – 53.0) <0.001 
Hospital mortality 46.2% (45.4 – 47.0) 62.5% (57.9 – 67.0) <0.001 
Table 5-9 Medical admissions to ICU that received organ support. Numbers are cumulative 
total followed by percentages (with 95% confidence intervals) unless otherwise specified. 
 
APACHE II score was available for 92.5% of ICU non-cancer patients and 90.4% of 
ICU cancer patients. The median APACHE II score was slightly higher for the 
cancer group compared with the non-cancer group (23 (IQR 18 – 28) vs. 22 (IQR 
16 – 28), p 0.004). Within this group of patients defined as medical ICU patients 
that had received organ support, respiratory support was the commonest mode 
of support within both the cancer and non-cancer groups at 92.6% and 95.2% 
respectively. Cardiovascular support was provided more frequently in the cancer 
group at 64.3% (95% CI 59.7 – 68.7) compared with 55.3% (95% CI 54.5 – 56.2) in 
the non-cancer group (p <0.001). Data pertaining to provision of renal 
replacement therapy was missing in 7.7% of non-cancer patients and 7.8% of 
cancer patients. Approximately one in six medical ICU patients that received 
organ support had renal replacement therapy and this did not differ between the 
cancer and non-cancer populations (16.3% (95% CI 12.9 – 20.2) and 16.2% (95% CI 
15.5 – 16.8)). Single organ support was less common in the cancer group with 
39.0% of patients compared with 46.5% in the non-cancer group.  
Mortality was higher in the cancer group with ICU mortality 48.4% (95% CI 43.7 – 
53.0) versus 34.5% (95% CI 45.4 – 47.0) (p <0.001) and hospital mortality 62.5% 
(95% CI 57.9 – 67.0) versus 46.2% (95% CI 45.4 – 47.0) (p <0.001). 
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5.4.4.2  Features of ICU medical admissions by underlying tumour type 
Table 5-10 documents the proportion of each tumour type within the group of 
cancer patients admitted under a medical specialty. ICU and hospital mortality 
can be seen to vary depending on the underlying cancer type and this may 
reflect differences in the critical illness experienced by the different subgroups. 
Cancer type Number 
of 
patients 
Percent 
of 
medical 
ICU 
cohort 
ICU mortality Hospital mortality 
Lung 161 24.6% 55.3% (27.3 – 63.1) 73.3% (65.8 – 79.9) 
Colorectal 147 22.5% 13.6% (8.5 – 20.2) 20.4% (14.2 – 27.8) 
Breast 50 7.6% 36.0% (22.9 – 50.8) 52.0% (37.4 – 66.3) 
Stomach 37 5.7% 37.8% (22.5 – 55.2) 45.9% (29.5 – 63.1) 
Oesophageal 34 5.2% 44.1% (27.2 – 62.1) 52.9% (35.1 – 70.2) 
Prostate 34 5.2% 32.4% (17.4 – 50.5) 50.0% (32.4 – 67.6) 
Head & Neck 26 4.0% 19.2% (6.6 – 39.4) 42.3% (23.4 – 63.1) 
Kidney 19 2.9% 10.5% (1.3 – 33.1) 31.6% (12.6 – 56.6) 
Uterus 11 1.7% 18.2% (2.3 – 51.8) 36.4% (10.9 – 69.2) 
Liver 11 1.7% 18.2% (2.3 – 51.8) 27.3% (6.0 – 61.0) 
Bladder 10 1.5% 20.0% (2.5 – 55.6) 40.0% (12.2 – 73.8) 
Testis 10 1.5% 70.0% (34.8 – 93.3) 80.0% (44.4 – 97.5) 
Pancreas 9 1.4% 44.4% (13.7 – 78.8) 44.4% (13.7 – 78.8) 
Ovary 8 1.2% 37.5% (8.5 – 75.5) 37.5% (8.5 – 75.5) 
Melanoma 7 1.1% 42.9% (9.9 – 81.6) 42.9% (9.9 – 81.6) 
Small 
intestine 
5 0.8% 40.0% (5.3 – 85.3) 40.0% (5.3 – 85.3) 
Mesothelioma 5 0.8% 60.0% (14.7 – 94.7) 60.0% (14.7 – 94.7) 
Thyroid 4 0.6% 0% (0 – 60.2)* 25.0% (0.6 – 80.6) 
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Cancer type Number 
of 
patients 
Percent 
of 
medical 
ICU 
cohort 
ICU mortality Hospital mortality 
Other 11 1.7% 27.3% (6.0 – 61.0) 45.5% (16.7 – 76.6) 
Unknown 39 6.0% 61.5% (44.6 – 76.6) 82.1% (66.5 – 92.5) 
Multiple 16 2.4% 31.3% (11.0 – 58.7) 37.5% (15.2 – 64.6) 
Total 654 100% 35.8% (32.1 – 39.6) 49.1% (45.2 – 53.0) 
Table 5-10 Frequency of specific tumour types in the medical ICU population and short-term 
mortality. Numbers are cumulative total followed by percentages (with 95% confidence 
intervals) unless otherwise specified. *One sided 97.5% confidence interval 
 
ICU clinical features are described for the four commonest tumours admitted to 
ICU as a medical admission in Table 5-11. The most frequent ICU medical cancer 
types were lung (24.6%), colorectal (22.5%), breast (7.6%), and stomach (5.7%). 
The underlying tumour type was unknown in 6.0% of this population. 
 
 
ICU Features Lung N=161 Colorectal 
N=147 
Breast N=50 Stomach N=37 
Median age 
(IQR) 
65 (60 – 72) 69 (62 – 76) 64 (53 – 69) 69 (63 – 74) 
Emergency 
hospital 
admission  
150 
93.2% (88.1 – 
96.5) 
78 
53.1% (44.7 – 
61.3) 
47 / 49 
95.9% (86.0 – 
99.5) 
20 
54.1% (36.9 – 
70.5) 
Sepsis 55.9% 11.6% 32.0% 13.5% 
Median 
APACHE II  
(IQR) 
Not recorded 
22  
(18 – 27) 
 
18  2.7% 
19    
(13 – 25) 
 
88  59.9% 
22.5  
(17.5 - 29) 
 
10  20% 
22  
(15 – 26) 
 
12  32.4% 
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ICU Features Lung N=161 Colorectal 
N=147 
Breast N=50 Stomach N=37 
Respiratory 
support 
 
     
Unknown 
130 / 159 
81.8% (74.9 – 
87.4) 
 
2  1.2% 
52 / 137 
38.0% (29.8 – 
46.6) 
 
10  6.8% 
10 / 49 
79.6% (65.7 – 
89.8) 
 
1  2.0% 
21 / 33 
63.6% (45.1 – 
79.6) 
 
4  10.8% 
CVS support    
 
 
Unknown 
86 / 159 
54.1% (46.0 – 
62.0) 
 
2  1.2% 
35 / 137 
25.5% (18.5 – 
33.7) 
 
10  6.8% 
25 / 49 
51.0 % (36.3 – 
65.6) 
 
1  2.0% 
15 / 33 
45.5% (28.1 – 
63.6) 
 
4  10.8% 
Renal support                   
 
 
 
Unknown 
10 / 142 
7.0% (3.4 – 
12.6) 
 
19  11.8% 
5 / 107 
4.7% (1.5 – 
10.6) 
 
40  27.2% 
6 / 45 
13.3% (5.1 – 
26.8) 
 
5  10.0% 
3 / 26 
11.5% (2.4 – 
30.2) 
 
11  29.7% 
Organ support 
0 
1 
2 
3 
Unknown for 
all modes 
 
25 
50 
76 
8 
2 
 
15.5% 
31.1% 
47.2% 
5.0% 
1.2% 
 
82 
23 
27 
5 
10 
 
55.8% 
15.6% 
18.4% 
3.4% 
6.8% 
 
7 
19 
18 
5 
1 
 
14.0% 
38.0% 
36.0% 
10.0% 
2.0% 
 
12 
8 
11 
3 
3 
 
32.4% 
21.6% 
29.7% 
8.1% 
8.1% 
ICU mortality 55.3%  
(47.3 – 63.1) 
13.6% 
(8.5 – 20.2) 
36.0% 
(22.9 – 50.8) 
37.8% 
(22.5 – 55.2) 
Hospital 
mortality 
73.3%  
(65.8 – 79.9) 
20.4%  
(14.2 – 27.8) 
52.0%  
(37.4 – 66.3) 
45.9%  
(29.5 – 63.1) 
Table 5-11 ICU features by commonest medical tumour types. Numbers are cumulative total 
followed by percentages (with 95% confidence intervals) unless otherwise specified. 
 
The populations with colorectal and stomach cancer had lower rates of 
emergency hospitalisation, sepsis and organ support when compared with that 
seen in patients with lung cancer or breast cancer. Only the colorectal group had 
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a corresponding lower median APACHE II score with associated lower ICU and 
hospital mortality. In contrast, lung cancer patients had high rates of sepsis, 
high use of multi-organ support (over half of the lung cancer cohort) and high 
ICU and hospital mortality. 
 
5.4.5 Survival following ICU admission 
Longer-term survival of ICU patients with and without cancer is demonstrated by 
the Kaplan Meier graph in Figure 5-2. This demonstrates that the initial survival 
advantage experienced by ICU cancer patients reverses in the first 12 months 
following admission. After the initial drop in survival associated with critical 
illness the group of patients without cancer have a very slow decline in mortality 
over the following four years. The ICU cancer group, however, has a more 
pronounced decrease in survival over time.  
 
Figure 5-2 Kaplan Meier survival analysis of patients with and without cancer following ICU 
admission (p <0.0001) 
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Table 5-12 details the mortality over time up to four years in ICU patients by the 
cancer and non-cancer subgroup. By one year there is a statistically significant 
difference in survival between the two groups in favour of those patients 
without cancer. 
Mortality Patients without cancer Patients with cancer P value 
Six months 34.7% (34.2 – 35.2) 34.4% (33.2 – 35.6) 0.557 
One year 36.8% (36.3 – 37.4) 42.2% (41.0 – 43.5) <0.001 
Four years 45.9% (45.4 – 46.5) 62.8% (61.6 – 64.0) <0.001 
Table 5-12 Mortality up to four years after ICU admission for patients with and without 
cancer. Numbers are percentages (with 95% confidence intervals) of patients who died 
during the study period. 
 
The initial survival advantage seen in cancer patients may be explained by the 
high proportion of surgical cancer admissions as these patients have lower 
utilisation of organ support and favourable short-term survival compared to 
surgical patients without cancer and medical patients as previously described. 
This is in contrast to the smaller proportion of medical cancer admissions where 
short-term survival is poorer than that in the medical population without cancer. 
Any survival advantage that the combined cancer group has in the initial period 
is not sustained in the longer-term. To further understand this surgical and 
medical ICU patients were analysed separately. 
 
5.4.5.1  Survival of ICU Surgical patients 
In the initial period of critical illness surgical cancer patients have a survival 
advantage over non-cancer patients. Longer-term survival of surgical ICU 
patients with and without cancer is demonstrated by Kaplan Meier graph in 
Figure 5-3. While the initial mortality associated with the acute critical illness 
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appears similar the patients in the cancer group have a higher mortality by six 
months (Table 5-13). The survival of the cancer group continues to diverge from 
the non-cancer group throughout the following four years. 
 
Figure 5-3 Kaplan Meier survival analysis of patients with and without cancer following 
surgical ICU admission (p <0.0001) 
 
By four years the mortality of surgical ICU cancer patients is 60.9% (95% CI 59.5 – 
62.2) compared with 39.7% (39.0 – 40.4) seen in the non-cancer surgical group. 
Mortality Patients without cancer Patients with cancer P value 
Six months 28.2% (27.6 – 28.9) 31.3% (30.1 – 32.6) <0.001 
One year 30.2% (29.6 – 30.9) 39.4% (38.1 – 40.7) <0.001 
Four years 39.7% (39.0 – 40.4) 60.9% (59.5 – 62.2) <0.001 
Table 5-13 Mortality up to four years after surgical ICU admission for patients with and 
without cancer. Numbers are percentages (with 95% confidence intervals) of patients who 
died during the study period. 
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5.4.5.2  Survival of ICU Medical patients 
The initial mortality associated with critical illness in ICU medical patients is 
greater than that seen in the surgical population. Unlike the surgical population, 
cancer patients have a higher initial mortality compared to patients without 
cancer. Figure 5-4 demonstrates long-term survival for ICU medical patients with 
and without cancer. For those patients without cancer the period following the 
critical illness has a continued slow decline in mortality. However, for the ICU 
medical patients with cancer the initial period of marked increase in mortality 
continues over a longer period.  
 
Figure 5-4 Kaplan Meier survival analysis of patients with and without cancer following 
medical ICU admission (p <0.0001) 
 
Table 5-14 describes the increased mortality observed in medical ICU cancer 
patients up to four years following ICU admission. 
Mortality Patients without cancer Patients with cancer P value 
Six months 42.9% (42.1 – 43.6) 59.5% (55.6 – 63.2) <0.001 
One year 45.1% (44.4 – 45.9) 66.1% (62.3 – 69.7) <0.001 
Four years 53.8% (53.0 – 54.6) 79.4% (76.1 – 82.4) <0.001 
Table 5-14 Mortality up to four years after medical ICU admission for patients with and 
without cancer. Numbers are percentages (with 95% confidence intervals) of patients who 
died during the study period. 
 
5.4.5.3  Survival by level of organ support 
Severity of illness and degree of organ failure would be expected to be 
associated with short-term outcomes. Kaplan Meier survival analysis was 
performed on patients with and without cancer for each level of provided organ 
support (Figure 5-5). This demonstrated an excess long-term mortality in the 
cancer group for each level of organ support provided. 
    
Figure 5-5 Kaplan Meier survival of patients with and without cancer by the number of organ 
support provided in ICU (*p<0.0001, ^p=0.0001) 
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5.5 Discussion 
5.5.1 Demographic and clinical baseline differences 
In an unselected, population-based cohort of general ICU admissions, we found 
that nearly one in seven ICU patients had been diagnosed with a solid tumour in 
the two years prior to admission. Cancer patients had a higher proportion of 
both surgical admissions and elective hospitalisations compared with the non-
cancer population. Even those cancer patients with a medical admission to 
hospital are more likely to be admitted to ICU with a surgical diagnosis. It is 
likely that the available treatments for patients with solid tumours will lead to a 
high proportion of patients undergoing elective hospitalisation for a surgical 
intervention at some point during their cancer treatment plan. Subsequent ICU 
admission for these patients may be part of planned post-operative care in those 
units that are combined HDU/ ICUs, due to surgical complications or as a result 
of unrelated medical or surgical problems.  
Compared to patients without cancer, cancer patients were older. In spite of the 
difference in age, APACHE II scores were slightly lower in the cancer group 
although this likely reflects the higher proportion of surgical admissions and 
those patients who did not receive organ support. There were a larger 
proportion of patients with missing APACHE II scores in the cancer group and this 
may represent those HDU admissions to combined units as these patients are 
excluded from APACHE scoring. Organ support was provided to approximately 
two thirds of cancer patients and over three quarters of non-cancer patients. 
This difference can be explained either by a lower frequency of organ failure in 
the cancer group or similar rates of organ failure in both groups but less organ 
support being offered to the cancer group. The lower APACHE II score in the 
cancer group suggests lower severity of illness for the cancer group, therefore, it 
is more likely that the former explanation is more likely and is in keeping with 
admission of a group of post-operative patients for observation and monitoring.  
Malignancy was the commonest reason for admission to ICU for the cancer 
cohort. This included any illness that was directly related to the tumour 
including cancer surgery and cancer-related complications. Malignancy was also 
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related to ICU admission for a small proportion of the non-cancer group (<1%). 
This may be due to diagnostic error at the time of ICU admission where 
malignancy has been suspected but not confirmed and the wrong diagnosis has 
been recorded in Wardwatcher. Alternatively it is possible that a patient with a 
diagnosis for cancer made outwith Scotland (and therefore not on the SMR06 
dataset) has been admitted to a West of Scotland ICU.  
Among the group of ICU patients that received organ support one in eight had a 
preceding diagnosis of solid tumour. Elective hospitalisations and surgical ICU 
admissions were again more common in the cancer group when compared with 
the non-cancer group. In addition the cancer group had a lower requirement for 
multi-organ support with the majority of patients only requiring single organ 
support, most commonly invasive mechanical ventilation.  
For both patients with and without cancer the clinical features varied between 
ICU surgical admissions and medical admissions and these groups were analysed 
separately.  
 
5.5.1.1  ICU Surgical admissions 
One in five surgical ICU patients had a preceding diagnosis of solid tumour. While 
cancer patients tended to be older this was less pronounced within the surgical 
cohort. In contrast to the non-cancer population those ICU surgical cancer 
patients had a much higher proportion of elective admission to hospital. 
Malignancy was the commonest reason for ICU admission for the cancer group. 
Other diagnostic categories were similar between both groups with sepsis, 
gastrointestinal/ liver disease and surgical complications as common causes for 
admission. Severity of illness scoring was missing for one in five non-cancer 
patients and two in five cancer patients. While the APACHE II score was the 
same for both groups the rate of organ support was less for the cancer group. 
This might suggest that organ failure was less common in the cancer group. If 
this were the case we would expect to see lower severity of illness scores in the 
cancer group. This was not the case, however, there were a higher proportion of 
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patients without APACHE scores in the cancer group and this might reflect a 
“well” cohort of patients admitted for post-operative HDU observation and 
therefore excluded from scoring. This may also explain the apparent beneficial 
survival of surgical cancer patients compared with the non-cancer group.  
Colorectal cancer made the largest contribution to the ICU cancer burden and 
was predominantly surgical admissions. Within the surgical group less than half 
of the colorectal cancer patients received any organ support during their ICU 
stay. It seems likely that the nature of colorectal cancer surgery leads to many 
patients being admitted for post-operative observation or HDU level care. The 
high turnover of these patients in ICU/ HDU and high incidence of the disease 
contributes to the dominance of this tumour type in surgical ICU admissions. 
Head and neck cancer was another common cancer within the surgical ICU 
population. In contrast to colorectal the majority of these patients received 
organ support during their stay, principally mechanical ventilation. Surgery for 
head and neck cancer is often carried out near the airway and may require 
either temporary or permanent formation of tracheostomy and a brief period of 
respiratory support in the post-operative period. More than two thirds of these 
patients were elective admissions to hospital and it seems likely that their ICU 
stay was part of a planned post-operative course. 
 
5.5.1.2  ICU Medical admissions 
Less than 4% of ICU medical admissions had a prior solid tumour diagnosis. There 
was a marked difference in the median age with cancer patients over a decade 
older. In contrast to surgical admissions the commonest reason for medical 
admission was sepsis for both cancer and non-cancer patients. Although median 
APACHE II score was similar for both groups there were a larger proportion of 
cancer patients with missing APACHE scores and a significantly greater number 
of patients that received no organ support. Mortality was substantially higher 
than that seen in the surgical group and there appeared to be an excess 
mortality in the cancer subgroup. High mortality among lung cancer patients 
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(who accounted for one in four of all cancer patients admitted from a medical 
specialty) made a major contribution to the overall higher mortality rate among 
medical patients.  
For those medical ICU patients that received organ support, only 3.3% had a 
preceding diagnosis of cancer. Although median APACHE II score was similar for 
the cancer and non-cancer groups, mortality was markedly higher in the cancer 
group. While respiratory and renal support was similar for both groups 
cardiovascular support was more common in the cancer group and this is 
reflected in a higher proportion of patients receiving two or more organ support 
in the cancer group.  
 
5.5.2 Determinants of short-term survival 
ICU and hospital mortality was lower for the cancer group overall. However, 
given the lower severity of illness score, larger proportion of surgical admissions 
and less frequent use of organ support it would be anticipated that mortality 
should be lower for this group.  
Surgical admissions had a more favourable outcome when compared with 
medical admissions and surgical cancer patients had lower ICU and hospital 
mortality rates than the surgical population without cancer. This may partly be 
explained by the inclusion of level 2 patients admitted for post-operative care to 
a combined ICU/ HDU. These patients are often admitted for monitoring 
purposes only and the cancer group had a higher proportion of patients without 
any organ support in their group. Additionally, the number of patients with a 
missing APACHE II score is higher for the surgical cancer cohort than the surgical 
non-cancer cohort. This may be due to level 2 admissions being excluded from 
APACHE II scoring. However, further analysis of the subgroup of surgical patients 
that received organ support found that the APACHE II score was recorded for 
similar proportions of both groups but that the mortality differences still 
persisted. Thus, even in the group of patients that received organ support during 
their ICU stay, outcomes were more favourable in the cancer population 
  
203 
compared with the population without cancer. The surgical cancer group with 
organ support may still be benefitting from the high proportion of elective 
hospitalisations where there has been an opportunity for pre-operative 
optimisation and patient selection. In addition the cancer group had lower 
utilisation of multi-organ support, with the majority of patients only requiring 
single organ support, most commonly ventilation. Furthermore, there may be 
less physiological stress associated with “cancer surgery” compared with surgery 
in the non-cancer group such as that required for vascular surgery or trauma 
surgery. 
Medical admissions to ICU had higher ICU and hospital mortality rates than the 
surgical group and these rates were worse for the cancer population when 
compared with the population without cancer. One in five ICU medical 
admissions with cancer did not receive any organ support during their time in 
ICU. This compares with one in eight ICU medical admissions without cancer and 
yet the outcomes favour those patients without cancer. This difference in 
mortality between medical patients with and without cancer is even more 
pronounced when assessing the group of ICU medical admissions that received 
organ support. This may be partly explained by differences in age as the cancer 
group had a median age of 12 years older than the non-cancer group. An 
additional explanation may be the high incidence of sepsis in both groups. 
Cancer patients are likely to be immunosuppressed due to either their 
underlying tumour or its treatment. Higher mortality for patients with sepsis 
might be expected where the immune system is not functioning adequately. 
 
5.5.3 Determinants of longer-term survival 
Longer-term survival was worse for cancer patients in both the surgical and 
medical ICU population when compared to patients without cancer. The 
mortality rate between the two groups became progressively divergent during 
the four-year follow up period. Mortality for surgical ICU patients was 
consistently higher in the cancer group at six months (31.3% vs. 28.2%), one-year 
(39.4% vs. 30.2%) and four-years (60.9% vs. 39.7%). Longer-term mortality was 
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even higher in the medical population and greater for those with cancer at six 
months (59.5% vs. 42.9%), one-year (66.1% vs. 45.1%) and four-years (79.4% vs. 
53.8%). The difference in survival between the ICU patients with and without 
cancer may be attributed to the underlying cancer or the treatment burdens 
associated with cancer.  
Longer-term survival deteriorated with increasing organ support during the ICU 
stay. Analysis of survival by level of organ support demonstrated worse outcome 
within the cancer group compared to the non-cancer group for each level. This 
impact of organ support on longer-term survival has not yet been described in 
the literature and is a novel finding. The severity of critical illness may impact 
upon the subsequent therapeutic options available for cancer treatment. For 
example, major surgery or aggressive chemotherapy may not be considered 
appropriate in a patient recovering from severe critical illness with multi-organ 
support. It is possible that the pro-inflammatory state associated with multi-
organ failure accelerates the underlying neoplastic process making certain 
cancers more aggressive. The nature of ICU admission may be important as 
cancer patients presenting to ICU with advanced disease and complications of 
the malignancy may be both more prone to critical illness and already likely to 
have a poor outcome from their underlying tumour. A prospective study is 
required to assess which of these factors account for the differences observed in 
this study. 
 
5.5.4 Comparisons with published literature 
This study has demonstrated that cancer is a common morbidity in the general 
ICU population. While one in twenty solid tumour patients are admitted to ICU, 
one in seven ICU patients has a preceding solid tumour diagnosis. The prevalence 
is similar to that seen in previous studies by Taccone et al of European general 
ICUs in 2002 [87] and Bos et al of ICUs in the Netherlands between 2007 and 
2011 [95]. In contrast to the study by Taccone et al, who described similar 
outcomes in cancer and non-cancer patients, this study demonstrated lower 
hospital mortality for cancer patients in the initial period following admission. 
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This is partly due to difference in case-mix with nearly 90% of cancer patients 
having a surgical ICU admission compared to 70% in Taccone et al’s study. The 
lower short-term mortality experienced by ICU cancer patients in this study is 
only seen in those with a surgical ICU admission. Outcomes were less favourable 
among the medical cancer patients when compared with medical patients 
without cancer. This difference was exaggerated further when comparing the 
medical patients that received organ support where outcomes for the cancer 
group were particularly poor. While the study by Bos et al demonstrated slightly 
higher mortality in surgical cancer patients compared with surgical non-cancer 
patients, this paper was on the subset of ICU patients who had been admitted to 
ICU as an emergency and elective ICU admissions were excluded. The 
significantly higher mortality in medical cancer patients compared with medical 
non-cancer patients demonstrated by Bos et al is in keeping with that which has 
been described here.  
In this study, hospital mortality for lung cancer patients was 51.4% for surgical 
ICU admissions and 73.3% for medical ICU admissions. Several studies of ICU lung 
cancer patients report hospital mortalities of between 54-65% [85, 107, 119, 
121, 126, 138, 139, 142]. This population differs from these previous 
investigations in that they had mainly involved specialised ICUs, or subsets of 
lung cancer patients with specific co-morbidities, thus making extrapolation to 
general ICUs difficult. Severity of illness for both groups of lung cancer patients 
within this population was high, with elevated median APACHE II scores and 
increased use of multi-organ support. Many of the original lung cancer studies 
were performed in countries where ICU is more readily available and therefore 
utilised for patients with a lower burden of critical illness. The study by Bos et 
al, which was based in a general ICU population, described a hospital death rate 
of 48.6% among unplanned medical lung cancer patients, and 6.5% among 
surgical patients. The difference in mortality for surgical lung cancer patients is 
striking and is particularly surprising given that nearly two thirds of the surgical 
lung cancer population in this study had been an elective hospitalisation. 
Severity of illness scores and subsequent use of organ support in the Bos 
population was low and it is likely that they are more representative of an HDU 
population rather than what would be considered a true ICU population in the 
UK. 
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One-year mortality of ICU cancer patients has previously been described ranging 
from 35.9 – 88.0% [111, 113, 124, 143, 146]. The significant variation in 
outcomes can largely be attributed to the patient case-mix studied within each 
publication including exclusively patients with metastatic disease in the study by 
Caruso et al, non-resectable lung cancer by the study by Toffart et al and 
elective oesophagectomy patients in the study by Cense et al. Oeyen et al 
described a mixed group of solid tumour patients with largely surgical ICU 
admissions (81%) with low severity of illness scores and requirement for organ 
support. One-year mortality in the Oeyen series was 35.9%, and similar to the 
39.4% one-year survival described here in ICU surgical cancer patients. The four-
year mortality in surgical ICU cancer patients of 60.9% is similar to that 
previously described by Bissell et al of 62.8% in a group of post-operative 
oesophagectomy patients that required a readmission to ICU within the UK [122]. 
 
5.5.5 Strengths and weaknesses 
This is a large study of a general ICU population across multiple sites within 
Scotland. Previous studies have often focused within the specialist oncological 
ICUs or in general ICUs outwith the UK where admission policies are different. As 
such this data gives a more accurate representation of the ICU features of 
patients with and without cancer in general ICUs in Scotland. A further strength 
of this study is the ability to report long-term survival. Limiting the reporting to 
early survival would have missed the significant changes in survival over time 
between the groups. 
The retrospective nature of this study limits the depth of information available. 
It is not possible to state which ICU admissions were directly attributable to the 
underlying cancer or where cancer was an incidental co-morbidity. Organ 
support has been used as a surrogate marker of organ failure but will 
underestimate the true prevalence as patients may not have organ failure severe 
enough to warrant support or they may have treatment limitations in place that 
preclude the use of organ support in spite of organ failure. 
  
207 
The ICU dataset includes data from several units that were mixed ICU/ HDU 
during the study period without a clear definition within the dataset as to which 
patients were level 2 and which were level 3. Due to the high turnover of 
elective post-operative patients in an HDU setting it may be that the cancer 
population is over-represented in this cohort by patients that wouldn’t be 
considered as true level 3 ICU patients. For this reason we performed separate 
analysis of those ICU patients who had received organ support during their ICU 
stay. The presence of organ support was used as an indication of level 3 
admission. It is possible that this will identify level 2 patients as level 3 
incorrectly. For example, a post-operative patient with an epidural in situ 
requiring vasoactive support for associated hypotension would generally be 
considered level 2 but would be included in the organ support subgroup of this 
study.  
While every attempt was made to minimise missing data it remains a limitation 
of the study. APACHE II score was missing for a significant proportion of patients. 
Patients may be excluded from APACHE II scoring for a number of reasons 
although commonly due to HDU admission rather than ICU admission. Data 
pertaining to organ support was mostly complete for respiratory and 
cardiovascular support but missing for renal support in 12% of patients. During 
the study period not all units had the ability to provide renal support and it is 
possible that this missing data originates in units where renal replacement 
therapy was not available. None the less, the true incidence or renal 
replacement therapy remains unknown as a result. 
 
 
5.6 Conclusions 
Cancer patients contribute a large proportion of ICU admission particularly those 
admitted under a surgical specialty. Compared to the group of ICU patients 
without cancer the ICU cancer population tend to be older with a high 
proportion of elective hospitalisations and are predominantly surgical 
  
208 
admissions. In addition, there is less frequent utilisation of organ support within 
the cancer population. While short-term outcomes appear to favour ICU cancer 
patients this effect is confined to the surgical population and is not maintained 
in the longer term. 
 
 
5.7 Key points 
 When compared with the ICU non-cancer population, ICU cancer patients 
tend to be older, with a higher proportion of elective hospitalisations and are 
predominantly admitted to ICU with a surgical problem. 
 There are a larger proportion of ICU cancer patients that do not receive 
organ support and it is possible that these represent a post-operative HDU 
population. 
 ICU and hospital mortality is lower for the ICU cancer population although 
this is due to the larger proportion of surgical patients. 
 Surgical ICU admissions have a favourable short-term mortality if they have 
an underlying cancer diagnosis. This may be explained by a potentially higher 
proportion of HDU admissions, lower utilisation of multi-organ support and a 
larger proportion of elective admissions with the opportunity for pre-
operative optimisation and also the nature of the cancer surgery compared 
with non-cancer surgery. 
 ICU cancer patients admitted with a medical diagnosis have poorer short-
term survival than non-cancer patients and this difference is even more 
pronounced in the subgroup of medical patients that received organ support. 
 ICU cancer patients have poorer long-term survival than ICU patients without 
cancer.  
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Chapter 6 What are the longer-term outcomes of 
cancer patients who have survived an ICU 
admission? 
 
6.1 Introduction 
Surviving a critical illness is not without consequences. These may include on 
going organ dysfunction, muscle weakness, functional limitation and 
psychological distress. All of these elements may contribute to the increased 
mortality risk seen in ICU survivors that persists for several years after ICU 
discharge [44]. While this may be problematic for all ICU survivors it may pose a 
particular difficulty for patients with an underlying cancer diagnosis, who are 
likely to require further medical interventions and treatment of the cancer. It is 
possible that treatment options may be limited by the impact of on going effects 
from the critical illness. Many factors are likely to impact upon long-term 
survival but it is unclear which factors associated with the critical illness and ICU 
admission impact on survival following ICU discharge. 
This study aims to assess these factors and the degree to which they influence 
longer-term survival in patients that have survived a critical illness with ICU 
admission and whether the presence of cancer changes the course of survival. In 
addition, this analysis seeks to ascertain whether criteria associated with the 
critical illness or factors relating underlying cancer are more important in 
determining survival.  
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6.2 Study questions 
6.2.1 How does the longer-term survival of patients that have 
survived ICU differ between those with and without cancer?  
Patients that survive ICU might be expected to have an increased mortality risk 
that may be impacted by a number of factors associated with the patient, co-
morbidities and critical illness. It would be of significant value to understand 
how long term mortality differs between ICU survivors with and without cancer 
and which factors are associated with changes to mortality risk. To better 
understand this I will construct a multivariable model to assess how cancer 
impacts on mortality risk when taking account of other predictors of mortality. 
 
6.2.2  In ICU cancer survivors how do the features associated 
with cancer impact upon mortality risk? 
Having assessed differences in survival between cancer and non-cancer patients I 
will then assess how mortality varies by underlying tumour type in patients that 
have survived ICU. For patients with colorectal cancer I will assess which factors 
impact on mortality risk (including cancer stage) by constructing a multivariate 
model. 
 
 
6.3 Methods 
Patients that had an ICU admission during the study period were considered to 
be an ICU survivor if they were alive 30 days after ICU discharge. This time 
period was chosen to allow for patients that were discharged to the ward, 
hospice or home for palliation. This group were then split into those with cancer 
and those without cancer as described previously. Survival data was available for 
all patients for the four-years following ICU admission date. 
 
6.3.1 Statistical analysis 
Kaplan Meier survival analysis was performed with log-rank test for statistical 
significance.  
Hazard ratios were calculated using Cox proportional hazards model. Those 
factors known at discharge from ICU were chosen for inclusion in analysis. This 
included the presence of cancer, patient age, sex, SIMD group, organ support, 
APACHE II score, ICU admission type (surgical/ medical) and diagnosis of sepsis 
at ICU admission. Continuous variables (age and APACHE II score) were grouped 
into those above and below certain cut offs. Various thresholds for these values 
were tested on univariate analysis and a value that was valuable both in terms of 
clinical impact and clinical importance were chosen. For age this threshold was 
a value of ≥60 years and for APACHE II a score of ≥20.  
For analysis of the patients with colorectal cancer additional features included 
year of cancer diagnosis and Dukes stage at diagnosis.  
Each variable was checked for proportionality using calculation of Schoenfeld 
residuals. Any variable with a p-value ≤0.2 had a log –log plot of survival 
calculated. This was then visually assessed for deviations from parallel lines. Any 
variable that did not meet the proportionality criteria were excluded from 
multivariate analysis. The multivariate model was then checked again using 
Schoenfeld residuals. 
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6.4 Results 
There were 41,689 ICU patients during the study period of which 29,326 (70.3%) 
were considered to be ICU survivors (alive 30 days following ICU discharge). ICU 
patients with cancer were more likely to meet this criterion than those ICU 
patients without cancer (76.9% versus 69.0%, p<0.001, Table 6-1).  
 Admitted to 
ICU 
Survived 30 days 
post ICU discharge 
Percent 
survived 
Patients without cancer 35,573 24,624 69.0% 
Cancer patients 6116 4702 76.9% 
All ICU patients 41,689 29,326 70.2% 
Table 6-1 Number of ICU survivors grouped by patients with and without cancer. 
 
 
6.4.1 Long-term survival of patients that have survived ICU 
Long-term survival for ICU survivors with and without cancer is demonstrated by 
Kaplan Meier survival analysis in Figure 6-1. This demonstrates poorer long-term 
survival for ICU survivors who have cancer. At the end of four years follow up 
80.5% of patients without cancer were still alive compared with only 46.7% in 
the group of patients with cancer (p<0.001).  
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Figure 6-1 Survival of ICU survivors with and without a cancer diagnosis (log rank p<0.0001) 
 
 
6.4.2 Risk of death following ICU survival 
Factors associated with critical illness, patient demographics and presence of 
cancer were analysed for effect on post-ICU mortality using Cox proportional 
hazards estimation. These factors are described in Table 6-2 and each variable 
was checked for meeting the PH assumption. 
Several factors potentially did not meet proportionality criteria using Schoenfeld 
residuals: the presence of cancer (p 0.0652), APACHE II score ≥20 (p=0.0007 
overall (APACHE II score ≥20  p=0.0026; APACHE II score missing p=0.275)), and 
number of organs supported (p<0.0001). These factors underwent additional 
graphical analysis. 
 
Factor Number of patients (%) N=29,326 
Or median value with IQR 
Cancer 4702 (16.0%) 
Median Age (IQR) 
Age at ICU ≥60 years 
58  
14,069 
(42 – 75) 
(48.0%) 
Male sex 
Unknown 
16,177 
1 
(55.2%) 
(0.0%) 
SIMD 
1 
2 
3 
4 
5 
Unknown 
 
8792 
6346 
4730 
3116 
2418 
3924 
 
(30.0%) 
(21.6%) 
(16.1%) 
(10.6%) 
(8.2%) 
(13.4%) 
Multi-organ support 7246 (24.7%) 
Median APACHE (IQR) 
APACHE ≥20 
Missing APACHE 
16 
7055 
5866 
(12 – 21) 
(24.1%) 
(20.0%) 
ICU Surgical admission 19,206 (65.5%) 
Sepsis on admission  4949 (16.9%) 
Table 6-2 Description of critical illness, patient demographics and presence of cancer in ICU 
survivors. 
 
When assessing the effect the presence of cancer has on mortality risk over time 
those patients with cancer have an increasing mortality risk as time progresses 
compared with those without cancer. However, by six months the lines are 
running parallel suggesting that from six months the effect of cancer on 
mortality risk is constant. 
When comparing the group with APACHE II scores greater or equal to 20 with 
those less than 20 the lines are very close to parallel with only a slight 
convergence after one year. The missing APACHE II score and score of less than 
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20 groups also appear to be close to parallel throughout. Differences detected 
between these groups are likely due to the large numbers involved rather than 
being due to a meaningful difference between the groups. 
The impact of number of organs supported on mortality over time appears to 
demonstrate similarity between those with no or one organ support and those 
with two or three organ support. The patients were therefore grouped as those 
with or without multi-organ support. The Schoenfeld residual for multi-organ 
support remained significant at p<0.0001. The log -log plot of survival by multi-
organ support demonstrated that from six months onwards the lines converge 
suggesting that prior to six-months the multi-organ support has a fixed effect on 
risk of mortality but that after six-months this effect is no longer fixed and 
becomes less with time.  
The proportional hazards assumption was therefore rejected for cancer and 
multi-organ support variables. A decision was made to segment into time periods 
at six months. This would allow analysis of factors associated with increased 
early mortality (in the first six months) and later mortality (from six months to 
four years). 
 
6.4.2.1  Factors associated with risk of death in the first six-months after ICU 
survival 
Patient demographics (age ≥60 years, sex and SIMD category), critical illness 
features (use of multi-organ support, APACHE II score, surgical admission to ICU 
and diagnosis of sepsis) and presence of cancer were all analysed for effect on 
mortality rates during the first six-months following ICU survival. On univariate 
analysis cancer, age ≥60 years, multi-organ support and APACHE II score ≥20 or 
missing were associated with an increased hazard ratio (Table 6-3).  
Factor Univariate HR 
(95% CI) 
P value Multivariate HR 
(95% CI) 
P value 
Cancer 2.66 (2.44 – 2.90) <0.001 2.37 (2.16 – 2.61) <0.001 
Age at ICU 
≥60 years 
3.14 (2.86 – 3.44) <0.001 2.56 (2.33 – 2.82) <0.001 
Male sex 1.05 (0.96 – 1.13) 0.273 -  
SIMD 
1 
2 
3 
4 
5 
Unknown 
 
1 
1.05 (0.94 – 1.18) 
0.97 (0.885 – 1.10) 
0.97 (0.84 – 1.12) 
1.01 (0.87 – 1.19) 
1.04 (0.91 – 1.18) 
 
- 
0.363 
0.595 
0.691 
0.863 
0.606 
 
- 
- 
- 
- 
- 
- 
 
Multi-organ 
support 
1.46 (1.34 – 1.59) <0.001 1.22 (1.11 – 1.34) <0.001 
APACHE ≥20 
Missing 
APACHE 
2.12 (1.94 – 2.32) 
1.28 (1.14 – 1.43) 
<0.001 
<0.001 
1.70 (1.54 – 1.88) 
1.03 (0.92 – 1.15) 
<0.001 
0.658 
ICU Surgical 
admission 
1.08 (0.99 – 1.18) 0.067 0.79 (0.72 – 0.87) <0.001 
Sepsis on 
admission  
1.09 (0.98 – 1.21) 0.099 0.98 (0.87 – 1.09) 0.694 
Table 6-3 Factors associated with mortality in the first six-months following ICU survival 
 
On checking the proportionality assumption, the test indicated some potential 
problems with cancer (p<0.0001), age (p=0.0111), multi-organ support (p=0.008) 
and APACHE II score groups (Global test p=0.036, for APACHE ≥20 vs. APACHE <20 
p=0.0113). The log -log plots of survival were generated for each of these 
variables. Looking at the plots, there was no distinct systematic deviation from 
parallel curves in those for age, multi-organ support or APACHE score and these 
factors were all included in the multivariate model. Figure 6-2 evaluates the 
proportionality assumption for the presence or absence of cancer. Here the 
curves can be seen to deviate in the first 14 days (ln= 2.6) during which time 
relatively few events occur. Following this point they remain parallel suggesting 
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a constant hazard ratio after this point. Given that the ratio is constant for the 
majority of the follow up period this factor has been included in the multivariate 
model. 
 
 
Figure 6-2 Log -log plot of survival by patients with cancer and without cancer  
 
Multivariate analysis identified cancer (HR 2.37), age ≥60 years (HR 2.56), multi-
organ support (HR 1.22), and APACHE II ≥20 score (HR 1.7) all to be associated 
with an increased mortality rate in the first six-months following ICU survival 
(Table 6-3). Surgical admission to ICU was associated lower mortality rates (HR 
0.79). 
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6.4.2.2  Factors associated with later risk of death after ICU survival 
The same factors were also analysed for effect on mortality rates after the first 
six-months following ICU survival. On univariate analysis cancer, age ≥60 years, 
male sex, multi-organ support, APACHE II score ≥20 or missing and surgical 
admission to ICU were associated with an increased hazard ratio (Table 6-4).  
Factor Univariate HR 
(95% CI) 
P value Multivariate HR 
(95% CI) 
P value 
Cancer 3.64 (3.44 – 3.87) <0.001 3.40 (3.18 – 3.63) <0.001 
Age at ICU ≥60 
years 
2.67 (2.51 – 2.83) <0.001 2.18 (2.04 – 2.32) <0.001 
Male sex 1.08 (1.02 – 1.14) 0.009 1.07 (1.01 – 1.13) 0.03 
SIMD 
1 
2 
3 
4 
5 
Unknown 
 
1 
1.08 (1.0 – 1.17) 
0.96 (0.88 – 1.04) 
1.02 (0.92 – 1.12) 
0.92 (0.82 – 1.03) 
1.06 (0.97 – 1.16) 
 
- 
0.051 
0.322 
0.752 
0.168 
0.223 
 
1 
0.95 (0.88 – 1.03) 
0.84 (0.77 – 0.91) 
0.87 (0.79 – 0.96) 
0.74 (0.66 – 0.83) 
0.96 (0.88 – 1.06) 
 
- 
0.234 
<0.001 
0.007 
<0.001 
0.416 
Multi-organ 
support 
1.15 (1.08 – 1.22) <0.001 1.01 (0.94 – 1.09) 0.752 
APACHE ≥20 
Missing APACHE 
1.63 (1.53 – 1.74) 
1.28 (1.19 – 1.37) 
<0.001 
<0.001 
1.41 (1.31 – 1.51) 
0.98 (0.90 – 1.05) 
<0.001 
0.523 
ICU Surgical 
admission 
1.10 (1.04 – 1.17) 0.001 0.74 (0.69 – 0.79) <0.001 
Sepsis on 
admission  
1.07 (0.99 – 1.15) 0.086 1.09 (1.00 – 1.18) 0.042 
Table 6-4 Factors associated with mortality in the longer term after ICU survival  
 
On checking the proportionality assumption, the test indicated some potential 
problems with cancer (p=0.0002) and age (p=0.0181). The log -log plots of 
survival were generated for each of these variables.  
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For cancer, there was no meaningful deviation from parallel lines on the plot 
suggesting the hazard ratio remains fairly constant throughout the study period. 
Figure 6-3 plots the mortality rates with time between the two age groups. 
There is variability in the mortality rates between the two groups during the first 
18 days (ln= -3) during which time there are relatively few events. Thereafter 
the difference in the mortality rates appears constant with parallel lines. Given 
that the lines are parallel for the majority of the follow up period this factor has 
been included in the multivariate model. 
 
Figure 6-3 Log -log plot of survival by age group 
 
Multivariate analysis identified cancer (HR 3.4), age ≥60 years (HR 2.18), male 
sex (HR 1.07), APACHE II ≥20 score (HR 1.41) and sepsis on admission to ICU (HR 
1.09) all to be associated with an increased mortality rate after six-months 
following ICU survival (Table 6-4). Lower mortality rates were seen in patients 
from more affluent SIMD quintiles and in those patients who had been admitted 
to ICU as a surgical admission (HR 0.74). 
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6.4.3 Impact of underlying cancer type on long-term outcome of 
ICU survivors 
Having identified cancer as one of the most important determinants of post-ICU 
survival I progressed to examine how long-term survival varies by underlying 
cancer type. Figure 6-4 demonstrates the impact of underlying tumour type on 
long-term survival of ICU survivors. This reports significant variation in survival 
for colorectal, head and neck, stomach, lung, oesophageal, kidney and breast 
cancer in addition to the group of patients with cancer of unknown origin.  
 
Figure 6-4 Survival following ICU by underlying cancer type (logrank p<0.0001) 
 
While patients with colorectal, head and neck, kidney and breast cancer can be 
seen to have better survival than other tumour types there is a steady decline in 
survival with time. Breast cancer patients who appear to have the most 
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favourable survival have a mortality of 36.8% at the end of the follow up period. 
Survival by each cancer type at the end of the four-year follow up period is 
recorded in Table 6-5. Four-year survival varies from 10.0% for those patients 
with underlying hepatocellular carcinoma to 73.3% in patients with testicular 
cancer.  
Cancer type Number of ICU survivors Four-year survival 
Colorectal 2069 54.0% 
Head and Neck 570 53.7% 
Stomach 358 31.3% 
Oesophageal 324 35.8% 
Kidney 211 59.2% 
Lung 162 28.4% 
Bladder 144 37.5% 
Breast 106 63.2% 
Prostate 102 56.9% 
Ovarian 101 28.7% 
Uterus 88 67.0% 
Pancreas 44 15.9% 
Small intestine 41 56.1% 
Liver 30 10.0% 
Thyroid 25 71.0% 
Testicular 15 73.3% 
Melanoma 8 12.5% 
Other 78 50.0% 
Multiple 173 45.1% 
Unknown 39 25.6% 
Table 6-5 Four-year survival of ICU survivors by cancer type 
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Underlying cancer type has been demonstrated to have a significant impact upon 
survival in cancer patients following ICU discharge. Cox proportional hazard 
analysis comparing each tumour type to ICU survivors without cancer did not 
meet the proportional hazards assumption for any of the time periods. Each 
tumour type would therefore need to be analysed separately. 
 
6.4.4 Factors associated with mortality in colorectal cancer 
patients that survive ICU 
Of the group of cancer patients that had survived ICU 2,069 had colorectal 
cancer (44%). This group contributed the largest subgroup of cancer patients and 
was analysed for factors associated with mortality including patient 
demographics, critical illness and features associated with the underlying cancer 
(Table 6-6).  
  
223 
Factor Number of patients (%) N=2069       
Or median value with IQR 
Male sex 1184 (57.2%) 
Median age (IQR) 
Age ≥60 years 
70  
1687 
(62 – 77) 
(81.5%) 
SIMD 
1 
2 
3 
4 
5 
 
504 
584 
443 
272 
266 
 
(24.4%) 
(28.2%) 
(21.4%) 
(13.1%) 
(12.9%) 
Year of diagnosis 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
2007 
2008 
2009 
 
158 
200 
235 
228 
239 
198 
212 
258 
185 
156 
 
(7.6%) 
(9.7%) 
(11.4%) 
(11.0%) 
(11.6%) 
(9.6%) 
(10.2%) 
(12.5%) 
(8.9%) 
(7.5%) 
Dukes stage 
A 
B 
C 
D 
Unknown 
 
228 
727 
672 
235 
207 
 
(11.0%) 
(35.1%) 
(32.5%) 
(11.4%) 
(10.0%) 
Multi-organ support 348 (16.8%) 
Median APACHE (IQR) 
APACHE ≥20 
Missing APACHE 
16  
325 
901 
(13 – 20) 
(15.7%) 
(43.6) 
Table 6-6 Factors associated with critical illness, patient demographics and presence of 
cancer. 
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6.4.4.1 Factors associated with mortality risk in the first six-months following 
ICU survival 
On univariate analysis age ≥60 years, Dukes stage, multi-organ support and 
APACHE II score ≥20 were associated with an increased hazard ratio for death 
during the first six-months following ICU survival (Table 6-7). Male sex was 
associated with a reduced hazard ratio. The strongest influence on mortality risk 
on univariate analysis was cancer stage. However, the variable Dukes did not 
meet the proportionality assumption.  
When each factor was tested for proportionality, Dukes stage (p=0.0228) was 
identified as having potential problems. Graphical assessment of mortality risk 
by Dukes stage demonstrated that the lines can be seen crossing at several 
points and are not in a fixed relationship with each other. The proportionality 
assumption must be rejected for this variable and it has been excluded from the 
multivariate analysis. However, it is worth noting that Dukes stage had the 
greatest influence on mortality on univariate analysis and is likely to play an 
important role but cannot be forced to meet the proportionality assumption.  
The factors identified on multivariate analysis that impact upon short-term 
survival were age ≥60 years (HR 1.58) and APACHE II score ≥20 (HR 1.68) and 
male sex (HR 0.74). The proportionality assumption was met for all included 
factors on multivariate analysis. 
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Table 6-7 Factors associated with mortality risk in the first six-months in colorectal cancer 
patients that have survived ICU.  Hazard ratios with 95% confidence intervals. 
Variable Univariate HR  P value Multivariate HR  P value 
Male sex 0.76 (0.59 – 0.97) 0.031 0.74 (0.57 – 0.94) 0.016 
Age ≥60 years 1.76 (1.20 – 2.60) 0.004 1.58 (1.07 – 2.34) 0.022 
SIMD                 1 
2 
3 
4 
5 
1.0 
1.05 (0.75 – 1.47) 
1.04 (0.72 – 1.49) 
0.72 (0.46 – 1.15) 
0.87 (0.56 – 1.35) 
- 
0.778 
0.838 
0.172 
0.530 
1.0 
1.10 (0.79 – 1.54) 
1.07 (0.74 – 1.53) 
0.75 (0.47 – 1.19) 
0.89 (0.57 – 1.38) 
- 
0.574 
0.723 
0.227 
0.591 
Year of diagnosis 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
2007 
2008 
2009 
 
1 
1.27 (0.72 – 2.22) 
0.83 (0.46 – 1.50) 
1.07 ( 0.61 – 1.89) 
1.16 ( 0.67 – 2.01) 
1.06 (0.59 – 1.90) 
0.82 (0.45 – 1.45) 
0.80 (0.45 – 1.43) 
0.95 (0.52 – 1.73) 
0.71 (0.36 – 1.40)  
 
- 
0.409 
0.542 
0.812 
0.606 
0.848 
0.517 
0.456 
0.858 
0.324 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
 
Dukes stage      
A 
B 
C 
D 
Unknown 
 
1 
5.04 (1.83 – 13.86) 
6.93 (2.54 – 18.93) 
19.62 (7.17 – 53.73) 
10.42 (3.70 – 29.31) 
 
 
0.002 
<0.001 
<0.001 
<0.001 
 
- 
- 
- 
- 
- 
 
 
 
Multi-organ 
support 
1.48 (1.10 – 2.00) 0.009 1.19 (0.85 – 1.65) 0.313 
APACHE ≥20 
Missing APACHE 
1.81 (1.32 – 2.48) 
0.87 (0.65 – 1.16) 
<0.001 
0.352 
1.68 (1.21 – 2.34) 
- 
0.002 
- 
ICU Surgical 
admission 
1.22 (0.68 – 2.18) 0.498 -  
Sepsis on 
admission  
0.94 (0.58 – 1.52) 0.813 -  
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6.4.4.2 Factors associated with mortality risk after six months of survival in 
CRC ICU survivors 
The same factors were assessed for impact on longer-term mortality from six-
months to four years. Univariate analysis identified age ≥60 years, year of cancer 
incidence, Dukes stage and APACHE II score ≥20 as impacting on mortality risk 
(Table 6-8). 
On multivariate analysis, the factors associated with lower mortality rates in the 
longer term included age <60 years, cancer diagnosis later in the study period 
and favourable cancer stage. The strongest influence on mortality risk was 
cancer stage (Dukes). Missing APACHE II score was also favourable. 
All factors met the proportionality assumption on both univariate and 
multivariate analysis. 
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Table 6-8 Factors associated with late mortality risk after the first six-months in colorectal 
cancer patients that have survived ICU. Hazard ratios with 95% confidence intervals. 
Variable Univariate HR P value Multivariate HR P value 
Male sex 1.00 (0.86 – 1.17) 0.956 - - 
Age ≥60 years 1.34 (1.10 – 1.64) 0.004 1.49 (1.22 – 1.83) 0.001 
SIMD                   1 
2 
3 
4 
5 
1.0 
0.88 (0.72 – 1.08) 
0.90 (0.72 – 1.11) 
0.81 (0.63 – 1.04) 
0.80 ( 0.62 – 1.04) 
- 
0.229 
0.319 
0.098 
0.096 
1.0 
0.85 (0.69 – 1.04) 
0.88 (0.70 – 1.09) 
0.79 (0.61 – 1.03) 
0.77 (0.59 – 1.00) 
- 
0.117 
0.247 
0.078 
0.047 
Year of diagnosis 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
2007 
2008 
2009 
 
1 
0.70 (0.50 – 0.98) 
0.84 (0.61 – 1.14) 
0.77 (0.56 – 1.06) 
0.64 (0.46 – 0.88) 
0.59 (0.42 – 0.84) 
0.72 (0.52 – 1.00) 
0.61 (0.44 – 0.83) 
0.54 (0.38 – 0.77) 
0.51 (0.35 – 0.74) 
 
- 
0.038 
0.256 
0.104 
0.007 
0.003 
0.048 
0.002 
0.001 
<0.001 
 
1 
0.78 (0.55 – 1.09) 
0.89 (0.64 – 1.22) 
0.80 (0.57 – 1.11) 
0.62 (0.44 – 0.86) 
0.66 (0.46 – 0.94) 
0.77 (0.55 – 1.08) 
0.63 (0.46 – 0.88) 
0.48 (0.34 – 0.69) 
0.49 (0.33 – 0.72) 
 
- 
0.146 
0.464 
0.180 
0.005 
0.021 
0.133 
0.006 
<0.001 
<0.001 
Dukes stage 
A 
B 
C 
D 
Unknown 
 
1 
1.78 (1.25 – 2.55) 
3.72 (2.63 – 5.27) 
8.16 (5.63 – 11.85) 
3.45 (2.32 – 5.12) 
 
 
0.002 
<0.001 
<0.001 
<0.001 
 
1 
1.76 (1.23 – 2.52) 
3.89 (2.74 – 5.51) 
8.66 (5.96 – 12.59) 
3.67 (2.46 – 5.48) 
 
- 
0.002 
<0.001 
<0.001 
<0.001 
Multi-organ 
support 
1.17 (0.96 – 1.42) 0.120 1.04 (0.83 – 1.30) 0.936 
APACHE ≥20 
Missing APACHE 
1.28 (1.03 – 1.57) 
0.86 (0.73 – 1.01) 
0.024 
0.062 
1.21 (0.97 – 1.52) 
0.80 (0.67 – 0.97) 
0.096 
0.020 
ICU Surgical 
admission 
0.91 (0.67 – 1.24) 0.564 - - 
Sepsis on 
admission  
0.93 (0.69 – 1.24) 0.602 - - 
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6.5 Discussion 
6.5.1 Long-term survival of patients that survive ICU 
Patients with cancer that survive ICU have an excess mortality when compared 
to an unmatched cohort of ICU survivors that do not have cancer. By the end of 
the four-year follow up period 53.3% of cancer patients had died compared with 
19.5% in the group of ICU survivors without cancer. While cancer patients tend 
to be older than the general ICU population, it seems likely that this increased 
mortality is predominantly attributable to the on going neoplastic process. 
 
6.5.2 Factors associated with increased mortality risk in ICU 
survivors 
This study assessed factors within the general ICU population that were 
associated with an increased mortality risk in the intermediate and longer-term 
after ICU survival. In the first six months, factors associated with the critical 
illness have a modest effect including APACHE II ≥20 score (HR 1.7), multi-organ 
support (HR 1.22) and surgical admission to ICU (HR 0.79). The presence of 
cancer, if the proportionality assumption is correct, had a greater impact with a 
HR 2.37 (95% CI 2.16 – 2.61, p<0.001) with a similar effect seen for patient age 
≥60 years at admission to ICU (HR 2.56 (95% CI 2.33 – 2.82, p<0.001). The 
persisting impact of critical illness into this stage is not altogether unsurprising 
as an increased severity of critical illness might be expected to have some 
lasting effects. 
Analysis of those factors associated with differences in mortality in the longer-
term (up to four years) demonstrated that the presence of cancer had the 
greatest impact. There was a three-fold increase in mortality risk in the cancer 
population when compared with ICU survivors without cancer. Those factors 
associated with the original critical illness severity had a lesser impact, with the 
hazard ratio for APACHE II ≥20 score falling to 1.41 and the effect of multi-organ 
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support no longer statistically significant. Surgical admission to ICU continued to 
have a protective effect with a HR 0.74 (95% CI 0.69 – 0.79, p<0.001). This may 
reflect a population of patients with a lower burden of serious co-morbidity than 
that seen in the medical population. Sepsis on admission to ICU had a very weak 
impact on increasing mortality risk (HR 1.09). Patient related factors associated 
with increased mortality in the longer-term included age ≥60 years at ICU 
admission, which more than doubled mortality risk and male sex, which had a 
very small impact upon mortality risk (HR 1.07). Analysis of SIMD demonstrated 
improved survival probability in patients from the more affluent area SIMD 
quintiles three, four and five.  
 
6.5.3 Factors associated with increased mortality risk in ICU 
cancer survivors 
Within the ICU survivor cancer population the underlying tumour type had a 
large impact upon post-ICU survival varying from 10.0% at four-years in patients 
with hepatocellular carcinoma to 73.3% in patients with testicular cancer. 
Favourable outcomes were demonstrated in patients with breast cancer, 
testicular cancer, thyroid cancer and uterine cancer where outcomes within the 
non-ICU population are positive. Other tumour types where selection bias may 
have meant that those undergoing curative surgery were likely to be admitted to 
a critical care unit for peri-operative support also performed relatively well. 
These included patients with colorectal cancer, head and neck cancer or kidney 
tumours. Prior analysis had described large proportions of surgical admissions for 
these tumour types and in addition to curative surgical intervention it is likely 
that these patients had low rates of co-morbidities otherwise major surgical 
intervention may have been deemed unsuitable.  
Colorectal cancer patients that had survived ICU underwent additional analysis. 
Data pertaining to cancer stage was more available for colorectal cancer 
patients than many of the other cancer groups. As this group contributed the 
largest proportion of the cancer subtypes this additional data was used to 
determine whether cancer specific features were important in determining 
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mortality risk following ICU survival. While cancer treatment data was available 
for a large proportion of this population a decision was made to exclude this 
from analysis. Many treatment options are only available after a certain period 
of survival or where patients are in good general health and it may be unknown 
at the time of ICU discharge which treatments will be delivered to any individual 
patient. Further analysis could include this data but would require complex 
statistical techniques such as propensity scoring or time dependent survival.  
The analysis of the first six months following ICU survival was limited due to 
cancer stage not meeting the proportionality assumption. Dukes stage was 
identified on univariate analysis to have the greatest impact on mortality risk 
and as such it is possible that the most important factor was excluded from the 
multivariate model. However, Dukes stage clearly violated the proportionality 
assumption and to include this factor in analysis would lead to inaccurate and 
unreliable results. It is beyond the scope of this research to perform the 
sophisticated statistical analysis that would be required to overcome this issue. 
While the analysis was limited by the lack of stage it did identify other factors 
that impacted on mortality including a modest effect with age ≥60 years (HR 
1.58), APACHE II score ≥20 (HR 1.68) and male sex (HR 0.74).  
Examination of those factors associated with longer-term outcome (from six-
months to four-years) in colorectal cancer patients that had survived ICU found 
that cancer stage had the strongest link with mortality risk. Dukes staging 
classifies patients by degree of tumour invasion (Dukes A no invasion, Dukes B 
muscle invasion) and by the degree of spread (Dukes C lymph node involvement, 
Dukes D metastatic disease). In ICU survivors the longer-term mortality risk for 
patients with Dukes D was eight-fold that of patients with Dukes A disease. Year 
of cancer incidence also had an important role to play with outcomes for cancer 
patients (and possibly ICU survivors) improving with time. This demonstrated 
that those diagnosed at the end of the study period in 2009 had half the 
mortality risk as those diagnosed at the beginning in 2000. This may represent 
improvements in both the management of cancer and critical illness but may 
also be impacted by the increasing number of HDU beds included in the ICUs 
during the study period. Although high APACHE II score did not impact on longer-
term outcome, missing APACHE II data was associated with a mildly favourable 
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survival. This reduction in mortality risk may represent the cohort of patients 
who are admitted to ICU as a HDU patient and are therefore excluded from 
APACHE scoring. These patients are often admitted electively for post-operative 
monitoring and the favourable outcome may be attributed to pre-operative 
optimisation, patient selection bias and potential curative intervention. 
 
6.5.4 Comparisons with published literature 
This study assessed survival of patients that had survived ICU and identified 
factors that were associated with mortality. A similar study was published in 
2008 by Williams et al of nearly 20,000 patients admitted to a single-centre 
hospital in Australia between 1987 and 2002 [44]. This identified older age, 
severe co-morbidity, ICU diagnostic group, new malignancy, high severity of 
illness score and peak number of organ failures were associated with higher 
mortality risk in the first year and in the subsequent 15-years, with the addition 
of male gender and prolonged ICU length of stay. Of these age was the strongest 
factor associated with mortality risk followed by co-morbidity then new 
malignancy. New malignancy referred to a cancer that was diagnosed during the 
same hospitalisation that the ICU admission occurred. In their cohort new 
malignancy was associated with a HR 4.61 in the first year then HR 2.61 for the 
following 14 years. The difference in the hazard ratios reported in this analysis 
(HR 2.37 for the first six-months and HR 3.40 for six-months to four-years) may 
be explained by a combination of factors. The increased early mortality 
described by Williams et al may be in part due to the manner in which cancer 
has been defined, as these patients were presenting to ICU with the cancer 
diagnosed during the same inpatient stay. This precludes the opportunity to 
provide any optimisation or advanced planning. Furthermore, cancer and ICU 
management has changed over the time period studied by Williams et al and 
that studied in this study. Finally, there were less than 300 cases of new 
malignancy in Williams et al ICU survivors cohort, so long-term survival analysis 
will be limited by the relatively small numbers. 
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Brinkman et al assessed the mortality risk of over 90,000 ICU patients after 
hospital discharge in a 2013 publication [180]. This Dutch multi-centre study 
described adjusted hazard ratios for the one-year mortality after discharge for a 
number of subgroups. Patients admitted to ICU with cancer had a HR 1.94, 
similar to the six month hazard ratio described in this study (2.37).  
Shack et al have previously published on the negative impact of deprivation 
measured by SIMD quintiles on cancer survival [181]. This is consistent with the 
results of this study, which noted a small effect on mortality risk in the longer-
term for ICU survivors with colorectal cancer. The effect of deprivation was also 
noted in the non-cancer ICU population. Hutchings et al have previously noted 
an association between poor socioeconomic status and hospital mortality [182] 
however, the impact on longer-term outcomes has not been previously assessed. 
In concordance with the findings of this study, Shack et al also noted that 
survival in cancer patients was improving over time and this may be explained by 
screening programmes in addition to more effective and safer treatment 
combinations. 
Cancer stage is known to be an important determinant of long-term survival and 
was found to be the major factor associated with longer-term outcome in ICU 
survivors with colorectal cancer. Data from the National Cancer Intelligence 
Network (NCIN) found that five-year survival varied from 93.2% in Dukes A, 77.0% 
in Dukes B, 47.7% in Dukes C to 6.6% in patients with Dukes D disease [183]. The 
effect demonstrated in this study is not quite as striking. However, this may in 
part be due to selection bias, with patients suffering from Dukes D disease only 
admitted if all other factors are favourable in addition to those patient with 
Dukes A disease only requiring an ICU admission due to co-morbidities or 
additional illness burden. 
 
6.5.5 Strengths and limitations 
This multi-centre study is one of the largest of its kind and as a result has 
facilitated assessment of the impact of a variety of variables on survival 
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following ICU. The additional data within the colorectal cancer dataset allowed 
further analysis of the largest subgroup of ICU cancer survivors and the major 
factors that impact upon mortality. 
Due to the retrospective nature of this study there were limitations placed on 
which variables could be analysed. As a result performance status, which is 
regarded as an important factor in determining survival from cancer, has not 
been assessed. Nor has the impact of other specific co-morbidities, which may 
have an important role to play. Furthermore, the cancer registry only records 
point specific information such that stage is recorded at cancer incidence but 
there is no longitudinal data as to how this changes with time. As such it is 
unknown whether the cancer stage is different at the time of ICU admission.  
While every effort has been made to ensure reliability of the results the 
problems encountered with the proportional hazards assumption led to 
difficulties. Time segmenting the survival into intermediate and late survival 
overcame most of these issues. However, when analysing intermediate survival 
of colorectal cancer ICU survivors I was unable to include cancer stage in the 
multivariate model due to lack of proportionality. As a result it is likely that the 
multivariate analysis of factors associated with mortality in the first six months 
following ICU survival does not include the most important factor- cancer stage. 
 
 
6.6 Key points 
 In ICU survivors the presence of cancer has the largest impact upon mortality 
risk in the longer-term with a risk of death over three times greater than in 
the non-cancer population. 
 Additional factors associated with higher mortality risk within the first six 
months following ICU survival included older age, multi-organ support, high 
APACHE score and medical admission to ICU. 
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 Between six months and four years the factors associated with higher 
mortality risk included cancer, older age, male sex, poorer socioeconomic 
status, high APACHE score, medical admission to ICU and sepsis on ICU 
admission. 
 Survival varies considerably by underlying tumour type. 
 Cancer related factors such as tumour type and stage have an important role 
in determining mortality risk in the longer term for survivors of ICU with 
cancer. 
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Chapter 7 Discussion 
In the face of major advances in both critical care and oncology, the 
requirement for cancer critical care is likely to become more widespread. While 
the literature to date suggests that outcomes for cancer patients in ICU are 
improving, it falls short of providing evidence to guide ICU admission policies. 
Realistic medicine involves supporting the patient to reach the treatment 
decision that is right for them [184]. By identifying factors associated with poor 
ICU outcome clinicians can highlight the potential for increased risk to an 
individual in addition to detailing the specific burdens of ICU care. With these 
discussions patients can have a better understanding of what critical care is 
likely to entail and the potential for a good outcome after undertaking 
admission. For some patients this will result in an unrestricted ICU admission but 
for others the burden of ICU may be too onerous and a preference for palliative 
care explored. The future of critical care for cancer patients therefore needs to 
be tailored to the individual patient taking account of their needs and 
preferences. 
This thesis aims to assist in these conversations by describing the outcomes for 
disparate groups of cancer patients that have received critical care and 
describing those factors associated with prognosis after ICU admission. It is 
beyond the scope of this work to comment on patients with critical illness who 
are not admitted to ICU where outcomes might be expected to be particularly 
poor. 
 
 
7.1 Summary of findings and clinical implications 
This thesis describes the literature available for outcomes in patients with solid 
tumours after ICU admission in the manner of a meta-analysis before going on to 
describe in detail a cohort of ICU cancer patients.  
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7.1.1 Systematic review and meta-analysis 
The meta-analysis performed at the start of this work summarised the results of 
47 published papers that described outcomes in patients with solid tumours after 
admission to ICU. Hospital mortality varied significantly from 4.6% to 76.8%, 
reflecting variations in case mix with regards to underlying tumour type and ICU 
admission policies. The average mortality across all studies of 38.2% is difficult 
to interpret in the face of such wide differences in practice. Survival beyond 
hospital mortality was only reported in 12 of the identified studies and again 
varied widely owing to population differences. 
Several studies attempted to identify factors associated with survival and a 
number of common themes were noticeable. Short-term mortality was 
commonly related to the critical illness with high severity of illness scores, organ 
support, medical ICU admissions and sepsis associated with mortality. Whilst 
tumour type was not demonstrated to be associated with mortality in any of the 
individual studies, the average mortality by tumour types when pooled across all 
studies varied widely. This likely reflects the different critical illness and 
admission patterns seen for differing tumour types. 
The literature on this subject has been limited, to date, by lack of detail in 
many of the studies. Outcomes are often reported for an undifferentiated group 
of “cancer” patients or a subset such as those with metastatic disease or with a 
specific critical illness. Twelve of the studies did not report any measure of 
severity of illness in spite of this factor being so closely linked with outcome and 
varying significantly across publications. Furthermore, many of the studies have 
been set in specialised oncological ICUs where the mixture of tumour types and 
expertise may be different to that in a general ICU.  
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7.1.2 Rate of ICU admission in the solid tumour population 
This study has demonstrated that ICU is an important feature for cancer 
patients, with one in twenty admitted to ICU within two years of diagnosis with 
a high associated mortality. Admission to ICU tended to occur soon after the 
cancer diagnosis and was most commonly due to a surgical condition. The rate of 
ICU admission did not always reflect cancer incidence rates and was greatest for 
bowel malignancies and for those tumours that require peri-operative support 
for tumour resection surgery, such as head and neck cancers, stomach cancer 
and oesophageal cancer.  
Mortality for those admitted to ICU was high with one in four dying before 
hospital discharge. Mortality varied by cancer type and was higher in emergency 
admissions, medical admissions and in patients that received organ support.  
The study was unable to identify patients that suffered a critical illness but were 
not admitted to ICU or those who were admitted to a stand alone HDU. It is 
therefore possible that this study underestimates the real need for cancer 
critical care. It is interesting to note that the UK has both poorer cancer 
outcomes and considerably lower provision of ICU beds than most other 
developed countries. While this study cannot conclude that a greater provision 
of ICU beds would contribute to improvements in cancer survival in the UK it 
does raise interesting questions. The necessity for ICU after a diagnosis of cancer 
should not be ignored and further exploration of the benefits of increased 
surveillance for early signs of critical illness and a greater capacity to offer ICU 
to cancer patients might be beneficial.  
 
7.1.3 Differences between the ICU cancer population compared 
with the ICU population without cancer 
Compared with the population without cancer, ICU cancer patients tended to be 
older, with a higher proportion of surgical admissions and less frequent 
utilisation of organ support. The surgical and medical populations varied 
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significantly in terms of patient demographics, admission diagnosis, severity of 
illness and survival and as such it was necessary to describe these groups 
separately. 
When considering short-term outcomes a diagnosis of cancer should not preclude 
admission to ICU. For those patients admitted from a surgical specialty, hospital 
mortality favours those with an underlying cancer diagnosis. This may be due to 
a larger proportion of elective hospitalisations within the cancer group (where 
pre-operative optimisation has been available) or due to differences in the 
nature of surgical procedures. In the group of patients admitted to ICU with a 
medical diagnosis, hospital mortality was higher in the cancer population at 
49.1% versus 41.7%, however, this difference became more marked in those that 
received organ support at 62.5% versus 46.2%. This might be partly explained by 
the older population, greater use of multi-organ support for the cancer group 
and the high prevalence of sepsis in a potentially immunocompromised cohort. 
While mortality is higher for the cancer group it would not necessarily prevent 
ICU admission, however, the patient and family should be counselled about the 
potential for poor outcome after admission to ICU. 
While the mortality risk is greatest around the time of ICU admission, survival 
continues to decline in the four years after admission. The mortality difference 
between those patients with and without cancer becomes more pronounced with 
time and there is a clear survival disadvantage for the cancer group. By four 
years approximately one third of ICU cancer patients were alive compared with 
over half of the ICU patients without cancer. Again, the survival disadvantage 
was more marked for the medical admission group. The difference in survival 
between the ICU patients with and without cancer may be attributed to the 
underlying cancer or the treatment burdens associated with the cancer. 
 
7.1.4 The effect of cancer on survival following ICU  
Having survived an ICU admission the factor that had the greatest impact on on 
going mortality risk after six months was the presence of cancer. Patients with 
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cancer had a risk of death greater than three times that seen in the population 
without cancer. Other factors that impacted upon mortality risk included older 
age, male sex, social deprivation, high APACHE II score, medical admission and 
sepsis on ICU admission.  
Within the group of patients with cancer the survival rates varied significantly by 
underlying tumour type. For ICU survivors with an underlying diagnosis of 
colorectal cancer, mortality risk after six months was influenced by tumour 
stage, year of cancer diagnosis, older age and social deprivation. Of these, 
tumour stage (Dukes) had the largest impact. These results suggest that details 
pertaining to the cancer prognosis have the strongest impact upon long-term 
survival. 
While a diagnosis of cancer should not necessarily preclude an admission to ICU 
it is worth noting that these patients do not have the same life expectancy as 
the group without cancer. When discussing ICU admission with cancer patients 
both short and long term survival should be considered particularly with 
reference to any individual risk factors such as cancer type, cancer stage and 
patient age. With this information patients can be helped to reach a decision 
that is acceptable to them in terms of treatment burden and chances of survival 
following ICU admission thus facilitating individualised care in the era of realistic 
medicine [184]. 
 
 
7.2 Reflections on the strengths/ weaknesses 
This work is based on a large population of patients both in terms of over 
100,000 cancer patients and over 40,000 ICU patients. As a result the 6116 ICU 
patients with cancer studied is one of the largest population of cancer patients 
in a general ICU population that has been described. These findings therefore 
are representative of practice in general hospitals and suitable to generalisation. 
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However, because this study was carried out in a region of a single country, 
results must be extrapolated with caution. 
This thesis used a two-year window between cancer diagnosis and admission to 
ICU to identify ICU cancer patients. With increasing time since diagnosis, 
patients become cancer survivors rather than remain cancer patients and thus 
their malignancy would be of decreasing relevance to subsequent 
hospitalisations. If the follow up period had been extended to 5 years after 
diagnosis the sample of ICU cancer patients would have only increased by 
approximately 10%.  
Details pertaining to the underlying malignancy have been taken from verified 
cancer registration data. As this data is linked to the national death records I 
have been able to describe survival for this group of patients beyond the 
standard hospital discharge and up to four years after ICU admission. As 
demonstrated by the results, survival for ICU cancer patients does not remain 
static and long-term follow up studies such as this are important for informing 
future practice. 
As with all studies which employ administrative data there were several 
limitations. These include that the standard of data collection was not as high as 
that expected in prospective research, and that because of the limitations of the 
data which was recorded, there were restrictions on what could be evaluated. 
Many of the studies identified in the systematic review described an association 
between performance status and survival. Unfortunately, performance status 
was not documented in the cancer registry or ICU Wardwatcher systems and I 
was therefore unable to assess the impact of this potentially important factor. A 
prospective study of this topic would allow collection of detailed baseline 
information including performance status, in addition to identifying patients 
with critical illness who were not admitted to ICU. However, such a study would 
either be limited in survival time data or take a long period of time to complete. 
It is possible that the geography involved has introduced bias as a patient from 
the West of Scotland that was admitted to an ICU outwith the 16 pre-specified 
West of Scotland ICUs would not be identified. This could potentially occur if a 
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patient developed critical illness requiring immediate treatment while in a 
different region of the country. It seems probable that the numbers of patients 
that this could apply to is small and unlikely to impact significantly on the 
results of this study. As residency in the West of Scotland was pre-specified, 
patients with a cancer diagnosis outwith this region that were admitted to a 
West of Scotland ICU would not have been included in the ICU cohort.  
Six of the 16 ICUs functioned as a combined ICU/ HDU at some point during the 
study period with the proportion of HDU funded beds contributing between 7% to 
23% of the total bed numbers. HDU differs from ICU both in terms of staffing and 
in patient population. Patients admitted to HDU may have a less severe form of 
critical illness with only one organ failure or may have been admitted for 
observation and monitoring following an operative procedure. These latter 
patients are not necessarily suffering from a critical illness although may be at 
risk of developing one. Due to the high turnover of elective post-operative 
patients in an HDU setting it may be that the cancer population is over-
represented in this cohort by patients that wouldn’t be considered as true level 
3 ICU patients. While we had information on those HDU patients admitted to a 
combined ICU/ HDU we did not have data for those patients admitted to a stand 
alone HDU as those units were not using the Wardwatcher audit database during 
the time period. The ICU cancer group had a higher proportion of patients with 
non-recorded APACHE scores and this is unlikely to be random. HDU admissions 
are excluded from APACHE scoring as the score is not validated for use for these 
patients and these patients therefore appear to have a missing score. If the ICU 
cancer group has a greater proportion of HDU patients then they would also be 
expected to have a greater proportion of non-recorded APACHE scores. 
It is possible that this could have introduced a misclassification bias, as patients 
admitted solely for post-operative monitoring and without critical illness were 
included in the dataset. For this reason a separate analysis of those ICU patients 
who had received organ support during their ICU stay was performed. The 
presence of organ support was used as an indication of level 3 care. It is possible 
that this will identify level 2 patients as level 3 incorrectly. For example, a post-
operative patient with an epidural in situ requiring vasoactive support for 
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associated hypotension would generally be considered level 2 but would be 
included in the organ support subgroup of this study.  
While every attempt was made to minimise missing data it remains a limitation 
of the study. In addition to missing APACHE, data pertaining to renal support was 
absent in 12% of patients. During the study period not all units had the ability to 
provide renal support and it is possible that this missing data originates in units 
where renal replacement therapy was not available. None the less, the true 
incidence or renal replacement therapy remains unknown as a result. 
 
 
7.3 Implications for further research and practice 
This thesis has described, in detail, the ICU cancer population, however, a 
number of questions remain unanswered.  
Long-term mortality of ICU cancer survivors is poor when compared with the 
group of patients without cancer. However, it is unknown how this compares to 
the population of cancer patients that are not admitted to ICU. It might be 
expected that having survived critical illness and the associated inflammatory 
insult and physiological disturbance, ICU cancer patients have a poorer prognosis 
than those without an ICU admission. However, it is likely that there is a 
selection bias associated with ICU admission as ICU physicians are only likely to 
admit patients with reasonable chronic health and perceived outcomes. Future 
work should compare long-term survival between these two groups and take 
account of variables that are likely to impact upon outcome such as tumour 
type, tumour stage, patient age and social deprivation. If possible, co-
morbidities and performance status would also be accounted for. This would be 
best achieved with a prospective trial that could also account for patients with 
critical illness that were not admitted to ICU. However, the follow up time 
required for a long-term survival study would take several years to complete. In 
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the interim, further retrospective analysis of this dataset would address many of 
these questions and provide a starting point for future studies. 
While this study has demonstrated that one in twenty cancer patients are 
admitted to ICU, it makes no evaluation of those cancer patients with critical 
illness who are not admitted. The UK has one of the lowest provisions of ICU 
beds per head of population in Europe. Furthermore, compared with the rest of 
Western Europe, survival of cancer patients in the UK is poor. Most of the 
international differences in cancer survival are explained by early mortality 
when operative interventions and aggressive anticancer therapy are likely to be 
administered. This work demonstrates that ICU admission is most common early 
after cancer diagnosis but it is unknown whether current ICU provision is 
adequate to meet the demand. A prospective study aimed at assessing the 
prevalence of critical illness in cancer patients with outcome data for both those 
that are, and those that are not, admitted to ICU might identify a need for an 
increase in provision. 
Prospective work would also have the advantage of identifying post-ICU 
treatment delivery. While the intention prior to ICU might be for aggressive 
treatment with an expected good outcome, it is not clear whether an ICU 
admission alters this course. It seems likely that critical illness will necessitate 
some changes to treatment plans such as delays in surgery or chemotherapy or 
alterations to chemotherapy regimes or dosing. Changes to these may have 
subsequent impact upon survival such that the outcomes for post-ICU cancer 
patients follow a different course. Patients treated with chemotherapy at the 
Beatson Oncology Centre in the West of Scotland have their prescriptions 
documented on the Chemocare database. There is an opportunity for merging 
the Chemocare database with this dataset. Analysis of the Chemocare data 
would allow differentiation of treatment regimes for cancer patients with and 
without an ICU admission and how this impacts upon survival. This would go 
some way to informing clinical practice in terms of advising patients of changes 
to their expected journey following an ICU admission. 
Finally, the focus of this thesis has been regarding the ICU care of cancer 
patients, however, this dataset also allows for analysis of the rates of cancer in 
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the population of ICU survivors. Critical illness involves a marked inflammatory 
process. This may be exacerbated by interventions such as invasive mechanical 
ventilation. Most patients during their ICU stay will undergo exposure to ionising 
radiation with x-rays and CT scanning common in ascertaining a diagnosis and 
monitoring treatment. As such, it is possible that ICU survivors have a higher risk 
of cancer than the general population. Further analysis of this data would allow 
documentation of tumour-specific rates among those patients that have survived 
an ICU admission.  
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Chapter 8 Appendices   
8.1 Systematic review additional tables 
 
Table 8-1 and 8-2 describe the setting and patient characteristics of the included 
studies. 
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Author Setting Design Study population Exclusions 
Adam (2008)  USA 1998-2005; 
single centre 
general ICU 
Retrospective 139 lung cancer patients admitted to MlCU  ICU stay <24 hours, routine 
postoperative care, cancer 
remission >2 years, ICU 
readmission 
Aldawood (2010) Saudi Arabia 
1999-2009; 
single centre 
general ICU 
Prospective 51 ICU patients with lung cancer Postoperative lung resection 
patients, age <16 years, brain 
death victims 
Andréjak  (2011)  France 1996-
2006; 2 general 
MICUs 
Retrospective 76 patients with advanced lung cancer  (no 
curative surgical option, stage 3B, 4 NSCLC 
or SCLC) requiring MICU admission 
Lung cancer diagnosed/ staged 
after ICU admission, disease 
remission >5 years, ICU stay <24 
hours (except if died), routine 
postoperative care, readmissions 
Anisoglou  (2013)  Greece 2008-
2011; single 
centre 
oncological ICU 
Retrospective  105 lung cancer patients with acute 
respiratory failure requiring ICU 
ICU stay <24 hours, routine 
postoperative care 
Azoulay (2004)  France 1997-
2002; single 
centre general 
ICU 
Prospective 203 patients with haematological/solid 
tumours admitted to ICU with acute 
respiratory failure 
 Nil 
Bissell (2013)  UK 1998-2009; 
single centre 
general ICU 
Retrospective 43 patients requiring readmission to ICU 
following elective oesophagectomy for 
malignancy 
 Nil 
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Author Setting Design Study population Exclusions 
Bonomi (2012)  USA 1992-2005; 
multicentre 
ICUs 
Retrospective  1134 patients with NSCLC stage IIIB/ IV 
admitted to MICU with respiratory, cardiac, 
or neurological diseases, renal failure, or 
sepsis 
Age <65 years 
Bos (2012)  Netherlands 
2007-2011; 80 
general ICUs   
Retrospective 15211 patients with an APACHE IV diagnosis 
of haematological or solid tumour and an 
unplanned admission to ICU.  
Elective ICU admission 
Caruso (2010)  Brazil; single 
centre 
oncological ICU 
Retrospective 83 patients with metastatic solid cancer 
admitted to ICU during 1 calendar year 
 Readmissions 
Cense (2006)  Netherlands 
1994-2000; 2 
general ICUs 
Prospective 109 patients undergoing a transthoracic 
resection for adenocarcinoma of the  
middistal oesophagus or gastric cardia 
 Age <18 years, ASA >3 
Chawla (2009) USA 2004-06, 
single centre 
oncological ICU 
Retrospective 25 patients with solid/ haematological 
cancer admitted to ICU within 48 hours of 
planned or actual hospital discharge 
 Nil 
Chou (2012)  Taiwan 2007-
2008, single 
general ICU 
Retrospective 70 patients with stage III-IV lung cancer 
requiring mechanical ventilator support for 
sepsis-related respiratory failure 
Nil 
Christodoulou 
(2007)  
Greece 2001-05; 
single centre 
general ICU 
Retrospective  69 patients with solid tumours admitted to 
ICU 
Routine postoperative monitoring 
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Author Setting Design Study population Exclusions 
Darmon (2005)  France 1997-
2003; single 
centre general 
ICU 
Prospective  100 patients with organ failure, inoperable 
solid tumour or hematologic malignancy 
diagnosed <30 days before ICU admission, in 
immediate need of chemotherapy and 
eligible to receive chemotherapy 
Previous chemotherapy 
de Almeida 
(2012) 
Brazil 2009; 
single centre 
oncology ICU 
Prospective 122 patients with solid or haematological 
tumour admitted to ICU 
Age <18 years old, palliative care, 
haemorrhagic shock, end-stage 
renal disease,  patients in other 
studies, expected death within 24 
h, discharged within 24 hours 
Ertan (2008)  Turkey 1998-
2004; single 
centre general 
ICU 
 Not stated 102 patients who underwent emergency 
surgery for colorectal cancer and admitted 
to ICU 
 Diagnostic uncertainty or 
insufficient clinical data 
Jennens (2002) Australia 1993-
2001; 3 general 
ICUs 
Retrospective 20 patients with lung cancer (SCLC) 
admitted to ICU 
 Nil 
Kopterides (2011) Greece 2005-07; 
2 general ICUs 
Prospective  126 patients with solid/ haematological 
cancer admitted to ICU 
Age <18 years, ICU readmissions, 
routine post-op monitoring 
Leath (2006) USA 1999-2004; 
single centre 
general ICU 
Retrospective 185 gynaecological oncology patients 
admitted to ICU following surgery 
Patients undergoing outpatient 
procedures or surgery at a 
different centre or non-surgical 
admissions 
Lecuyer (2007)  France  2001-
04, single 
general ICU 
Prospective 188 consecutive patients with solid/ 
haematological cancer requiring mechanical 
ventilation and presence of at least one 
other organ failure 
HIV, allogenic stem cell transplant 
recipients 
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Author Setting Design Study population Exclusions 
Libório (2011)  Brazil 2006-08; 
single centre 
oncological ICU 
Prospective 288 patients with solid/ haematological 
cancer admitted to ICU 
ESRF, previous renal transplant, 
obstructive nephropathy, ICU stay 
<24 hours, ICU readmissions 
Maccariello 
(2011) 
Brazil 2004-08; 
14 general ICUs 
in 3 centres 
Prospective  773 consecutive (118 with cancer) patients 
requiring renal replacement therapy for AKI 
in ICU 
ESRF, ICU stay <24 hours, ICU 
readmissions, non-AKI indication 
for RRT 
McGrath (2010)  UK 2004-08; 
single centre 
oncological ICU 
Retrospective 
2004-06; 
Prospective 
2006-08  
185 patients with solid/ haematological 
cancer admitted to ICU 
Routine post-op monitoring 
Mendoza (2008) USA 2003-04, 
single centre 
general ICU 
Retrospective  147 patients with solid cancer admitted to 
ICU 
 Nil 
Mourad (2014) France 2009-
2011; single 
oncology ICU 
Prospective 76 cancer patients with septic shock and 
persistent hypotension requiring vasopressor 
therapy 
Age <18years, valvular heart 
disease, regional myocardial 
ischaemia or previous MI, 
therapeutic limitation decision 
prior to admission 
Namendys-Silva 
(2010)  
Mexico 2007; 
single centre 
oncological ICU 
Prospective 177 patients with solid cancer admitted to 
ICU 
Age <16 years, routine post-
operative care, ICU readmissions 
Namendys-Silva 
(2011)  
Mexico 2008-10; 
single centre 
oncological ICU 
Prospective 82 patients with solid/ haematological 
cancer with septic shock in ICU 
Age <18 years, ICU readmissions 
Namendys-Silva 
(2013)  
Mexico 2007; 
single centre 
oncological ICU 
Prospective 92 patients with gynaecological cancer 
admitted to ICU 
Age <16 years, routine post-
operative care, ICU readmissions 
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Author Setting Design Study population Exclusions 
Oeyen (2013)  Belgium 2008-
2009; single 
centre general 
MICU & SICU 
Prospective 483 patients with solid or haematological 
malignancy admitted to ICU 
Readmissions, remission >5 years, 
post op cardiac surgery 
Okiror (2012)  UK 2003-2008, 
single centre 
thoracic ICU 
Retrospective  30 patients with lung cancer admitted to ICU 
as an emergency following lung resection.  
Nil  
Park (2009) UK 1995-2007; 
181 general 
ICUs 
Retrospective 7227 patients admitted to ICU following 
elective oesophageal surgery for malignancy 
 Nil 
Reichner (2006) USA 2002-04; 
single centre 
general ICU 
Retrospective 47 patients with lung cancer admitted to ICU  Nil 
Roques (2009) France 1997-
2006; single 
centre general 
ICU 
Prospective 105 lung cancer patients admitted to ICU Postoperative lung resection 
patients, ICU readmission 
Slatore (2012)  USA 1992-2007; 
multicentre 
ICUs 
Retrospective  49373 patients with lung cancer admitted to 
ICU within 5 years of diagnosis 
Age <66 years at diagnosis, patient 
with incomplete or without 
Medicare billing information, 
routine postoperative ICU 
admission, in situ cancer, 
diagnosis of cancer post mortem 
Soares (2005)  Brazil 2000-04; 
single centre 
oncological ICU 
Prospective 772 consecutive patients with solid/ 
haematological cancer admitted to ICU 
Cancer remission >5 years, ICU 
stay <24 hours, acute coronary 
syndrome, routine postoperative 
care, ICU readmissions 
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Author Setting Design Study population Exclusions 
Soares (2007)  Brazil 2000 – 
2005; single 
centre 
oncological ICU 
Prospective 121 patients with head and neck cancer 
admitted to ICU because of severe acute 
complications 
ICU stay <24hours, routine 
postoperative care, readmission, 
complete cancer remission >5 
years 
Soares (2007) 
 
Brazil & France 
2000-05; 1 
oncology  & 1 
general ICU 
Retrospective 152 lung cancer patients admitted to ICU Age <18 years, cancer remission >5 
years, ICU stay <24 hours, routine 
postoperative care, ICU 
readmission 
Soares (2010) Brazil 2007; 28 
ICUs 
Prospective 753 patients with solid/ haematological 
cancer admitted to ICU 
Age <18 years, cancer remission >5 
years, ICU stay <24 hours, routine 
postoperative care, ICU 
readmission 
Song (2007)  South Korea 
2001-05; single 
centre 
oncological ICU 
Retrospective 94 patients who underwent resection for 
lung or oesophageal cancer and subsequently 
required readmission to ICU  
Single wedge resection 
Song (2011)  South Korea 
2002-08; single 
centre general 
ICU 
Retrospective 62 consecutive patients with solid/ 
haematological cancer who received 
chemotherapy in ICU 
Patients receiving prior on-going 
chemotherapy or treatment with 
corticosteroids only 
Song (2012)  South Korea 
2010; single 
centre 
oncological ICU 
Retrospective  199 solid/ haematological cancer patients 
admitted to ICU via medical emergency 
team intervention 
Limitation of care decision or 
refusal of ICU admission 
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Author Setting Design Study population Exclusions 
Souza-Dantas 
(2011)  
Brazil 2000-07; 
single centre 
oncological ICU 
Prospective  94 patients with solid/ haematological 
cancer and neutropenia admitted to ICU 
matched to 94 non-neutropenic patients 
Age <18 years, cancer remission >5 
years, ICU stay <24 hours, routine 
postoperative care, ICU 
readmissions 
Taccone (2009)  24 European 
countries  2002;  
198 general 
ICUs 
Prospective 473 patients with solid/ haematological 
cancer admitted to ICU 
Age <15 years old, routine 
postoperative observation if >24 
hours, ICU readmissions 
Toffart (2011)  France 2000-07; 
3 general ICUs 
Retrospective 103 ICU patients with a past or present 
history of non-resectable lung cancer  
Postoperative care 
Unseld (2013)  Switzerland 
2002; single 
centre MICU 
Retrospective 74 patients with solid/ haematological 
malignancy admitted to MICU 
 Nil 
Welsch (2011)  Germany 2001-
2008; single 
centre general 
ICU 
Prospective 96 patients with pancreatic head 
adenocarcinoma admitted to ICU post 
operatively for >24 hours 
Patients with ampullary 
adenocarcinomas, intraductal 
papillary mucinous neoplasms, 
distal bile-duct carcinomas, and 
other malignant and benign 
pancreatic pathologies  
Zuber (2012)  France 1997-
2008; 41 
general ICUs 
Secondary 
analysis of 
prospective 
database of 
225481 ICU 
patients  
3437 patients with solid/ haematological 
cancer admitted to ICU with septic shock 
ICU readmission 
Table 8-1 Description of studies included in the systematic review of patients with solid tumours in ICU. aincludes haematological cancer patients 
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Author Number of solid tumour patients; tumour types (%) Meta-
static 
disease 
(%) 
Severity of illness 
mean (SD) or median 
(IQR) 
Age mean 
(SD) or 
median 
(IQR) 
Adam (2008)  139; NSCLC  (69%), SCLC (13%) 40% SAPS III 41.8 (22.9), 
APACHE III 59.0 (25.1) 
64.2 (10.2) 
Aldawood 
(2010)  
51; NSCLC (51%) SCLC (14%) - APACHE II 25.6 (8.13) 58 (16.2) 
Andréjak 
(2011) 
76; NSCLC (64.5%), SCLC (38.2%) 59.2% SAPS II 43 (16.5), 
APACHE II 22 (7.7) 
63.0 (9.9) 
Anisoglou 
(2013)  
105 lung cancer patients; 80% NSCLC, 13% SCLC 72.4% APACHE II 23.4, SOFA 
9.4 
68.3 (10.4) 
Azoulay (2004)  19; lung (52.6%), breast (47.4%) -  - 53a (41-63) 
Bissell (2013)  43 oesophageal cancer patients; adenocarcinoma (90.7%), squamous 
cell (4.7%), GIST (4.7%) 
0%  - 65 (1.6) 
Bonomi (2012) 1134 NSCLC; adenocarcinoma (45.4%), squamous cell (32.2%), large 
cell (8.6%), other (13.8%) 
54.5% - 73 (69-78) 
Bos (2012)  12290 patients with solid tumours 30% APACHE IV 88.1 (36.3)a - 
Caruso (2010)  83; breast (19.3%), lung (14.5%), head & neck (8.4%), colon (6%), 
stomach (6%), melanoma (6%), prostate (6%), pancreas (4.8%) 
100% SAPS II 47.5 (40-60) 61.4 (51-
71) 
Cense (2006)  109; oesophageal (100%) 14.7%  - 62 
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Author Number of solid tumour patients; tumour types (%) Meta-
static 
disease 
(%) 
Severity of illness 
mean (SD) or median 
(IQR) 
Age mean 
(SD) or 
median 
(IQR) 
Chawla (2009) 21; bladder (14.3%), colorectal (7.1%), lung (14.3%), pancreatic 
(7.1%) 
- - 63.9 (15.9) 
Chou (2012)  70; lung (100%)  APACHE II 24.3 (6.7) 
SOFA 7.1 (3.1) 
74.5 (12.0) 
Christodoulou  
(2007)  
69; lung (39.1%), colorectal (13%), ovarian (8.6%), breast (7.2%), 
pancreas (5.8%), prostate (5.8%), brain (4.3%), nasopharynx (4.3%), 
bladder (4.3%), kidney (2.9%), stomach (2.9%), oesophagus (1.4%) 
89.9% APACHE II 18.1 (8.3) 61.3 (13.3) 
Darmon (2005) 12; sarcoma (33%), breast (17%), testicular (17%), NSCLC (8%) - SAPS II 39 (30-48) 47 (32-61) 
de Almeida 
(2012) 
106; not specified 35.2% APACHE II 14 (10-20) a 63 (61-65) 
a 
Ertan (2008)  102; colorectal (100%) - -  61 (18-97) 
Jennens (2002) 20; SCLC (100%) - - 67  
Kopterides 
(2011) 
90; lower GI (33.3%), upper GI (25.6%), urogenital (14.4%), lung 
(12.2%), breast (8.9%) 
- SOFA 8.0 (5.0), SAPS II 
45.1 (22.2), APACHE II 
18.8(10.1) 
65.3 (14.4) 
Leath (2006)  185; Ovarian (39%), Endometrial (21%), cervical (12%), other (8%), 
benign disease (20%) 
- APACHE II 11.6 60 
Lecuyer (2007) 56; lung and breast (46%) - - 51.5a 
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Author Number of solid tumour patients; tumour types (%) Meta-
static 
disease 
(%) 
Severity of illness 
mean (SD) or median 
(IQR) 
Age mean 
(SD) or 
median 
(IQR) 
Libório  (2011) 258; gastrointestinal (30.2%), urological (25.6%), head & neck 
(16.3%), lung (6.9%), breast (6.9%) 
- SOFA 5.8 (3.4), SAPS II 
35 (19.4), APACHE II 
10.3 (5.9) 
58.8 (17.4) 
Maccariello 
(2011) 
86; lower GI (29%), urogenital (20.9%), liver/ biliary (17.4%), upper 
GI (12.8%), lung (7%) 
31.4% SOFA 9 (7-11), SAPS II 
49.3 (12.7) 
70.0 (13.9) 
McGrath (2010) 70; lung (21.4%), breast (15.7%), oesophagus (11.4%), ovarian (5.7%) 41.4% SOFA 5.5, APACHE II 
17.1 
57.1 (12.8) 
Mendoza 
(2008)  
147; lung (23%), colorectal (12%), breast (7%), prostate (6%), 
pancreas (5%) 
51.7%  - 63.5 (13.5) 
Mourad (2014) 26; not specified - SAPS II 57 (45.7-69)a, 
SOFA 11 (9-13)a 
58 (49-66)a 
Namendys-
Silva (2010)  
177; GI (22.6%), head and neck (20.3%), lung (2.3%), genitourinary 
(5.1)%, gynaecological (29.4%), breast (3.4%), gem-cell (5.6%), 
prostate (1.1%), sarcoma (4%) skin and soft tissue (6.2%) 
- SOFA 3 (1-8), APACHE II 
12 (11-14) 
52.4 (17.3) 
Namendys-
Silva (2011)  
56; colorectal (17.9%), cervix (17.9%), sarcoma (12.5%), upper GI 
(12.5%), breast (8.9%) 
33.9% SOFAa 9.1 (3) in 
survivors vs. 11.7 (3) in 
non survivors, APACHE 
IIa 15 (13-19.5) in 
survivors vs. 18 (16-23) 
in non survivors 
52.5 (14.7) 
a 
Namendys-
Silva (2013) 
92; cervix (67.3%), ovarian (21,2%) - SOFA 4.4 (4), APACHE II 
12.4 (2) 
56.5 (12.8) 
Oeyen (2013)  398; lower GI (26%), upper GI (25%), lung (15%),   urogenital (8.5 %), 
brain (8 %), head and neck (7 %), breast (4 %) 
46% SOFA 3 (2-5), APACHE II 
13 (11-18) 
62 (54-69) 
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Author Number of solid tumour patients; tumour types (%) Meta-
static 
disease 
(%) 
Severity of illness 
mean (SD) or median 
(IQR) 
Age mean 
(SD) or 
median 
(IQR) 
Okiror (2012) 30; 100% NSCLC - - 71 (7) 
Park (2009)  7227; oesophageal (100%) - SAPS II 25.1 (10.5), 
APACHE II 13.9 (4.8) 
64.3 (9.9) 
Reichner 
(2006)  
47; NSCLC (83%), SCLS (15%) 64% SOFA 4.7 (3.3) 65 (10) 
Roques (2009)  105; NSCLC (83%), SCLC (17%) 64% SAPS II 40 (21) SOFA 4.4 
(4.7) 
64.8 (10.6) 
Slatore (2012) 49373; NSCLC (80.3%), SCLC (13.1%), Other (6.6%) 45.7%  - 75 (71-79) 
Soares (2005)  642; GI (17.1%), head & neck (16.2%), brain (16.2%), lung (11.8%), 
upper GI (11.4%), urogenital (10.1%), breast (5.9%) 
21.4% SOFA 6.5 (3.9), SAPS II 
43.6 (18.9) 
57.6 (16.4) 
Soares (2007)  121; oral cavity (30%); larynx (25%), pharynx (14%), thyroid (9%), 
salivary gland (7%), paranasal sinuses (6%), other (9%) 
35% SAPS II 49.6 (17.8), 
SOFA 7.2 (3.6) 
 63.3 
(14.7) 
Soares (2007) 
 
143; squamous-cell carcinoma (39%), adenocarcinoma (34%), SCLC 
(17%), large cell (6%), other (3%) 
31% SAPS II 47.4 (21.0) 61.6 (9.9) 
Soares (2010)  667; lower GI (18.3%), urogenital (12.3%), upper GI (12.3%), lung 
(8.7%), brain (8.5%), head & neck (8.4%), breast (7.5) 
29.1% SAPS II 32.1 (7.2)a,  
SAPS III 48.7 (19.0) a 
SOFA 7 (5 -10)a 
61.2 
(15.4)a 
Song (2007)  94; oesophageal (39.4%), lung cancer (60.6%) - APACHE III 53.8 (24.5) 65.9 (7.3) 
Song (2011)  13; lung (46.2%), sarcoma (23%), bladder (7.7%), breast (7.7%), 
gastric (7.7%), germ cell (7.7%) 
- SOFA 10 (6-14), SAPS II 
53 (41-68) 
50 (37-63) 
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Author Number of solid tumour patients; tumour types (%) Meta-
static 
disease 
(%) 
Severity of illness 
mean (SD) or median 
(IQR) 
Age mean 
(SD) or 
median 
(IQR) 
Song (2012)  104; not specified - SAPS III 80 (67-93)a, 
SOFA 8 (5-11)a 
60 (51-70) 
a 
Souza-Dantas 
(2011) 
60; GI (26.7%), urogenital (16.7%) - SOFA 11 (8-14), SAPS II 
61.6 (16.5) 
50 (32-65) 
Taccone (2009)  404; not specified 24.8% SOFA 4.6 (3.6), SAPS II 
36.8 (17.6) 
66.4 (12.1) 
Toffart (2011)  103; squamous cell (32%), adenocarcinoma (25%), SCLC (20%), large 
cell (11%) 
61% SAPS II 33 (25-46) 
LOD 3 (1-4) 
61 (54-68) 
Unseld (2013)  42; urogenital (42%), lung (24%), gastrointestinal (16%), head (9%), 
other (7%) 
- SAPS II 39 (28-53), SOFA 
5 (3-9) 
66 (57-73) 
Welsch (2011)   96; pancreas (100%) 7% - - 
Zuber (2012)  2119; lung (16.8%), GI (16.6%), genitourinary (16.3%) 41.9% 
 
SAPS II 63.4 (25.1) 62.2 (14.3) 
Table 8-2 Patient characteristics from studies included in the systematic review. aincludes haematological cancer patients. 
  
259 
8.2 Ethics Approval Letter 
 
  
260 
 
  
261 
 
  
262 
 
 
 
 
  
263 
8.3 Diagnostic groupings 
SICS Diagnosis Diagnostic group 
Anaphylactic shock Anaphylaxis 
Anaphylaxis Anaphylaxis 
Acute lung injury ARDS 
ARDS ARDS 
Burns Burns related 
Carbon monoxide poisoning Burns related 
Smoke inhalation Burns related 
Cardiac Arrest (In hospital) Cardiac arrest 
Cardiac Arrest (Out of hospital) Cardiac arrest 
Cardiac failure Cardiac failure 
Cardiogenic shock Cardiac failure 
Poor left ventricular function Cardiac failure 
Disseminated intravascular coagulation Coagulation disorder 
Other acquired coagulation disorder Coagulation disorder 
Other coagulation disorder Coagulation disorder 
Thrombotic disorders Coagulation disorder 
Venous thrombosis (including DVT) Coagulation disorder 
Adverse reaction to therapeutic drug Drug related 
Alcohol abuse/dependence Drug related 
Drug abuse/dependence Drug related 
Drug overdose/misuse Drug related 
Drug toxicity Drug related 
Fulminant hepatic failure (paracetamol 
induced) Drug related 
Other drug related problem Drug related 
Self-poisoning Drug related 
Suxamethonium apnoea Drug related 
Toxicity of therapeutic drug Drug related 
Diabetes mellitus (co-existing) Endocrine/ Metabolic disorder 
Diabetic ketoacidosis Endocrine/ Metabolic disorder 
Hypoglycaemia Endocrine/ Metabolic disorder 
Non-ketotic diabetic coma Endocrine/ Metabolic disorder 
Acromegaly Endocrine/ Metabolic disorder 
Cushing's disease Endocrine/ Metabolic disorder 
Hyperthermia Endocrine/ Metabolic disorder 
Hypoadrenalism Endocrine/ Metabolic disorder 
Hypothermia Endocrine/ Metabolic disorder 
Other adrenal disorder Endocrine/ Metabolic disorder 
Other endocrine disorder Endocrine/ Metabolic disorder 
Other pituitary disorder Endocrine/ Metabolic disorder 
Phaeochromocytoma Endocrine/ Metabolic disorder 
Disorders of metabolism (inherited) Endocrine/ Metabolic disorder 
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Disorders of metabolism (other) Endocrine/ Metabolic disorder 
Other metabolic disorder Endocrine/ Metabolic disorder 
Obesity Endocrine/ Metabolic disorder 
Goitre Endocrine/ Metabolic disorder 
Hyperthyroidism Endocrine/ Metabolic disorder 
Hypothyroidism Endocrine/ Metabolic disorder 
Other thyroid disorder Endocrine/ Metabolic disorder 
Diverticular disease with perforation GI perforation 
Duodenal ulcer (perforated) GI perforation 
Gastric ulcer (perforated) GI perforation 
Perforated duodenal ulcer GI perforation 
Perforated gall bladder GI perforation 
Perforated gastric ulcer GI perforation 
Lower GI perforation GI perforation 
Oesophageal perforation GI perforation 
Acute appendicitis with perforation GI perforation 
Anastamotic leak GI perforation 
Hysterectomy Gynaecology 
Other gynaecological problem Gynaecology 
Perforated uterus Gynaecology 
Duodenal ulcer (bleeding) Haemorrhage 
Gastric ulcer (bleeding) Haemorrhage 
Gynaecological bleeding Haemorrhage 
Haemorrhage from duodenal ulcer Haemorrhage 
Haemorrhage from gastic erosion/stress ulcer Haemorrhage 
Haemorrhage from gastric ulcer Haemorrhage 
Haemorrhage from stress ulceration Haemorrhage 
Haemothorax Haemorrhage 
Haemothorax (non-traumatic) Haemorrhage 
Hypovolaemic/haemorrhagic shock Haemorrhage 
Lower GI haemorrhage Haemorrhage 
Massive blood loss/transfusion without shock Haemorrhage 
Massive blood transfusion Haemorrhage 
Oesophageal variceal haemorrhage Haemorrhage 
Other/unspecified upper GI haemorrhage Haemorrhage 
Post-partum haemorrhage Haemorrhage 
Retroperitoneal haematoma Haemorrhage 
Retroperitoneal haematoma/coll Haemorrhage 
Pancreatic pseudocyst Hepatobiliary 
Acalculous cholecystitis Hepatobiliary 
Acute cholecystitis Hepatobiliary 
Biliary obstruction Hepatobiliary 
Other gall bladder or bile duct disorder Hepatobiliary 
Other pancreatic disorder Hepatobiliary 
Acute pancreatitis Hepatobiliary 
Chronic pancreatitis Hepatobiliary 
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Acute MI Ischaemic heart disease 
Acute myocardial ischaemia Ischaemic heart disease 
Chronic ischaemic heart disease Ischaemic heart disease 
Other ischaemic heart disease Ischaemic heart disease 
Unstable angina Ischaemic heart disease 
Alcoholic liver disease Liver disease 
Cryptogenic cirrhosis Liver disease 
Fulminant hepatic failure (other) Liver disease 
Hepatitis (other) Liver disease 
Hepato-renal failure Liver disease 
Other hepatic disease Liver disease 
Primary biliary cirrhosis Liver disease 
Primary sclerosing cholangitis Liver disease 
Viral hepatitis (any type) Liver disease 
Bladder tumour Malignancy 
Bone tumour Malignancy 
Secondary brain tumour Malignancy 
Breast cancer Malignancy 
Primary brain tumour Malignancy 
Large bowel malignancy Malignancy 
Large/small bowel malignancy Malignancy 
Disseminated malignancy Malignancy 
Gastric carcinoma Malignancy 
Other GI malignancy Malignancy 
Small bowel malignancy Malignancy 
Acute leukaemia Malignancy 
Chronic leukaemia Malignancy 
Hodgkin's lymphoma Malignancy 
Myeloma Malignancy 
Non-Hodgkin's lymphoma Malignancy 
Other haematological malignancy Malignancy 
Hepato-biliary malignancy Malignancy 
Hepatocellular cancer Malignancy 
Hepatic metastases Malignancy 
Carcinoma (bronchus/lung) Malignancy 
Oesophageal carcinoma Malignancy 
Ovarian carcinoma Malignancy 
Pancreatic carcinoma Malignancy 
Prostate tumour Malignancy 
Kidney tumour Malignancy 
Spinal tumour Malignancy 
Teratoma Malignancy 
Thyroid tumour Malignancy 
Upper airway/oral carcinoma Malignancy 
Other genito-urinary tract tumour Malignancy 
Uterine/cervical carcinoma Malignancy 
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Other autoimmune disorder Miscellaneous 
Vasculitis Miscellaneous 
Vasulitis Miscellaneous 
HIV/AIDS Miscellaneous 
Immunocompromised (by disease) Miscellaneous 
Immunocompromised (by treatment) Miscellaneous 
Not documented Miscellaneous 
Other haematological disorder Miscellaneous 
Endoscopy Miscellaneous 
Interventional radiology/cardiology Miscellaneous 
Multiple surgical procedures Miscellaneous 
Pre-op assessment/monitoring/optimisation Miscellaneous 
Radiological coiling/embolisation Miscellaneous 
Other surgery Miscellaneous 
Other chronic psychiatric disorder Miscellaneous 
Self-inflicted injury Miscellaneous 
Arthritis Musculoskeletal 
Hip surgery (including replacement) Musculoskeletal 
Knee surgery (including replacement) Musculoskeletal 
Orthopaedic surgery to multiple sites Musculoskeletal 
Osteoporosis Musculoskeletal 
Other bone disease Musculoskeletal 
Other chronic physical disorder Musculoskeletal 
Other lower limb surgery Musculoskeletal 
Other muscular disorder Musculoskeletal 
Other orthopaedic surgery Musculoskeletal 
Other skin disorder Musculoskeletal 
Other soft tissue trauma Musculoskeletal 
Other spinal disorder Musculoskeletal 
Other spinal surgery Musculoskeletal 
Pathological fracture Musculoskeletal 
Pelvic surgery Musculoskeletal 
Peripheral muscular disorders Musculoskeletal 
Rhabdomyolisis Musculoskeletal 
Rheumatoid arthritis Musculoskeletal 
Skull fracture Musculoskeletal 
Spinal fusion Musculoskeletal 
Thoracic/lumbar injury (minus cord damage) Musculoskeletal 
Thoracic/lumbar injury (plus cord damage) Musculoskeletal 
Upper limb surgery Musculoskeletal 
Fat embolism Musculoskeletal 
Central respiratory depression Neurological disorder 
Coma (other) Neurological disorder 
Coma (Unknown cause) Neurological disorder 
Encephalitis Neurological disorder 
Hepatic encephalopathy Neurological disorder 
  
267 
Metabolic coma Neurological disorder 
Hanging Neurological disorder 
Hypoxic brain damage Neurological disorder 
Near drowning Neurological disorder 
Intracerebral contusions/haematoma Neurological disorder 
Intracerebral haemorrhage Neurological disorder 
Intracranial aneurysm Neurological disorder 
Subarachnoid haemorrhage (aneurysm) Neurological disorder 
Subarachnoid haemorrhage (other) Neurological disorder 
Subdural haematoma Neurological disorder 
Extradural haematoma Neurological disorder 
Cerebral infarction Neurological disorder 
CNS demyelination Neurological disorder 
CNS inflammation Neurological disorder 
Diffuse brain injury Neurological disorder 
Diffuse head injury Neurological disorder 
Guillan Barre syndrome Neurological disorder 
ICU neuropathy/myopathy Neurological disorder 
Multiple sclerosis Neurological disorder 
Myaesthenia gravis Neurological disorder 
Other CNS disorder Neurological disorder 
Other neurological vascular disorder Neurological disorder 
Other peripheral nervous system disorder Neurological disorder 
Paraplegia (existing) Neurological disorder 
Paraplegia (new) Neurological disorder 
Quadraplegia (existing) Neurological disorder 
Quadraplegia (new) Neurological disorder 
Respiratory failure due to neuromuscular 
disease Neurological disorder 
Spinal myelitis Neurological disorder 
Transient ischaemic attack Neurological disorder 
Amniotic fluid embolism Obstetric disorder 
Ectopic pregnancy Obstetric disorder 
Other obstetric problem Obstetric disorder 
Other obstetric/gynaecological surgery Obstetric disorder 
Toxaemia/PIH/eclampis/pre-eclampsia Obstetric disorder 
Atrial fibrillation Other Cardiac 
Heart block Other Cardiac 
Other arrhythmia Other Cardiac 
Supraventricular tachycardia Other Cardiac 
Ventricular tachycardia Other Cardiac 
Cardiomyopathy Other Cardiac 
Congenital heart disease Other Cardiac 
Essential hypertension Other Cardiac 
Fluid overload Other Cardiac 
Functioning cardiac transplant Other Cardiac 
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Mediastinitis Other Cardiac 
Other cardiac disease Other Cardiac 
Other hypertension Other Cardiac 
Other shock Other Cardiac 
Pericardial effusion/disease Other Cardiac 
Secondary hypertension Other Cardiac 
Systemic embolism Other Cardiac 
Aortic regurgitation Other Cardiac 
Aortic stenosis Other Cardiac 
Existing prosthetic valve Other Cardiac 
Mitral regurgitation Other Cardiac 
Mitral stenosis Other Cardiac 
Other or unspecified valvular disease Other Cardiac 
GI obstruction (adhesions) Other Gastro 
GI obstruction (any hernia) Other Gastro 
GI obstruction (ileus) Other Gastro 
GI obstruction (other) Other Gastro 
GI obstruction (tumour) Other Gastro 
GI obstruction (volvulus) Other Gastro 
Large bowel ischaemia/infarction Other Gastro 
Small bowel ischaemia/infarction Other Gastro 
Crohn's disease Other Gastro 
Ulcerative colitis Other Gastro 
Diverticular disease without perforation Other Gastro 
Hernia (incisional) Other Gastro 
Hernia (inguinal) Other Gastro 
Hernia (inguinal, umbilical, or femoral) Other Gastro 
Hernia (umbilical) Other Gastro 
Malnutrition/malabsorbtion Other Gastro 
Other intestinal disease Other Gastro 
Other nutritional disorder Other Gastro 
Other retroperitoneal collection/abscess Other Gastro 
Other retroperitoneal patholog Other Gastro 
Other splenic disorder Other Gastro 
Splenectomy Other Gastro 
Stress ulceration Other Gastro 
Acute appendicitis without perforation Other Gastro 
Functioning renal transplant Renal disorder 
Gomerulonephritis Renal disorder 
Other renal disease Renal disorder 
Acute on chronic renal failure Renal disorder 
ARF (cause unknown) Renal disorder 
ARF (nephro-toxic agent) Renal disorder 
ARF (rhabdomyolysis) Renal disorder 
ATN Renal disorder 
Chronic renal failure (dialysis-dependent) Renal disorder 
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Chronic renal failure (NOT dialysis-dependent) Renal disorder 
Non-functional/rejected renal transplant Renal disorder 
Obstructive renal failure Renal disorder 
Other acute renal failure Renal disorder 
Benign prostatic hypertrophy Renal disorder 
Other genito-urinary tract disorder Renal disorder 
Renal/ureteric calculi Renal disorder 
Asthma (acute) Respiratory disorder 
Asthma (co-existing) Respiratory disorder 
Bronchiectasis Respiratory disorder 
Broncho-pleural fistula Respiratory disorder 
Caval obstruction Respiratory disorder 
Chronic respiratory disease (Restrictive/chest 
wall/spine) Respiratory disorder 
COPD/emphysema (co-existing) Respiratory disorder 
COPD-acute exacerbation Respiratory disorder 
Cystic fibrosis Respiratory disorder 
Existing lung transplant Respiratory disorder 
Existing tracheostomy Respiratory disorder 
Neurogenic pulmonary oedema Respiratory disorder 
Other chest infection Respiratory disorder 
Other chronic respiratory disease Respiratory disorder 
Other pleural disorder Respiratory disorder 
Other pulmonary oedema Respiratory disorder 
Other pulmonary vascular disorder Respiratory disorder 
Other respiratory disease Respiratory disorder 
Pleural effusion Respiratory disorder 
Pneumothorax Respiratory disorder 
Pneumothorax (non-traumatic) Respiratory disorder 
Pulmonary contusion Respiratory disorder 
Pulmonary fibrosis Respiratory disorder 
Pulmonary fibrosis/alveolitis Respiratory disorder 
Pulmonary haemorrhage Respiratory disorder 
Pulmonary hypertension Respiratory disorder 
Pulmonary thromboembolism Respiratory disorder 
Sleep apnoea Respiratory disorder 
Other upper airway problem Respiratory disorder 
Upper airway haemorrhage Respiratory disorder 
Upper airway obstruction Respiratory disorder 
Upper airway trauma Respiratory disorder 
Epileptic (controlled) Seizure disorder 
Seizures (not Status) Seizure disorder 
Status epilepticus Seizure disorder 
Pyelonephritis Sepsis 
Bacteraemia/septicaemia Sepsis 
Cellulitis Sepsis 
  
270 
Cerebral abscess Sepsis 
Chest infection-Aspiration Sepsis 
Chest infection-Atypical Sepsis 
Chest infection-Bacterial Sepsis 
Chest infection-Clinical (culture negative) Sepsis 
Chest infection-Fungal Sepsis 
Chest infection-PCP Sepsis 
Chest infection-TB Sepsis 
Chest infection-Viral Sepsis 
Chicken pox Sepsis 
Cholangitis Sepsis 
Croup Sepsis 
Empyema Sepsis 
Empyema of gall bladder Sepsis 
Epiglottitis Sepsis 
Hepatic abscess Sepsis 
Infective endocarditis Sepsis 
Meningitis Sepsis 
Meningococcal infection Sepsis 
MRSA Sepsis 
Necrotising fasciitis Sepsis 
Osteomyelitis Sepsis 
Other CNS infection Sepsis 
Other GI infection Sepsis 
Other infection Sepsis 
Other upper GI perforation Sepsis 
Pelvic sepsis Sepsis 
Peritonitis/abscess (no source identified) Sepsis 
Septic shock (GI tract) Sepsis 
Septic shock (renal tract) Sepsis 
Septic shock (respiratory) Sepsis 
Septic shock (source not specified) Sepsis 
Spinal abscess Sepsis 
Urinary tract infection Sepsis 
Extended recovery from anaesthesia Surgical complication 
Other anaesthetic complication Surgical complication 
Post-op respiratory failure Surgical complication 
Surgical complication Surgical complication 
Blunt trauma with brain injury Trauma 
Blunt trauma without brain injury Trauma 
Bowel trauma Trauma 
Cardiac/pericardial trauma Trauma 
Cervical spine injury (minus cord damage) Trauma 
Cervical spine injury (plus cord damage) Trauma 
Facial fracture Trauma 
Fracture of mandible Trauma 
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Fractured neck of femur Trauma 
Fractured ribs/sternum Trauma 
Haemothorax (traumatic) Trauma 
Hepatic trauma Trauma 
Kidney/ureteric trauma Trauma 
Large soft tissue injury Trauma 
Liver trauma Trauma 
Lower limb trauma Trauma 
Mediastinal trauma Trauma 
Mesenteric/bowel trauma Trauma 
Multiple procedures for trauma Trauma 
Multiple trauma (excluding brain) Trauma 
Multiple trauma (including diffuse brain injury) Trauma 
Multiple trauma (including extradural 
haematoma) Trauma 
Multiple trauma (including intracerebral 
contusions/haemato) Trauma 
Multiple trauma (including subdural 
haematoma) Trauma 
Myocardial contusions/trauma Trauma 
Other abdominal trauma Trauma 
Other chest/airway trauma Trauma 
Other head trauma Trauma 
Other maxillo-facial trauma Trauma 
Other multiple trauma Trauma 
Other orthopaedic trauma Trauma 
Other spinal trauma Trauma 
Other trauma Trauma 
Other traumatic brain injury Trauma 
Pelvic trauma Trauma 
Pneumothorax (traumatic) Trauma 
Splenic trauma Trauma 
Upper limb trauma Trauma 
Abdominal aortic aneurysm-NOT 
ruptured/leaking Vascular 
Abdominal aortic aneurysm-ruptured/leaking Vascular 
Aortic aneurysm repair (elective) Vascular 
Aortic aneurysm repair (emergency) Vascular 
Aortic dissection Vascular 
Aortic trauma Vascular 
Arterial aneurysm-other Vascular 
Carotid artery stenosis Vascular 
Carotid surgery Vascular 
Occlusive aortic disease Vascular 
Other aorta surgery Vascular 
Other vascular disease Vascular 
Other vascular surgery Vascular 
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Peripheral ishaemia Vascular 
Peripheral vascular disease (other than aorta) Vascular 
Thoracic aortic aneurysm Vascular 
Thoracoabdominal aortic aneurysm Vascular 
Table 8-3 SICS diagnosis and corresponding diagnostic group 
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